The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN®.
Updates in the 2.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 1.2013 version include:

**MS-1**
- The discussion section was updated to reflect the changes in the algorithm.

Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

**PREV-1**
- Last bullet deleted and replaced with this bullet: Lung cancer screening using low-dose CT (LDCT) is recommended in select high-risk smokers and former smokers (see the NCCN Guidelines for Lung Cancer Screening).

**DIAG-1** through **DIAG-A 2 of 2**
- New section added addressing the diagnostic evaluation of nodules suspicious of lung cancer.

**NSCL-1**
- New clinical stage added for “multiple lung cancers.”
- Stage IV (M1b) Disseminated metastases: deleted “Workup as clinically indicated.”

**NSCL-2**
- Pretreatment evaluation
  - Mediastinoscopy and/or EBUS/EUS changed to “Pathologic mediastinal lymph node evaluation.” (also applies to NSCL-4)
  - Footnote “g” added: “Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.” (also applies to NSCL-4)
  - PET/CT scan: “if not previously done” added. (also applies to NSCL-4, NSCL-6, and NSCL-10 through NSCL-12)
  - Footnote “h” modified: “Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. (also applies to NSCL-4, NSCL-6, NSCL-7, and NSCL-10 through NSCL-12)

**NSCL-3**
- Stage IIIA modified: T1-3, N2; T3- [7 cm], N1.
- Footnote “i” added: “Patients likely to receive adjuvant chemotherapy may be treated with induction chemotherapy as an alternative.”
- Footnote “o” modified: “High-risk patients are defined by poorly differentiated neuroendocrine tumors (including lung neuroendocrine tumors [excluding well-differentiated neuroendocrine tumors]), vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, **and incomplete lymph node sampling** (Nx).

**NSCL-5**
- The following footnotes were deleted and incorporated into the Principles of Radiation Therapy section:
  - Footnote “o”: “In the preoperative chemoradiation setting, a total dose of 45-50 Gy in 1.8 to 2 Gy fractions should be used to treat all volumes of gross disease, although preoperative chemoradiotherapy should be avoided if a pneumonectomy is required, to avoid postoperative pulmonary toxicity.
  - Footnote “q”: In the definitive chemoradiation setting, a total dose of 60 to 70 Gy in 1.8 to 2 Gy fractions should be used to treat all volumes of gross disease.
Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

**NSCL-5** (continued)
- Footnote "s" modified: “If full-dose chemotherapy not given concurrently with RT as initial treatment, give additional 4 cycles of full-dose chemotherapy.” (also applies to NSCL-10, and NSCL-11)
- Footnote “t” added: “Consider RT boost if chemoradiation given as initial treatment.”

**NSCL-6**
- Separate pulmonary nodules: Mediastinoscopy replaced with “Pathologic mediastinal lymph node evaluation.”

**NSCL-7**
- “No progression” changed to No apparent progression.

**NSCL-8**
- Separate pulmonary nodules
  - Nodal status added after surgery to be consistent with NSCL-7.
  - Surgery, N2, margins positive: “+ chemotherapy” added to concurrent Chemoradiation.
  - Footnote “n” added: “The panel recommends concurrent chemoradiation for R2 resections and sequential chemoradiation for R1 resections.”
- Stage IIIA modified, (T4, N0-1) Unresectable: “Definitive” added to concurrent chemoradiation. Additional chemotherapy deleted.

**NSCL-8 and NSCL-9**
- New section added addressing “Multiple lung cancers.”

**NSCL-10**
- N3 negative: link changed from NSCL-2 to NSCL-7.
- N3 positive: “Definitive” added to concurrent chemoradiation. Additional chemotherapy deleted.

**NSCL-11**
- Ipsilateral mediastinal node positive and Contralateral mediastinal node positive: “Definitive” added to concurrent chemoradiation. Additional chemotherapy deleted.

**NSCL-12**
- Mediastinoscopy replaced with “Pathologic mediastinal lymph node evaluation.”
- Footnote “g” added: “Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.”
- T1-2, N0-1; T3, N0 after initial treatment: all category 2B designations removed (SABR, chemotherapy, chemotherapy following surgery, and surgery following chemotherapy).
- Footnote “aa” modified: “Patients with N2 disease have a poor prognosis and systemic therapy should may be considered.”

**NSCL-13**
- Surveillance: “for routine follow-up” removed after “PET or brain MRI is not indicated.”

**NSCL-14**
- Locoregional recurrence: Resectable recurrence, “SABR” added as an option.
- Locoregional recurrence: SVC obstruction, stent clarified as “SVC stent.”

**NSCL-15**
- Evaluation of Metastatic Disease modified, “Establish histologic subtype with adequate tissue for molecular testing.”
Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

NSCL-15 (continued)
- Adenocarcinoma, Large Cell, NSCLC NOS
  - Testing results modified: “EGFR mutation or ALK negative or unknown.”
- Squamous cell carcinoma, testing recommendation modified: EGFR mutation and ALK testing are not routinely recommended except in never smokers and small biopsy specimens.

NSCL-16
- Continuation maintenance chemotherapy:
  - Bevacizumab + pemetrexed added with category 2A recommendation and the following footnote “kk”: “If bevacizumab was used with a first-line pemetrexed/platinum chemotherapy regimen.”
  - Pemetrexed changed from a “category 2A” recommendation to a “category 1” recommendation.
  - “Observation” changed to “close observation.” (also applies to NSCL-18)
  - Footnote “ll”: abstract reference updated with publication. (also applies to NSCL-18)

NSCL-17
- Adenocarcinoma, large cell, NSCLC NOS; EGFR mutation discovered during first-line chemotherapy: “May add erlotinib to current chemotherapy” changed to a “category 2A” recommendation from a “category 2B” recommendation.
  - Therapy added for progression on erlotinib.
    - “Symptomatic, brain, isolated lesion: Consider local therapy and continue erlotinib.”
    - “Symptomatic, brain, multiple lesions: Consider WBRT and continue erlotinib.”
    - “Symptomatic, systemic, isolated lesion: Consider local therapy and continue erlotinib.”
    - “Symptomatic, systemic, multiple lesions: Consider systemic therapy ± erlotinib.”
    - “Asymptomatic: Continue erlotinib.”
  - Footnote “qq” added: “Biopsy on progression to determine mechanism of acquired resistance, because proportion of patients will transform to SCLC at progression.”
  - Footnote “rr” added: “Beware of flare phenomenon in subset of patients who discontinue EGFR TKI. If disease flare occurs, restart EGFR TKI.”

NSCL-A 1 of 4
- Pathologic evaluation
  - Bullet 1 modified: The purpose of pathologic evaluation is to precisely classify the histologic type of lung cancer and to determine all staging parameters as recommended by the AJCC, including tumor size, the extent of invasion (pleural and bronchial), adequacy of surgical margins, and presence or absence of lymph node metastasis. Further, determination of the specific molecular abnormalities of the tumor is critical for predicting sensitivity or resistance to a growing number of targeted therapies drugable targets, primarily tyrosine kinase inhibitors (TKIs) (see Molecular Diagnostic Studies in this section).
Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

**NSCL-A 1 of 4 (continued)**
- Pathologic evaluation: bullet 6 modified, judicious limited use of ancillary IHC studies in small tissue samples is strongly recommended, thereby preserving critical tumor tissue for molecular studies, particularly in patients with advanced-stage disease. A limited panel of p63 and TTF-1 should suffice for most diagnostic problems.

**NSCL-A 2 of 4**
- Immunohistochemical Staining, bullet 3, sub-bullet 4 modified: The panel of TTF-1 and p63 (or alternatively p40) may be useful in refining the diagnosis in small biopsy specimens to either adenocarcinoma or squamous cell carcinoma in small biopsy specimens previously generically classified as NSCLC, not otherwise specified (NOS).

**NSCL-A 3 of 4**
- Molecular Diagnostic Studies in Lung Cancer, EGFR, and KRAS
  - Sub-bullet 2 modified: There is a significant association between EGFR mutations—especially exon 19 deletion and exon 21 mutation (L858R) and exon 18 (G719X) mutations—and response sensitivity to TKIs.

- Sub-bullet 3 added: “The exon 20 insertion mutation may predict resistance to clinically achievable levels of TKIs.”

- Sub-bullet 7 modified: Resistance to TKI therapy is associated with KRAS mutation. With second-site acquired EGFR mutations within the EGFR kinase domain, amplification of alternative kinases (such as MET), histologic transformation from NSCLC to SCLC, and epithelial to mesenchymal transition (EMT), such as T790M.

- Molecular Diagnostic Studies in Lung Cancer, ALK (EML4-ALK changed to ALK throughout section)
  - Sub-bullet 1 modified: Anaplastic lymphoma kinase (ALK) gene rearrangements, in a subset of anaplastic large cell lymphomas (ALCL), have been recognized for over 15 years. They represent the fusion between ALK and various partner genes, including echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusions have recently been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC. EML4-ALK NSCLC and ALK fusions have been identified in a subset of patients with NSCLC.
  - Sub-bullet 3 modified: The current standard method for detecting EML4-ALK NSCLC is fluorescence in situ hybridization (FISH), although other methods are currently being evaluated, including polymerase chain reaction (PCR) and IHC. A big advantage of FISH is that a commercially available probe set, developed for the diagnosis of ALK-rearranged anaplastic large cell lymphomas (ALCL), is applicable for the diagnosis of ALK-rearranged lung adenocarcinomas. The IHC tests used to diagnose ALK-rearranged ALCLs in clinical laboratories worldwide are inadequate for the detection of the majority of most ALK-rearranged lung adenocarcinomas. This inadequacy is because of is due to the lower level of ALK expression in ALK-rearranged NSCLCs compared with ALK-rearranged ALCLs. A molecular diagnostic test that uses FISH was recently approved by the FDA to determine which patients with lung adenocarcinoma are ALK positive.

**NSCL-B**
- Extensive revisions to the Principles of Radiation Therapy section.

**NSCL-C**
- The following regimens were added for Concurrent Chemotherapy/RT:
  - “Carboplatin AUC 5 on day 1, pemetrexed 500 mg/m² on day 1 every 21 days for 4 cycles; concurrent thoracic RT (nonsquamous)”
  - “Cisplatin 75 mg/m² on day 1, pemetrexed 500 mg/m² on day 1 every 21 days for 3 cycles; concurrent thoracic RT (nonsquamous)”
Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

**NSCL-C (continued)**

**NSCL-D 1 of 4**
- Heads added to improve the clarity and readability of this section.
- **Evaluation**
  - Bullet 1 modified: Determination of resectability, *surgical staging, and pulmonary resection* should be performed by board-certified thoracic surgeons who perform lung cancer surgery as a prominent part of their practice.
  - Bullet 2 added: “CT and PET used for staging should be within 60 days before proceeding with surgical evaluation.”
  - Bullet 3 modified: Resection, including wedge resection, is the preferred local treatment modality (other modalities include radiofrequency ablation, cryotherapy, and stereotactic ablative RT [SABR]). Thoracic surgical oncology consultation should be part of the evaluation of any patient being considered for curative local therapy. In cases where SABR is considered for high-risk patients, a multidisciplinary evaluation (including a radiation oncologist) is recommended.
  - Bullet 4 removed, as it has been combined with bullet 1: Surgical staging and pulmonary resection should be performed by board-certified thoracic surgeons who perform lung cancer surgery as a prominent part of their practice.
  - Last bullet added: “In current smokers who stop smoking, consider waiting 4 weeks before surgery to maximize outcomes after surgery.”
- **Resection**
  - Bullet 2 modified: In high-volume centers with significant VATS experience, VATS lobectomy in selected patients results in improved early outcomes (decreased pain, reduced hospital length of stay, more rapid return to function, fewer complications) without compromise of cancer outcomes.
  - Bullet 4 modified: T3 (extension/invasion) and T4 (local invasion/extension) tumors require en-bloc resection of the involved structure with negative margins. If a surgeon or center is uncertain about potential complete resection, consider obtaining an additional surgical opinion from a high-volume specialized center.

**NSCL-D 2 of 4**
- **Margins and Nodal Assessment**
  - Bullet 2 modified: N1 and N2 node resection and mapping (ATS map) *should be a routine component of lung cancer resections* - a minimum of three N2 stations sampled or complete lymph node dissection.
  - Bullet 4 modified: Complete resection requires free resection margins, systematic node dissection or sampling, no extracapsular nodal extension of the tumor, and the highest mediastinal node negative for tumor. The resection is defined as incomplete whenever there is involvement of resection margins, extracapsular nodal extension, unremoved positive lymph nodes, or positive pleural or pericardial effusions. A complete resection is referred to as R0, microscopically positive resection as R1, and macroscopic residual tumor as R2.
Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

**NSCL-D 2 of 4 (continued)**

- **Margins and Nodal Assessment**
  - Last bullet modified: Consider referral to medical oncologist for resected stage IB, and Consider referral to radiation oncologist for resected stage IIIA.

- **Role of Surgery in Patients With Stage IIIA (N2) NSCLC**
  - The first section was modified as follows:
    
    The role of surgery in patients with pathologically documented N2 disease remains controversial. This population is heterogeneous. On one side of the spectrum we have a patient with negative pre-operative evaluation of the mediastinum, found to have involvement of a single station at the time of surgery. On the other side we have patients with multiple pathologically proven malignant lymph node (LN) greater than 3 cm. Most would consider the first patient a candidate for resection, while the majority would recommend definitive chemoradiotherapy, without surgery for the second. The goal of this text is to review concepts in the therapy of patients with stage IIIA (N2) NSCLC, based on the review of available evidence by the panel members of the NCCN guidelines committee. The panel recognizes that there are Two randomized trials that have evaluated the role of surgery in this population and that both did not but neither showed an overall survival benefit with the use of surgery. However, this population is heterogeneous and we the panel believes that these trials did not sufficiently evaluate the nuances present with the heterogeneity of N2 disease and the likely oncologic benefit of surgery in specific clinical situations.
  
  - Bullet 2, sentence added: “If N2 disease is noted in patients undergoing VATS, the surgeon may consider stopping the procedure so that induction therapy can be administered before surgery; however, continuing the procedure is also an option.”
  
  - Bullet 4 modified: The presence of N2 positive lymph nodes substantially increases the likelihood of positive N3 lymph nodes. Pathologic evaluation of the mediastinum must include evaluation of the subcarinal station and contralateral lymph nodes. EBUS +/- EUS have provided additional techniques for minimally invasive pathologic mediastinal staging that are complementary to mediastinoscopy. Even when these modalities are employed, it is important to have an adequate evaluation of the number of stations involved and biopsy and documentation of negative contralateral lymph node involvement prior to a final treatment decision.

**NSCL-D 3 of 4**

- **Role of Surgery in Patients With Stage IIIA (N2) NSCLC**
  
  - Bullet 1 modified: It may be preferable to sample mediastinal lymph nodes by EBUS/EUS prior to initiating therapy, preserving mediastinoscopy and mediastinal lymph node dissection until the planned surgical resection. Repeat mediastinoscopy, while possible, is technically difficult and has a lower accuracy compared to primary mediastinoscopy. One possible strategy is to perform EBUS (± EUS) in the initial pre-treatment evaluation and to reserve mediastinoscopy for nodal restaging after neoadjuvant therapy.
  
  - Bullet 3 deleted, as it has been combined with bullet 1 on this page: “Radiographic methods have poor positive and negative predictive values in the evaluation of the mediastinum after neoadjuvant therapy. Repeat mediastinoscopy, while possible, is technically difficult and has a lower accuracy compared to primary mediastinoscopy. One possible strategy is to perform EBUS (± EUS) in the initial pre-treatment evaluation and reserve mediastinoscopy for nodal restaging after neoadjuvant therapy.”
  
  - Bullet 6 modified: When neoadjuvant chemoradiotherapy is used with doses lower than the ones considered those used for standard definitive therapy, all efforts should be made to minimize any possible breaks in radiotherapy for surgical evaluation. Treatment breaks of more than 1 week are considered unacceptable.
Updates in the 1.2013 version of the Guidelines for Non-Small Cell Lung Cancer from the 3.2012 version include:

**NSCL-D 3 of 4 (continued)**
- Role of Surgery in Patients With Stage IIIA (N2) NSCLC
  - Bullet 7, sentence added: “If a surgeon or center is uncertain about the feasibility or safety of resection after definitive doses of radiation, consider obtaining an additional surgical opinion from a high-volume specialized center. These operations may also benefit from additional considerations of soft tissue flap coverage in the radiation field resection.”
  - Last bullet, sentence added: “In addition, there is no evidence that adding RT to induction regimens for patients with operable stage IIIA (N2) disease improves outcomes compared to induction chemotherapy.” Reference 17 added.

**NSCL-E**
- Modified title of page to “Chemotherapy Regimens for Neoadjuvant and Adjuvant Chemotherapy.”
- Deleted headings of “Published Chemotherapy Regimens” and “Other Acceptable Cisplatin-based Regimens.”
- Clarified number of cycles as “4 cycles” for the cisplatin/gemcitabine and cisplatin/docetaxel regimens.
- Footnote deleted: “These regimens can be used as neoadjuvant chemotherapy. They are to be given for 3 cycles prior to localized therapy. See Discussion for further information and references.”

**NSCL-F 1 of 3**
- First-line therapy
  - Bullet 3 modified: Erlotinib is as a first-line therapy in patients with EGFR mutation.
  - Previous bullet 9 removed: In locally advanced NSCLC, concurrent chemotherapy and thoracic irradiation is superior to radiation alone and sequential chemotherapy followed by radiation.
  - Bullet 9 modified: Cisplatin or carboplatin have been proven effective in combination with any of the following agents: paclitaxel, docetaxel, gemcitabine, etoposide, vinblastine, vinorelbine, pemetrexed, or albumin-bound paclitaxel.

**NSCL-F 2 of 3**
- Continuation maintenance
  - Sub-bullet 3 added: “Continuation of bevacizumab + pemetrexed after 4 to 6 cycles of bevacizumab, pemetrexed, cisplatin/carboplatin, for patients with histologies other than squamous cell carcinoma.”
- Switch maintenance
  - Sub-bullet 4 modified: Close follow-up surveillance of patients without therapy is a reasonable alternative to switch maintenance.

**NSCL-F 3 of 3**

**NSCL-G**
- “Herpes zoster vaccine” added as an annual immunization in long-term follow-up.
- Cancer screening recommendations: text removed and links to Guidelines remain.

**ST-2**
- Table 2 added to the Guidelines “Anatomic Stage and Prognostic Groups.”
LUNG CANCER PREVENTION AND SCREENING

- Lung cancer is a unique disease in that the major etiologic agent is an addictive product that is made and promoted by an industry. Approximately 85% to 90% of cases are caused by voluntary or involuntary (second-hand) cigarette smoking. Reduction of lung cancer mortality will require effective public health policies to prevent initiation of smoking, U.S. Food and Drug Administration (FDA) oversight of tobacco products, and other tobacco control measures.
- Persistent smoking is associated with second primary cancers, treatment complications, drug interactions, other tobacco-related medical conditions, diminished quality of life, and reduced survival.
- Reports from the Surgeon General on both active smoking (http://www.cdc.gov/tobacco/data_statistics/sgr/2004/pdfs/executivesummary.pdf) and second-hand smoke show that both cause lung cancer. The evidence shows a 20% to 30% increase in the risk of lung cancer from second-hand smoke exposure associated with living with a smoker (http://surgeongeneral.gov/library/reports/smokeexposure/fullreport.pdf). Every person should be informed of the health consequences, addictive nature, and mortal threat posed by tobacco consumption and exposure to tobacco smoke, and effective legislative, executive, administrative, or other measures should be contemplated at the appropriate governmental level to protect all persons from exposure to tobacco smoke (www.who.int/tobacco/framework/final_text/en/).
- Further complicating this problem, the delivery system of lung carcinogens also contains the highly addictive substance, nicotine. Reduction of lung cancer mortality will require widespread implementation of Agency for Healthcare Research and Quality (AHRQ) Guidelines (www.ahrq.gov/path/tobacco.htm#Clinic) to identify, counsel, and treat patients with nicotine habituation.
- Patients who are current or former smokers have significant risk for the development of lung cancer; chemoprevention agents are not yet established for these patients. When possible, these patients should be encouraged to enroll in chemoprevention trials.
- Lung cancer screening using low-dose CT (LDCT) is recommended in select high-risk smokers and former smokers (see the NCCN Guidelines for Lung Cancer Screening).
Nodule suspicious for lung cancer → Multidisciplinary evaluation → Smoking cessation counseling

Patient factors
- Age
- Smoking history
- Previous cancer history
- Family history
- Occupational exposures
- Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis)
- Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms)

Radiologic factors
- Size, shape, and density of the pulmonary nodule
- Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes)
- Fluorodeoxyglucose (FDG) avidity on PET imaging

See Evaluation of Findings

---

a Multidisciplinary evaluation including thoracic surgeons, thoracic radiologists, and pulmonologists to determine the likelihood of a cancer diagnosis and the optimal diagnostic or follow-up strategy.
b Risk calculators can be used to quantify individual patient and radiologic factors but do not replace evaluation by a multidisciplinary diagnostic team with substantial experience in the diagnosis of lung cancer.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**FINDINGS**

<8 mm pulmonary nodule → Radiologic surveillance  
See **NCCN Guidelines for Lung Cancer Screening**

>8 mm solid non-calcified nodule → Consider PET-CT scan  
Low suspicion of lung cancer → LDCT at 3 mo  
Suspicion of lung cancer → Biopsy or Surgical excision

≤10 mm non-solid or part-solid nodule → Radiologic surveillance  
See **NCCN Guidelines for Lung Cancer Screening**

>10 mm non-solid or part-solid nodule → LDCT in 3-6 mo  
Stable → LDCT in 6-12 mo or Biopsy or Consider surgical excision  
Increase in size → Surgical excision

**FOLLOW-UP**

- **c**
  - No cancer → See **NCCN Guidelines for Lung Cancer Screening**
  - Cancer confirmed → See NSCL-1 or appropriate NCCN Guidelines

**DISCUSSION**

- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Note: A positive PET result is defined as a standard uptake value (SUV) in the lung nodule greater than the baseline mediastinal blood pool. A positive PET scan finding can be caused by infection or inflammation, including absence of lung cancer with localized infection, presence of lung cancer with associated (eg, postobstructive) infection, and presence of lung cancer with related inflammation (nodal, parenchymal, pleural). A false-negative PET scan can be caused by a small nodule, low cellular density (nonsolid nodule or ground glass opacity [GGO]), or low tumor avidity for FDG (eg, adenocarcinoma in situ [previously known as bronchoalveolar carcinoma], carcinoid tumor).

**DIAG-2**
PRINCIPLES OF DIAGNOSTIC EVALUATION

- Patients with a strong clinical suspicion of stage I or II lung cancer (based on risk factors and radiologic appearance) do not require a biopsy before surgery.
  - A biopsy adds time, costs, and procedural risk and may not be needed for treatment decisions.
  - A preoperative biopsy may be appropriate if a non-lung cancer diagnosis is strongly suspected that can be diagnosed by FNA.
  - A preoperative biopsy may be appropriate if an intraoperative diagnosis appears difficult or very risky.
  - If a preoperative tissue diagnosis has not been obtained, then an intraoperative diagnosis (ie, wedge resection or needle biopsy) is necessary before lobectomy, bilobectomy, or pneumonectomy.

- Bronchoscopy should preferably be performed during the planned surgical resection, rather than as a separate procedure.
  - Bronchoscopy is required before surgical resection (see NSCL-2).
  - A separate bronchoscopy may not be needed for treatment decisions before the time of surgery and adds time, costs, and procedural risk.
  - A preoperative bronchoscopy may be appropriate if a central tumor requires pre-resection evaluation for biopsy, surgical planning (eg, potential sleeve resection), or preoperative airway preparation (eg, coring out an obstructive lesion).

- Invasive mediastinal staging is recommended before surgical resection for most patients with clinical stage I or II lung cancer (see NSCL-2).
  - Patients should preferably undergo invasive mediastinal staging as the initial step before the planned resection (during the same anesthetic procedure), rather than as a separate procedure.
  - A separate staging procedure adds time, costs, coordination of care, inconvenience, and an additional anesthetic risk.
  - Preoperative invasive mediastinal staging may be appropriate for a strong clinical suspicion of N2 or N3 nodal disease or when intraoperative cytology or frozen section analysis is not available.

- In patients with suspected NSCLC, many techniques are available for tissue diagnosis.
  - Diagnostic tools that should be routinely available include:
    - Sputum cytology
    - Bronchoscopy with biopsy and transbronchial needle aspiration (TBNA)
    - Image-guided transthoracic needle aspiration (TTNA)
    - Thoracentesis
    - Mediastinoscopy
    - Video-assisted thoracic surgery (VATS) and open surgical biopsy
  - Diagnostic tools that provide important additional strategies for biopsy include:
    - Endobronchial ultrasound (EBUS)–guided biopsy
    - Navigational bronchoscopy

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
The preferred diagnostic strategy for an individual patient depends on the size and location of the tumor, the presence of mediastinal or distant disease, patient characteristics (such as pulmonary pathology and/or other significant comorbidities), and local experience and expertise.

Factors to be considered in choosing the optimal diagnostic step include:

- Anticipated diagnostic yield (sensitivity)
- Diagnostic accuracy including specificity and particularly the reliability of a negative diagnostic study (that is, true negative)
- Adequate volume of tissue specimen for diagnosis and molecular testing
- Invasiveness and risk of procedure
- Efficiency of evaluation
  - Access and timeliness of procedure
  - Concomitant staging is beneficial, because it avoids additional biopsies or procedures. It is preferable to biopsy the pathology that would confer the highest stage (that is, to biopsy a suspected metastasis or mediastinal lymph node rather than the pulmonary lesion).
- Technologies and expertise available

Decisions about the optimal diagnostic steps for suspected stage I to III lung cancer should be made by thoracic radiologists, interventional radiologists, and board-certified thoracic surgeons who devote a significant portion of their practice to thoracic oncology. Multidisciplinary evaluation may also benefit from involvement of a pulmonologist with experience in advanced bronchoscopic techniques for diagnosis, depending on local expertise.

The least invasive biopsy with the highest yield is preferred as the first diagnostic study.

- Patients with central masses and suspected endobronchial involvement should undergo bronchoscopy.
- Patients with peripheral (outer one-third) nodules should have navigational bronchoscopy, radial EBUS, or TTNA.
- Patients with suspected nodal disease should be biopsied by EBUS, navigational bronchoscopy, or mediastinoscopy.
  - Esophageal ultrasound (EUS)–guided biopsy provides additional access to station 5, 7, 8, and 9 lymph nodes if these are clinically suspicious.
  - TTNA and anterior mediastinotomy (that is, Chamberlain procedure) provide additional access to anterior mediastinal (station 5 and 6) lymph nodes if these are clinically suspicious.
- Lung cancer patients with an associated pleural effusion should undergo thoracentesis and cytology. A negative cytology result on initial thoracentesis does not exclude pleural involvement. An additional thoracentesis and/or thorascoscopic evaluation of the pleura should be considered before starting curative intent therapy.
- Patients suspected of having a solitary site of metastatic disease should preferably have tissue confirmation of that site if feasible.
- Patients suspected of having metastatic disease should have confirmation from one of the metastatic sites if feasible.
- Patients who may have multiple sites of metastatic disease—based on a strong clinical suspicion—should have biopsy of the primary lung lesion or mediastinal lymph nodes if it is technically difficult or very risky to biopsy a metastatic site.
Non-Small Cell Lung Cancer (NSCLC) — Initial Evaluation

**Clinical Stage**

- **Stage I, peripheral (T1ab, N0)**
- **Mediastinal CT negative (lymph nodes <1 cm)**
- **Stage I, central (T1ab-T2a, N0)**
- **Stage IIA (T1-3, N1)**
- **Stage IIB (T3, N0)**
- **Mediastinal CT negative (lymph nodes <1 cm)**
- **Stage IIIB (T3 invasion, N0)**
- **Stage IIIA (T4 extension, N0-1; T3, N1)**
- **Stage IIIA (T1-3, N2)**
- **Separate pulmonary nodule(s)**
- **Multiple lung cancers**
- **Stage IIIB (T1-3, N3) mediastinal CT positive**
- **Contralateral (lymph nodes ≥1 cm) or palpable supraclavicular lymph nodes**
- **Stage IIIB (T4 extension, N2-3) on CT**
- **Stage IV (M1a)**
- **Solitary metastasis with resectable lung lesion**
- **Stage IV (M1b)**
- **Disseminated metastases**

**Initial Evaluation**

- **Pathology review**
- **H&P (include performance status + weight loss)**
- **CT chest and upper abdomen, including adrenals**
- **CBC, platelets**
- **Chemistry profile**
- **Smoking cessation advice, counseling, and pharmacotherapy**
- **Supportive Care**

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**See Principles of Pathologic Review (NSCL-A).**


**Based on the CT of the chest: Peripheral = outer third of lung. Central = inner two thirds of lung.**

**For patients considered to have stage IIB and stage III tumors, where more than one treatment modality (surgery, radiation therapy, or chemotherapy) is usually considered, a multidisciplinary evaluation should be performed.**
**NCCN Guidelines Version 2.2013**

**Non-Small Cell Lung Cancer**

---

### PRETREATMENT EVALUATION

**Stage IA (peripheral T1ab, N0)**
- PFTs (if not previously done)
- Bronchoscopy (intraoperative preferred)
- Pathologic mediastinal lymph node evaluation\(^g\) (category 2B)
- PET/CT scan\(^h\) (if not previously done)

**Stage IB (peripheral T2a, N0)**
- PFTs (if not previously done)
- Bronchoscopy
- Pathologic mediastinal lymph node evaluation\(^g\)
- PET/CT scan\(^h\) (if not previously done)
- Brain MRI (Stage II, Stage IA [category 2B])

**Stage I (central T1ab–T2a, N0)**
- PFTs (if not previously done)
- Bronchoscopy
- Pathologic mediastinal lymph node evaluation\(^g\)
- PET/CT scan\(^h\) (if not previously done)
- Brain MRI (Stage II, Stage IA [category 2B])

**Stage II (T1ab–2ab, N1; T2b, N0)**
- PFTs (if not previously done)
- Bronchoscopy
- Pathologic mediastinal lymph node evaluation\(^g\)
- PET/CT scan\(^h\) (if not previously done)
- Brain MRI (Stage II, Stage IA [category 2B])

**Stage IIB (T3, N0)**
- PFTs (if not previously done)
- Bronchoscopy
- Pathologic mediastinal lymph node evaluation\(^g\)
- PET/CT scan\(^h\) (if not previously done)
- Brain MRI (Stage II, Stage IA [category 2B])

---

\(^d\) T3, N0 related to size or satellite nodules.

\(^f\) Testing is not listed in order of priority and is dependent upon clinical circumstances, institutional processes, and judicious use of resources.

\(^g\) Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

\(^h\) Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

\(^i\) See Principles of Radiation Therapy (NSCL-B).

\(^j\) See Chemotherapy Regimens used with Radiation Therapy (NSCL-C).

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
# NCCN Guidelines Version 2.2013
## Non-Small Cell Lung Cancer

### INITIAL TREATMENT
- **Stage IA (T1ab, N0)**
  - Margins negative (R0)\(^m\)
  - Margins positive (R1, R2)\(^m\)
  - Observe
  - Reresection (preferred) or RT\(^i\) (category 2B)

- **Stage IB (T2a, N0); Stage II A (T2b, N0)**
  - Margins negative (R0)\(^m\)
  - Margins positive (R1, R2)\(^m\)
  - Observe or Chemotherapy\(^p\) (category 2B) in high-risk patients\(^o\)
  - Reresection (preferred) ± chemotherapy\(^p,q\) or RT\(^i,j\) ± chemotherapy\(^j,p\) (chemotherapy for stage IIA)

- **Stage II A (T1ab-T2a, N1); Stage II B (T3, N0; T2b, N1)**
  - Margins negative (R0)\(^m\)
  - Margins positive (R1, R2)\(^m,n\)
  - Chemoradiation\(^i,j,n\) + chemotherapy\(^j,p\)

- **Stage III A (T1-3, N2; T3, N1)**
  - Margins negative (R0)\(^m\)
  - Margins positive (R1, R2)\(^m,n\)
  - Chemotherapy\(^p\) (category 1) + RT\(^i\)

### FINDINGS AT SURGERY
- Surgical exploration and resection\(^k\) + mediastinal lymph node dissection or systematic lymph node sampling\(^l\)
- \(^m\)R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.
- \(^n\)The panel recommends concurrent chemoradiation for R2 resections and sequential chemoradiation for R1 resections.

### ADJUVANT TREATMENT
- High-risk patients are defined by poorly differentiated tumors (including lung neuroendocrine tumors [excluding well-differentiated neuroendocrine tumors]), vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, and incomplete lymph node sampling (Nx). These factors independently may not be an indication and may be considered when determining treatment with adjuvant chemotherapy. (See Principles of Surgical Therapy, NSCL-D)
- \(^o\)High-risk patients are defined by poorly differentiated tumors (including lung neuroendocrine tumors [excluding well-differentiated neuroendocrine tumors]), vascular invasion, wedge resection, tumors >4 cm, visceral pleural involvement, and incomplete lymph node sampling (Nx). These factors independently may not be an indication and may be considered when determining treatment with adjuvant chemotherapy. (See Principles of Surgical Therapy, NSCL-D)

### Note:
- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Discussion

Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan positive in the mediastinum, lymph node status needs pathologic confirmation.

### Note:

All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### NCCN Guidelines Version 2.2013
Non-Small Cell Lung Cancer

#### CLINICAL PRESENTATION

<table>
<thead>
<tr>
<th>Condition</th>
<th>Initial Treatment</th>
<th>Adjuvant Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Superior sulcus tumor (T3 invasion, N0-1)</td>
<td>Preoperative concurrent chemoradiation</td>
<td>Surgery + chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surgery + chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surgical reevaluation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Resectable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unresectable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Complete definitive RT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chemotherapy if not given as initial treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reresection + chemotherapy if not given as initial treatment</td>
</tr>
<tr>
<td>Superior sulcus tumor (T4 extension, N0-1)</td>
<td>Preoperative concurrent chemoradiation</td>
<td>Surgery (preferred) or Concurrent chemoradiation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Margins negative (R0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Margins positive (R1, R2)</td>
</tr>
<tr>
<td>Marginally resectable</td>
<td>Definitive concurrent chemoradiation</td>
<td>Surgery</td>
</tr>
<tr>
<td>Unresectable</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**NCCN Guidelines Version 2.2013\(^\text{a}\)**

**Non-Small Cell Lung Cancer**

### CLINICAL ASSESSMENT

#### PRETREATMENT EVALUATION

- **Stage IIIA (T1–3, N2)**
  - PFTs (if not previously done)
  - Bronchoscopy
  - Pathologic mediastinal lymph node evaluation\(^g\)
  - PET/CT scan\(^h\) (if not previously done)
  - Brain MRI

- **Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)**
  - PFTs (if not previously done)
  - Bronchoscopy
  - Pathologic mediastinal lymph node evaluation\(^g\)
  - Brain MRI
  - PET/CT scan\(^h\) (if not previously done)

### MEDIASTINAL BIOPSY FINDINGS AND RESECTABILITY

- N2, N3 nodes negative
  - See Treatment T 1-3, N0-1 (NSCL-7)
- N2 nodes positive
  - See Treatment (NSCL-7)
- N3 nodes positive
  - See Stage IIIB (NSCL-10)
- Metastatic disease
  - See Treatment for Metastasis solitary site (NSCL-12) or distant disease (NSCL-14)
- Separate pulmonary nodule(s), same lobe (T3, N0) or ipsilateral non-primary lobe (T4, N0)

- Stage IV (N0, M1a):
  - Contralateral lung (solitary nodule)
  - See Treatment (NSCL-8)
- Extrathoracic metastatic disease
  - See Treatment for Metastasis solitary site (NSCL-12) or distant disease (NSCL-14)

\(^g\)Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

\(^h\)Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

\(\text{NSCL-6}\)
# NCCN Guidelines Version 2.2013
## Non-Small Cell Lung Cancer

### MEDIASTINAL BIOPSY FINDINGS

<table>
<thead>
<tr>
<th>T1-3, N0-1 (including T3 with multiple nodules in same lobe)</th>
<th>Resectable</th>
<th>Surgery[^k]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unresectable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T1-2, T3 (≥7 cm), N2 nodes positive[^k]</th>
<th>・Brain MRI</th>
<th>・PET/CT scan[^h], if not previously done</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative for M1 disease</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>T3 (invasion), N2 nodes positive</th>
<th>・Brain MRI</th>
<th>・PET/CT scan[^h], if not previously done</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative for M1 disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[^h]: Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

[^i]: See Principles of Radiation Therapy (NSCL-B).

[^j]: See Chemotherapy Regimens used with Radiation Therapy (NSCL-C).

[^k]: See Principles of Surgical Therapy (NSCL-D).

### INITIAL TREATMENT

<table>
<thead>
<tr>
<th>Surgical resection[^k] + mediastinal lymph node dissection or systematic lymph node sampling</th>
<th>N0–1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margins negative (R0)[^m]</td>
<td>N2</td>
</tr>
<tr>
<td>Margins positive (R1, R2)[^m,n]</td>
<td></td>
</tr>
</tbody>
</table>

### ADJUVANT TREATMENT

<table>
<thead>
<tr>
<th>Chemotherapy[^p] (category 1) + RT[^i]</th>
<th>Surgery[^k] ± chemotherapy[^p] (category 2B) ± RT[^i] (if not given)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemoradiation[^i,j,n] + chemotherapy[^i,p]</td>
<td>RT[^i] (if not given) ± chemotherapy[^p]</td>
</tr>
</tbody>
</table>

[^m]: R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.

[^n]: The panel recommends concurrent chemoradiation for R2 resections and sequential chemoradiation for R1 resections.

[^p]: See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-E).

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)\(^i\)\(^u\)  
- Separate pulmonary nodule(s), same lobe (T3, N0) or ipsilateral non-primary lobe (T4, N0)  
  - Surgery\(^k\)  
  - N0–1  
    - See NSCL-3 for T3 or NSCL-5 for T4  
    - Margins negative (R0)\(^m\)  
      - Chemotherapy\(^p\) + RT\(^i\)  
    - N2  
      - Margins positive (R1, R2)\(^m,n\)  
      - Chemoradiation\(^i,j,n\) + chemotherapy\(^i,p\)  
      - Surveillance (NSCL-13)  
- Disease outside of chest  
  - See Systemic Therapy for Metastatic Disease (NSCL-15)  
  - Pathologic mediastinal lymph node evaluation\(^g\)  
  - N2-3  
  - See Systemic Therapy for Metastatic Disease (NSCL-15)  
  - N0-1  
  - See Initial Treatment (NSCL-9)  
- No disease outside of chest  
  - Surveillance (NSCL-13)  
- No disease outside of chest  
  - See Initial Treatment (NSCL-9)  
- Stage IV (N0, M1a): Contralateral lung (solitary nodule)  
  - Treat as two primary lung tumors if both curable  
  - See Evaluation (NSCL-1)  

Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.  
Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.  
See Principles of Radiation Therapy (NSCL-B).  
See Chemotherapy Regimens used with Radiation Therapy (NSCL-C).  
See Principles of Surgical Therapy (NSCL-D).  
R0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.  
The panel recommends concurrent chemoradiation for R2 resections and sequential chemoradiation for R1 resections.  
See Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy (NSCL-E).  
Lesions with different cell types (eg, squamous cell carcinoma and adenocarcinoma) may be different primary tumors. This analysis may be limited by small biopsy samples. However, lesions of the same cell type are not necessarily metastases.  
For guidance regarding the evaluation, workup, and management of subsolid pulmonary nodules, please see the diagnostic evaluation of a nodule suspicious for lung cancer (DIAG-1).
Clinical Management

**INITIAL TREATMENT**

- **Multiple lung cancers**
  - **Asymptomatic**
    - **Multiple lesions**
      - **Low risk of becoming symptomatic**
        - **Observation**
          - **Surveillance** (NSCL-13)
      - **High risk of becoming symptomatic**
        - **Definitive local therapy possible**
          - **Definitive local therapy not possible**
            - **Consider palliative chemotherapy ± local palliative therapy**
  - **Symptomatic**
    - **Solitary lesion (metachronous disease)**
      - **Definitive local therapy possible**
      - **Definitive local therapy not possible**
        - **Consider palliative chemotherapy ± local palliative therapy**

---

**Discussion**

- **Note:** All recommendations are category 2A unless otherwise indicated.
  - Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**References**

- See Principles of Radiation Therapy (NSCL-B).
- See Principles of Surgical Therapy (NSCL-D).
- Lesions at low risk of becoming symptomatic can be observed. However, if the lesion(s) becomes symptomatic or becomes high risk for producing symptoms, treatment should be considered.
- Lung-sparing resection is preferred, but tumor distribution and institutional expertise should guide individual treatment planning.
Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan positive in the mediastinum, lymph node status needs pathologic confirmation.

If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 4 cycles of full-dose chemotherapy.

See Principles of Radiation Therapy (NSCL-B).

See Chemotherapy Regimens used with Radiation Therapy (NSCL-C).

If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 4 cycles of full-dose chemotherapy.
## CLINICAL ASSESSMENT

<table>
<thead>
<tr>
<th>Stage IIIB (T4 extension, N2–3)</th>
<th>PRETREATMENT EVALUATION</th>
<th>INITIAL TREATMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• PET/CT scan(^h) (if not previously done)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Brain MRI</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pathologic confirmation of N2–3 disease by either:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ Mediastinoscopy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ Supraclavicular lymph node biopsy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ Thoracoscopy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ Needle biopsy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ Mediastinotomy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ EUS biopsy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▶ EBUS biopsy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contralateral mediastinal node negative (T4, N3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ipsilateral mediastinal node negative (T4, N0-1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ipsilateral mediastinal node positive (T4, N2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Contralateral mediastinal node positive (T4, N3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic disease</td>
<td></td>
</tr>
</tbody>
</table>

### Stage IV, M1a: pleural or pericardial effusion

- Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate

  - Negative\(^x\)

  - Positive\(^x\)

### Discussion

\(^h\) Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

\(^i\) See Principles of Radiation Therapy (NSCL-B).

\(^j\) See Chemotherapy Regimens used with Radiation Therapy (NSCL-C).

\(^s\) If full-dose chemotherapy is not given concurrently with RT as initial treatment, give additional 4 cycles of full-dose chemotherapy.

\(^x\) While most pleural effusions associated with lung cancer are due to tumor, there are a few patients in whom multiple cytopathologic examinations of pleural fluid are negative for tumor and fluid is non-bloody and not an exudate. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element. Pericardial effusion is classified using the same criteria.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**PRETREATMENT EVALUATION**

**CLINICAL ASSESSMENT**

- Pathologic mediastinal lymph node evaluation\(^g\)
- Bronchoscopy
- Brain MRI
- PET/CT scan\(^h\) (if not previously done)

**Stage IV, M1b: solitary site**

Brain\(^y\) → Surgical resection, followed by whole brain RT (WBRT) (category 1) or stereotactic radiosurgery (SRS) or SRS + WBRT (category 1 for one metastasis) or SRS alone

**Adrenal** → Pathologic diagnosis by needle or resection

- Local therapy for adrenal lesion (if lung lesion\(^2\) curable, based on T and N stage) (category 2B)\(^a^a\) or See Systemic Therapy for Metastatic Disease (NSCL-15)

**INITIAL TREATMENT**

- Surgical resection of lung lesion\(^k\) or Stereotactic ablative radiotherapy (SABR) of lung lesion or Chemotherapy\(^b^b\) → Surgical resection of lung lesion\(^k\)

- T1-2, N0-1; T3, N0

- T1-2, N2; T3, N1-2; Any T, N3; T4, Any N

\(^g\)Methods for evaluation include mediastinoscopy, mediastinotomy, EBUS, EUS, and CT-guided biopsy.

\(^h\)Positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If PET/CT scan is positive in the mediastinum, lymph node status needs pathologic confirmation.

\(^k\)See Principles of Surgical Therapy (NSCL-D).

\(^y\)See NCCN Guidelines for Central Nervous System Cancers.

\(^a^a\)Patients with N2 disease have a poor prognosis and systemic therapy should be considered.

\(^b^b\)See Systemic Therapy for Advanced or Metastatic Disease (NSCL-F).

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
No evidence of clinical/radiographic disease), stages I-IV:
- H&P and chest CT ± contrast every 6-12 mo for 2 y (category 2B), then H&P and a non-contrast-enhanced chest CT annually (category 2B)
- Smoking cessation advice, counseling, and pharmacotherapy
- PET or brain MRI is not indicated
- See Cancer Survivorship Care (NSCL-G).

Locoregional recurrence

Distant metastases

See Therapy for Recurrence and Metastasis (NSCL-14)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
THERAPY FOR RECURRENCE AND METASTASIS

Locoregional recurrence

- **Endobronchial obstruction**
  - Laser/stent/other surgery
  - External-beam RT or brachytherapy
  - Photodynamic therapy

- **Resectable recurrence**
  - Resection (preferred)
  - External-beam RT or SABR

- **Mediastinal lymph node recurrence**
  - Concurrent chemoradiation (if RT not previously given)

- **Superior vena cava (SVC) obstruction**
  - Concurrent chemoradiation (if not previously given)
  - External-beam RT
  - SVC stent

- **Severe hemoptysis**
  - External-beam RT or brachytherapy
  - Laser or photodynamic therapy or embolization
  - Surgery

Distant metastases

- **Localized symptoms**
  - Palliative external-beam RT

- **Diffuse brain metastases**
  - Palliative external-beam RT

- **Bone metastasis**
  - Palliative external-beam RT + orthopedic stabilization, if risk of fracture
  - Consider bisphosphonate therapy or denosumab

- **Solitary metastasis**
  - See pathway for Stage IV, M1b, solitary site (NSCL-12)

- **Disseminated metastases**
  - See Systemic Therapy for Metastatic Disease (NSCL-15)

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

1 See Principles of Radiation Therapy (NSCL-B).
2 See NCCN CNS Guidelines.
3 See Systemic Therapy for Advanced or Metastatic Disease (NSCL-F).
**NSCL-15**

**Metastatic Disease**

- Establish histologic subtype\(^a\) with adequate tissue for molecular testing
- Smoking cessation counseling

**HISTOLOGIC SUBTYPE**

- **Adenocarcinoma**
- **Large Cell**
- **NSCLC NOS**

- **EGFR mutation testing\(^a\)** (category 1)
- **ALK testing\(^a,cc\)**

**EGFR mutation or ALK negative**

- **See First-Line Therapy (NSCL-16)**

**EGFR mutation positive**

- **See First-Line Therapy (NSCL-17)**

**ALK positive**

- **See First-Line Therapy (NSCL-17)**

**Squamous cell carcinoma**

- EGFR mutation and ALK testing are not routinely recommended\(^d\) except in never smokers and small biopsy specimens\(^e\)

- **See First-Line Therapy (NSCL-18)**

---

\(^a\) See Principles of Pathologic Review (NSCL-A).


\(^dd\) In patients with squamous cell carcinoma, the observed incidence is 2.7% with a confidence that the true incidence of mutations is less than 3.6% in patients with squamous cell carcinoma. This frequency of EGFR mutations does not justify routine testing of all tumor specimens. Forbes SA, Bharma G, Bamford S, et al. The catalogue of somatic mutations in cancer (COSMIS). Curr Protoc Hum Genet 2008;chapter 10:unit 10.11.


**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
ADENOCARCINOMA, LARGE CELL, NSCLC NOS: EGFR MUTATION AND ALK NEGATIVE

**FIRST-LINE THERAPY**

- **Doublet chemotherapy**<sup>bb</sup> (category 1) or
- **Bevacizumab + chemotherapy**<sup>bb,ff,gg</sup> (if criteria met)<sup>hh</sup> or
- **Cisplatin/pemetrexed** (category 1) (if criteria met)<sup>ii</sup> or
- **Cetuximab/vinorelbine/cisplatin**<sup>jj</sup> (category 2B)

**RESPONSE EVALUATION**

- **Tumor response evaluation**

**MAINTENANCE THERAPY**

- **Continuation of current regimen until disease progression** or
- **Continuation maintenance**<sup>bb</sup> bevacizumab (category 1) or cetuximab (category 1) or pemetrexed (category 1) or bevacizumab + pemetrexed<sup>kk</sup> or gemcitabine<sup>ll</sup> or
- **Switch maintenance**<sup>bb</sup> pemetrexed or erlotinib or
- **Close observation**

**PS 0-1**

- **Chemotherapy**<sup>bb</sup>

**PS 2**

- **Best supportive care only**

(See NCCN Guidelines for Palliative Care)

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

<sup>bb</sup>See Systemic Therapy for Advanced or Metastatic Disease (NSCL-F).
<sup>ff</sup>Bevacizumab should be given until progression.
<sup>gg</sup>Any regimen with a high risk of thrombocytopenia and the potential risk of bleeding should be used with caution in combination with bevacizumab.
<sup>hh</sup>Criteria for treatment with bevacizumab + chemotherapy: non-squamous NSCLC, and no recent history of hemoptysis. Bevacizumab should not be given as a single agent, unless as maintenance if initially used with chemotherapy.

<sup>kk</sup>Bevacizumab was used with a first-line pemetrexed/platinum chemotherapy regimen.


---

**NSCL-16**
ADENOCARCINOMA, LARGE CELL, NSCLC NOS: EGFR MUTATION OR ALK POSITIVE

FIRST-LINE THERAPY

EGFR mutation positive

- EGFR mutation discovered prior to first-line chemotherapy
  - Erlotinib^mm,nn,oo (category 1) → Progression^qq,rr
- EGFR mutation discovered during first-line chemotherapy
  - Switch maintenance: erlotinib^oo or May add erlotinib^oo,pp to current chemotherapy
- Biopsy on progression to determine mechanism of acquired resistance, because proportion of patients will transform to SCLC at progression.
- Beware of flare phenomenon in subset of patients who discontinue EGFR TKI. If disease flare occurs, restart EGFR TKI.

ALK positive

- Crizotinib^cc → Progression → See Second-line Therapy (NSCL-19)

^bb See Systemic Therapy for Advanced or Metastatic Disease (NSCL-F).
^oo For performance status 0-4.
^pp In areas of the world where gefitinib is available, it may be used in place of erlotinib.
^rr Beware of flare phenomenon in subset of patients who discontinue EGFR TKI. If disease flare occurs, restart EGFR TKI.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SQUAMOUS CELL CARCINOMA

FIRST-LINE THERAPY

**PS 0-1**
- Doublet chemotherapy\(^{bb}\) *(category 1)*
- Cetuximab/vinorelbine/cisplatin\(^{ll}\) *(category 2B)*

**PS 2**
- Chemotherapy\(^{bb}\)

**PS 3-4**
- Best supportive care
  - See NCCN Guidelines for Palliative Care

RESPONSE EVALUATION

- Tumor response or stable disease
  - Progression
    - Tumor response evaluation
    - 4-6 cycles (total)
    - Tumor response evaluation

- Continuation of current regimen until disease progression or
  - Continuation maintenance\(^{bb}\)
    - Cetuximab (category 1) or gemcitabine\(^{ll}\)
    - Switch maintenance\(^{bb}\)
      - Erlotinib or docetaxel (category 2B)
      - Close observation

MAINTENANCE THERAPY

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

\(^{bb}\) See Systemic Therapy for Advanced or Metastatic Disease (NSCL-F).


**SECOND-LINE THERAPY**

- **Performance status 0-2**
  - Docetaxel\(^{bb}\) or Pemetrexed (nonsquamous)\(^ {bb}\) or Erlotinib\(^ {bb,oo}\) or Platinum doublet ± bevacizumab (if erlotinib or crizotinib given as first-line and nonsquamous histologic type)
  - Progression

- **Performance status 3-4**
  - Erlotinib\(^ {bb,oo,ss}\) or Best supportive care only (See NCCN Guidelines for Palliative Care)

**THIRD-LINE THERAPY**

- If not already given: Docetaxel\(^ {bb}\) or Pemetrexed (nonsquamous)\(^ {bb}\) or Erlotinib\(^ {bb,oo}\)
  - Performance status 0-2
  - Progression

- Performance status 3, 4
  - Erlotinib\(^ {bb,oo,ss}\) or Best supportive care only (See NCCN Guidelines for Palliative Care)

**Best supportive care only** (See NCCN Guidelines for Palliative Care)

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

\(^{bb}\) See Systemic Therapy for Advanced or Metastatic Disease (NSCL-F).

\(^{oo}\) In areas of the world where gefitinib is available, it may be used in place of erlotinib.

\(^{ss}\) Erlotinib may be considered for PS 3 and 4 patients with EGFR mutation.
PRINCIPLES OF PATHOLOGIC REVIEW (1 of 4)

Pathologic Evaluation
- The purpose of pathologic evaluation is to classify the histologic type of lung cancer and to determine all staging parameters as recommended by the AJCC, including tumor size, the extent of invasion (pleural and bronchial), adequacy of surgical margins, and presence or absence of lymph node metastasis. Further, determination of the specific molecular abnormalities of the tumor is critical for predicting sensitivity or resistance to an increasing number of drugable targets, primarily tyrosine kinase inhibitors (TKIs) (see Molecular Diagnostic Studies in this section).
- The WHO tumor classification system has historically provided the foundation for the classification of lung tumors, including histologic types, clinical features, staging considerations, and the molecular, genetic, and epidemiologic aspects of lung cancer.
- The pathology diagnostic report should include the histologic classification as described by the WHO for carcinomas of the lung with squamous morphology, neuroendocrine differentiation, and other variant carcinomas. The recently published classification of adenocarcinoma should be used for this tumor subtype in resection specimens and small biopsies. Use of bronchioloalveolar carcinoma (BAC) terminology is strongly discouraged.
- The generic term “non-small cell lung cancer (NSCLC)” should be avoided as a single diagnostic term. In small biopsies of poorly differentiated carcinomas where immunohistochemistry (IHC) is used, the following terms are acceptable: “NSCLC favor adenocarcinoma” or “NSCLC favor squamous cell carcinoma.” Mutational testing (eg, epidermal growth factor receptor [EGFR]) should be performed in this setting.
- Although formalin-fixed paraffin-embedded tumor may be used for most molecular analyses, acquisition of fresh cryopreserved tumor tissue for advanced molecular studies should be considered.
- Limited use of IHC studies in small tissue samples is strongly recommended, thereby preserving critical tumor tissue for molecular studies, particularly in patients with advanced-stage disease. A limited panel of p63 and TTF-1 should suffice for most diagnostic problems.

Adenocarcinoma Classification
- Adenocarcinoma in situ (AIS; formerly BAC): ≤3 cm nodule, lepidic growth, mucinous, non-mucinous, or mixed mucinous/non-mucinous types.
- Minimally invasive adenocarcinoma (MIA): ≤3 cm nodule with ≤5 mm of invasion, lepidic growth, mucinous, non-mucinous, or mixed mucinous/non-mucinous types.
- Invasive adenocarcinoma, predominant growth pattern: lepidic >5 mm of invasion, acinar, papillary, micropapillary, or solid with mucin
- Invasive adenocarcinoma variants: mucinous adenocarcinoma, colloid, fetal, and enteric morphologies.
Immunohistochemical Staining

- Although the concordance is generally good between the histologic subtype and the immunophenotype seen in small biopsies compared with surgical resection specimens, caution is advised in attempting to subtype small biopsies with limited material or cases with an ambiguous immunophenotype.
- IHC should be used to differentiate primary pulmonary adenocarcinoma from the following—squamous cell carcinoma, large cell carcinoma, metastatic carcinoma, and malignant mesothelioma—and to determine whether neuroendocrine differentiation is present.9-11

Primary pulmonary adenocarcinoma

- An appropriate panel of immunohistochemical stains is recommended to exclude metastatic carcinoma to the lung.12
- TTF-1 is a homeodomain-containing nuclear transcription protein of the Nkx2 gene family that is expressed in epithelial cells of the embryonal and mature lung and thyroid. TTF-1 immunoreactivity is seen in primary pulmonary adenocarcinoma in the majority (70%-100%) of non-mucinous adenocarcinomas subtypes.13 Metastatic adenocarcinoma to the lung is virtually always negative for TTF-1 except in metastatic thyroid malignancies, in which case thyroglobulin is also positive.
- Napsin A—an aspartic proteinase expressed in normal type II pneumocytes and in proximal and distal renal tubules—appears to be expressed in >80% of lung adenocarcinomas and may be a useful adjunct to TTF-1.12
- The panel of TTF-1 and p63 (or alternatively p40) may be useful in refining the diagnosis to either adenocarcinoma or squamous cell carcinoma in small biopsy specimens previously classified as NSCLC, not otherwise specified (NOS).8

Neuroendocrine differentiation

- CD56, chromogranin, and synaptophysin are used to identify neuroendocrine tumors.
- Malignant mesothelioma versus pulmonary adenocarcinoma
  - The distinction between pulmonary adenocarcinoma and malignant mesothelioma (epithelial type) is made by using a panel of markers, including 2 with known immunopositivity in mesothelioma (but negative in adenocarcinoma) and 2 with known positivity in adenocarcinoma (but negative in mesothelioma).11
  - Immunostains relatively sensitive and specific for mesothelioma include WT-1, calretinin, D2-40, HMBE-1, and cytokeratin 5/6 (negative in adenocarcinoma).14,15
  - Antibodies immunoreactive in adenocarcinoma include CEA, B72.3, Ber-EP4, MOC31, CD15, and TTF-1 (negative in mesothelioma).8,11

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Molecular Diagnostic Studies in Lung Cancer

**EGFR and KRAS**
- EGFR is normally found on the surface of epithelial cells and is often overexpressed in a variety of human malignancies. Presence of EGFR-activating mutations represents a significant biological determinant for proper therapy selection in patients with lung cancer.
- There is a significant association between EGFR mutations—especially exon 19 deletion and exon 21 (L858R) and exon 18 (G719X) mutations—and sensitivity to TKIs.\(^{16-19}\)
- The exon 20 insertion mutation may predict resistance to clinically achievable levels of TKIs.\(^{20,21}\)
- EGFR and KRAS mutations are mutually exclusive in patients with lung cancer.\(^{22}\)
- KRAS mutations are associated with intrinsic TKI resistance, and KRAS gene sequencing could be useful for the selection of patients as candidates for TKI therapy.\(^{23}\)

The prevalence of EGFR mutations in adenocarcinomas is 10% of Western and up to 50% of Asian patients, with higher EGFR mutation frequency in non-smokers, women, and non-mucinous cancers. KRAS mutations are most common in non-Asians, smokers, and in mucinous adenocarcinoma.\(^{24}\) The most common EGFR mutations result in an arginine for leucine substitution at amino acid 858 in exon 21 (L858R) and in frame deletions at exon 19. Mutations are more common in non-mucinous lung adenocarcinoma with lepidic pattern (former BAC pattern) and in lung adenocarcinoma with papillary (and or micropapillary) pattern.

Primary resistance to TKI therapy is associated with KRAS mutation. Acquired resistance is associated with second-site mutations within the EGFR kinase domain, amplification of alternative kinases (such as MET), histologic transformation from NSCLC to SCLC, and epithelial to mesenchymal transition (EMT).

**ALK**
- Anaplastic lymphoma kinase (ALK) gene rearrangements represent the fusion between ALK and various partner genes, including echinoderm microtubule-associated protein-like 4 (EML4).\(^{25}\) ALK fusions have been identified in a subset of patients with NSCLC and represent a unique subset of NSCLC patients for whom ALK inhibitors may represent a very effective therapeutic strategy.\(^{26}\)
  - Crizotinib is an oral ALK inhibitor that is approved by the FDA for patients with locally advanced or metastatic NSCLC who have the ALK gene rearrangement (ie, ALK positive).

ALK NSCLC occurs most commonly in a unique subgroup of NSCLC patients who share many of the clinical features of NSCLC patients likely to harbor EGFR mutations.\(^ {27,28}\) However, for the most part, ALK translocations and EGFR mutations are mutually exclusive.\(^ {27,29-31}\) ALK translocations tend to occur in younger patients and in those with more advanced NSCLC, though this relationship has not been reported for EGFR mutant NSCLC.\(^ {31,32}\)

- The current standard method for detecting ALK NSCLC is fluorescence in situ hybridization (FISH), although other methods are currently being evaluated, including polymerase chain reaction (PCR) and IHC. A big advantage of FISH is that a commercially available probe set, developed for the diagnosis of ALK-rearranged anaplastic large cell lymphomas (ALCL), is applicable for the diagnosis of ALK-rearranged lung adenocarcinomas. The IHC tests used to diagnose ALK-rearranged ALCLs in clinical laboratories worldwide are inadequate for the detection of most ALK-rearranged lung adenocarcinomas.\(^ {33,34}\)
  - This inadequacy is because of the lower level of ALK expression in ALK-rearranged NSCLCs compared with ALK-rearranged ALCLs. A molecular diagnostic test that uses FISH was recently approved by the FDA to determine which patients with lung adenocarcinoma are ALK positive.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF PATHOLOGIC REVIEW (4 of 4) - References

**General Principles** (see Table 1. Commonly Used Abbreviations in Radiation Therapy)

- Determination of the appropriateness of radiation therapy (RT) should be made by board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice.
- RT has a potential role in all stages of NSCLC, as either definitive or palliative therapy. Radiation oncology input as part of a multidisciplinary evaluation or discussion should be provided for all patients with NSCLC.
- The critical goals of modern RT are to maximize tumor control and to minimize treatment toxicity. A minimum technological standard is CT-planned 3D-CRT.¹
- More advanced technologies are appropriate when needed to deliver curative RT safely. These technologies include (but are not limited to) 4D-CT and/or PET-CT simulation, IMRT/VMAT, IGRT, motion management, and proton therapy. Nonrandomized comparisons of using advanced technologies versus older techniques demonstrate reduced toxicity and improved survival.²⁻⁴
- Centers using advanced technologies should implement and document modality-specific quality assurance measures. The ideal is external credentialing of both treatment planning and delivery such as required for participation in RTOG clinical trials employing advanced technologies. Useful references include the ACR-ASTRO Practice Guidelines for Radiation Oncology (http://www.acr.org/~/media/ACR/Documents/PGTS/toc.pdf).

**Early-Stage NSCLC (Stage I)**

- SABR (also known as SBRT) is recommended for patients who are medically inoperable and who refuse to have surgery after thoracic surgery evaluation. SABR has achieved primary tumor control rates and overall survival, comparable to lobectomy and higher than 3D-CRT in nonrandomized and population-based comparisons in medically inoperable or older patients.⁵⁻¹⁰
- SABR is also an appropriate option for patients with high surgical risk (able to tolerate sublobar resection but not lobectomy, eg, ≥ age 75, poor lung function). SABR and sublobar resection achieve comparable cancer-specific survival and primary tumor control.⁶⁻¹² A prospective randomized cooperative group trial of sublobar resection versus SABR is ongoing.
- For institutions without an established SABR program, more modestly hypofractionated or dose-intensified conventionally fractionated 3D-CRT regimens are alternatives.¹³⁻¹⁴
- In patients treated with surgery, postoperative radiotherapy (PORT) is not recommended unless there are positive margins or upstaging to N2 (see Locally Advanced NSCLC below).

**Locally Advanced NSCLC (Stage II-III)**

- The standard of care for patients with inoperable stage II and stage III is concurrent chemoRT.¹⁵⁻¹⁷
  - http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/NonsurgicalTreatmentForNSCLCGoodPerformanceStatusDefinitiveIntent.pdf RT interruptions and dose reductions for manageable acute toxicities should be avoided by employing supportive care.
  - Sequential chemoRT or RT alone is appropriate for frail patients unable to tolerate concurrent therapy.¹⁶,¹⁹

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIATION THERAPY (2 of 9)

Locally Advanced NSCLC (Stage II-III) (continued)

- Accelerated RT regimens may be beneficial, particularly if not concurrent with chemotherapy (ie, in a sequential or RT-only approach).^{20,21}
- RT has a role before or after surgery.
  - Preoperative concurrent chemoRT is an option for patients with resectable stage IIIA (minimal N2 and treatable with lobectomy)^{22} and is recommended for resectable superior sulcus tumors.^{23-24}
  - Preoperative chemotherapy and postoperative RT is an alternative for patients with resectable stage IIIA.^{25,26}
  - The determination of resectability in trimodality therapy should be made prior to initiation of all treatment.
  - In patients with clinical stage I/II upstaged surgically to N2+, PORT appears to improve survival significantly as an adjunct to postoperative chemotherapy in non-randomized analyses.^{27,28} Although, the optimal sequence is not established, PORT is generally administered before postoperative chemotherapy. PORT with concurrent chemotherapy can be administered safely in medically fit patients^{29-31} and is recommended for positive resection margins.
  - PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques.^{32}

Advanced/Metastatic NSCLC (Stage IV)

- RT is recommended for local palliation or prevention of symptoms (such as pain, bleeding, or obstruction).
- Definitive local therapy to isolated or limited metastatic sites (oligometastases) (including but not limited to brain, lung, and adrenal gland) achieves prolonged survival in a small proportion of well-selected patients with good performance status who have also received radical therapy to the intrathoracic disease. Definitive RT to oligometastases, particularly SABR, is an appropriate option in such cases if it can be delivered safely to the involved sites.^{33-35}
- See the NCCN Guidelines for CNS Cancers regarding RT for brain metastases.

Target Volumes, Prescription Doses, and Normal Tissue Dose Constraints (See Tables 2-5 on NSCLB 6 of 9 and NSCLC 7 of 9)

- ICRU Reports 62 and 83 detail the current definitions of target volumes for 3D-RT and IMRT. GTV comprises the known extent of disease (primary and nodal) on imaging and pathologic assessment, CTV includes regions of presumed microscopic extent or dissemination, and PTV comprises the ITV (which includes margin for target motion) plus a set-up margin for positioning and mechanical variability.
  - See the NCCN Guidelines for CNS Cancers regarding RT for brain metastases.
- PTV margin can be decreased by immobilization, motion management, and IGRT techniques.
- Consistent delineation of normal structures is critical for evaluating plans for safety. The RTOG consensus lung contouring atlas is a useful resource.
- Commonly used prescription doses and normal tissue dose constraints are summarized in Tables 2-5. These are based on published experience, ongoing trials, historical data, modeling, and empirical judgment.^{37,38} Useful references include the recent reviews of normal organ dose responses from the QUANTEC project.^{39-43}
Node-negative early-stage SABR

- The high-dose intensity and conformity of SABR require minimizing the PTV.
- For SABR, intensive regimens of BED ≥ 100 Gy are associated with significantly better local control and survival than less intensive regimens. In the United States, only regimens of ≤ 5 fractions meet the arbitrary billing code definition of SBRT, but slightly more protracted regimens are appropriate as well. For centrally located tumors (defined as within 2 cm of the proximal bronchial tree), 4-10 fraction risk-adapted SABR regimens appear to be effective and safe, while 54-60 Gy in 3 fractions is unsafe and should be avoided. The dose for 5-fraction regimens is being studied prospectively in RTOG 0813.
- SABR is most commonly used for tumors up to 5 cm in size, though selected larger isolated tumors can be treated safely if normal tissue constraints are respected.
- Prescriptions doses incompletely describe the actual delivered doses, which also depend strongly on how the dose is prescribed (to the isocenter vs. an isodose volume covering a proportion of the PTV), the degree of dose heterogeneity, whether tissue density heterogeneity corrections are used, and the type of dose calculation algorithm. All of these must be considered when interpreting or emulating regimens from prior studies.

Locally advanced stage/conventionally fractionated RT

- IFI omitting ENI allows tumor dose escalation and is associated with a low risk of isolated nodal relapse, particularly in PET-CT staged patients. One randomized trial found improved survival for IFI versus ENI, possibly because it enabled dose escalation. IFI is reasonable in order to optimize definitive dosing to the tumor.
- The most commonly prescribed doses for definitive RT are 60-70 Gy in 2 Gy fractions. Doses of at least 60 Gy should be given. Dose escalation in RT alone, sequential chemoRT, or concurrent chemoRT is associated with better survival in non-randomized comparisons. Doses of up to 74 Gy with concurrent chemotherapy can be delivered safely when normal tissue dose constraints are respected. The final results from RTOG 0617, comparing 60 versus 74 Gy with concurrent chemotherapy are pending, but preliminarily, 74 Gy was not associated with improved overall survival at 1 year.
- Doses of 45 to 50 Gy in 1.8 to 2 Gy fractions are standard preoperative doses. Definitive RT doses delivered as preoperative chemoRT can safely be administered and achieve promising nodal clearance and survival rates, but require experience in thoracic surgical techniques to minimize the risk of surgical complications after high-dose RT.
- In PORT, the CTV includes the bronchial stump and high-risk draining lymph node stations. Standard doses after complete resection are 50 to 54 Gy in 1.8 to 2 Gy fractions, but a boost may be administered to high-risk regions including areas of nodal extracapsular extension or microscopic positive margins. Lung dose constraints should be more conservative as tolerance appears to be reduced after surgery. The ongoing European LungART trial provides useful guidelines for PORT technique.

Advanced stage/palliative RT

- The dose and fractionation of palliative RT should be individualized based on goals of care, symptoms, performance status, and logistical considerations. Shorter courses of RT provide similar pain relief as longer courses, but with a higher potential need for retreatment, and are preferred for patients with poor performance status and/or shorter life expectancy. When higher doses (>30 Gy) are warranted, 3D-CRT should be used to reduce normal tissue irradiation.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Radiation Therapy Simulation, Planning, and Delivery

- Simulation should be performed using CT scans obtained in the RT treatment position with appropriate immobilization devices. IV contrast with or without oral contrast is recommended for better target/organ delineation whenever possible in patients with central tumors or nodal disease. Because IV contrast can affect tissue heterogeneity correction calculations, density masking or use of a pre-contrast scan may be needed when intense enhancement is present.

- PET/CT significantly improves targeting accuracy, especially for patients with significant atelectasis and when IV CT contrast is contraindicated. A randomized trial of PET/CT versus CT-only RT planning demonstrated improved preemption of futile radical RT, decreased recurrences, and a trend toward improved overall survival with PET/CT RT planning. Given the potential for rapid progression of NSCLC, PET/CT should be obtained preferably within 4 weeks before treatment. It is ideal to obtain PET/CT in the treatment position.

- Tumor and organ motion, especially owing to breathing, should be assessed or accounted for at simulation. Options include fluoroscopy, inhale/exhale or slow scan CT, or, ideally, 4D-CT.

- Photon beam energy should be individualized based on the anatomic location of the tumors and beam paths. In general, photon energies between 4 to 10 MV are recommended for beams passing through low-density lung tissue before entering the tumor. When there is no air gap before the beam enters the tumor (such as for some large mediastinal tumors or tumors attached to chest wall), higher energies may improve the dose distribution, especially when using a smaller number of fixed beam angles.

- Tissue heterogeneity correction and accurate dose calculation algorithms that account for build-up and lateral electron scatter effects in heterogeneous density tissues are recommended. Heterogeneity correction with simple pencil beam algorithms is not recommended.

- Respiratory motion should be managed when motion is excessive. This includes (but is not limited to) forced shallow breathing with abdominal compression, accelerator beam gating with the respiratory cycle, dynamic tumor tracking, active breathing control (ABC), or coaching/biofeedback techniques. If motion is minimal or the ITV is small, motion-encompassing targeting is appropriate. A useful resource for implementation of respiratory motion management is the report of AAPM Task Group 76.

- IGRT—including (but not limited to) orthogonal pair planar imaging and volumetric imaging (such as CBCT or CT on rails)—is recommended when using SABR and 3D-CRT/IMRT with steep dose gradients around the target, when OARs are in close proximity to high-dose regions, and when using complex motion management techniques.
Table 1. Commonly Used Abbreviations in Radiation Therapy

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT</td>
<td>Radiation Therapy or Radiotherapy</td>
</tr>
<tr>
<td>2D-RT</td>
<td>2-Dimensional RT</td>
</tr>
<tr>
<td>3D-CRT</td>
<td>3-Dimensional Conformal RT</td>
</tr>
<tr>
<td>4D-CT</td>
<td>4-Dimensional Computed Tomography</td>
</tr>
<tr>
<td>AAPM</td>
<td>American Association of Physicists in Medicine</td>
</tr>
<tr>
<td>ABC</td>
<td>Active Breathing Control</td>
</tr>
<tr>
<td>ACR</td>
<td>American College of Radiology</td>
</tr>
<tr>
<td>ASTRO</td>
<td>American Society for Radiation Oncology</td>
</tr>
<tr>
<td>BED</td>
<td>Biologically Effective Dose</td>
</tr>
<tr>
<td>CBCT</td>
<td>Cone-Beam CT</td>
</tr>
<tr>
<td>CTV*</td>
<td>Clinical Target Volume</td>
</tr>
<tr>
<td>DVH</td>
<td>Dose-Volume Histogram</td>
</tr>
<tr>
<td>ENI</td>
<td>Elective Nodal Irradiation</td>
</tr>
<tr>
<td>GTV*</td>
<td>Gross Tumor Volume</td>
</tr>
<tr>
<td>ICRU</td>
<td>International Commission on Radiation Units and Measurements</td>
</tr>
<tr>
<td>IFI</td>
<td>Involved Field Irradiation</td>
</tr>
<tr>
<td>IGRT</td>
<td>Image-Guided RT</td>
</tr>
<tr>
<td>IMRT</td>
<td>Intensity-Modulated RT</td>
</tr>
<tr>
<td>ITV*</td>
<td>Internal Target Volume</td>
</tr>
<tr>
<td>MLD</td>
<td>Mean Lung Dose</td>
</tr>
<tr>
<td>OAR</td>
<td>Organ at Risk</td>
</tr>
<tr>
<td>OBI</td>
<td>On-Board Imaging</td>
</tr>
<tr>
<td>PORT</td>
<td>Postoperative RT</td>
</tr>
<tr>
<td>PTV*</td>
<td>Planning Target Volume</td>
</tr>
<tr>
<td>QUANTEC</td>
<td>Quantitative Analysis of Normal Tissue Effects in the Clinic</td>
</tr>
<tr>
<td>RTOG</td>
<td>Radiation Therapy Oncology Group</td>
</tr>
<tr>
<td>SABR</td>
<td>Stereotactic Ablative RT, also known as Stereotactic Body RT (SBRT)</td>
</tr>
<tr>
<td>V20</td>
<td>% Volume of an OAR receiving ( \geq 20 ) Gy</td>
</tr>
<tr>
<td>VMAT</td>
<td>Volumetric Modulated Arc Therapy</td>
</tr>
</tbody>
</table>

*Refer to ICRU Report 83 for detailed definitions.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Table 2. Commonly Used Doses for SABR

<table>
<thead>
<tr>
<th>Total Dose</th>
<th># Fractions</th>
<th>Example Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>25-34 Gy</td>
<td>1</td>
<td>Peripheral, small (&lt;2 cm) tumors, esp. &gt;1 cm from chest wall</td>
</tr>
<tr>
<td>45-60 Gy</td>
<td>3</td>
<td>Peripheral tumors and &gt;1 cm from chest wall</td>
</tr>
<tr>
<td>48-50 Gy</td>
<td>4</td>
<td>Central or peripheral tumors &lt;4-5 cm, esp. &lt;1 cm from chest wall</td>
</tr>
<tr>
<td>50-55 Gy</td>
<td>5</td>
<td>Central or peripheral tumors, esp. &lt;1 cm from chest wall</td>
</tr>
<tr>
<td>60-70 Gy</td>
<td>8-10</td>
<td>Central tumors</td>
</tr>
</tbody>
</table>

### Table 3. Maximum Dose Constraints for SABR*

<table>
<thead>
<tr>
<th>OAR/Regimen</th>
<th>1 Fraction</th>
<th>3 Fractions</th>
<th>4 Fractions</th>
<th>5 Fractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal Cord</td>
<td>14 Gy</td>
<td>18 Gy (6 Gy/fx)</td>
<td>26 Gy (6.5 Gy/fix)</td>
<td>30 Gy (6 Gy/fix)</td>
</tr>
<tr>
<td>Esophagus</td>
<td>15.4 Gy</td>
<td>30 Gy (10 Gy/fix)</td>
<td>30 Gy (7.5 Gy/fix)</td>
<td>32.5 Gy (6.5 Gy/fix)</td>
</tr>
<tr>
<td>Brachial Plexus</td>
<td>17.5 Gy</td>
<td>21 Gy (7 Gy/fix)</td>
<td>27.2 Gy (6.8 Gy/fix)</td>
<td>30 Gy (6 Gy/fix)</td>
</tr>
<tr>
<td>Heart/Pericardium</td>
<td>22 Gy</td>
<td>30 Gy (10 Gy/fix)</td>
<td>34 Gy (8.5 Gy/fix)</td>
<td>35 Gy (7 Gy/fix)</td>
</tr>
<tr>
<td>Great Vessels</td>
<td>37 Gy</td>
<td>39 Gy (13 Gy/fix)</td>
<td>49 Gy (12.25 Gy/fix)</td>
<td>55 Gy (11 Gy/fix)</td>
</tr>
<tr>
<td>Trachea &amp; Proximal Bronchi</td>
<td>20.2 Gy</td>
<td>30 Gy (10 Gy/fix)</td>
<td>34.8 Gy (8.7 Gy/fix)</td>
<td>32.5 Gy (6.5 Gy/fix)</td>
</tr>
<tr>
<td>Rib</td>
<td>30 Gy</td>
<td>30 Gy (10 Gy/fix)</td>
<td>30 Gy (7.5 Gy/fix)</td>
<td>32.5 Gy (6.5 Gy/fix)</td>
</tr>
<tr>
<td>Skin</td>
<td>26 Gy</td>
<td>30 Gy (10 Gy/fix)</td>
<td>36 Gy (9 Gy/fix)</td>
<td>40 Gy (8 Gy/fix)</td>
</tr>
<tr>
<td>Stomach</td>
<td>12.4 Gy</td>
<td>27 Gy (9 Gy/fix)</td>
<td>30 Gy (7.5 Gy/fix)</td>
<td>35 Gy (7 Gy/fix)</td>
</tr>
</tbody>
</table>

*Based on constraints used in recent and ongoing RTOG SABR trials (RTOG 0618, 0813, & 0915).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Table 4. Commonly Used Doses for Conventionally Fractionated and Palliative RT

<table>
<thead>
<tr>
<th>Treatment Type</th>
<th>Total Dose</th>
<th>Fraction Size</th>
<th>Treatment Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definitive RT with or without chemotherapy</td>
<td>60-74 Gy</td>
<td>2 Gy</td>
<td>6-7.5 weeks</td>
</tr>
<tr>
<td>Preoperative RT</td>
<td>45-50 Gy</td>
<td>1.8-2 Gy</td>
<td>5 weeks</td>
</tr>
<tr>
<td>Postoperative RT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative margins</td>
<td>50-54 Gy</td>
<td>1.8-2 Gy</td>
<td>5-6 weeks</td>
</tr>
<tr>
<td>Extracapsular nodal extension or microscopic positive margins</td>
<td>54-60 Gy</td>
<td>1.8-2 Gy</td>
<td>6 weeks</td>
</tr>
<tr>
<td>Gross residual tumor</td>
<td>60-70 Gy</td>
<td>2 Gy</td>
<td>6-7 weeks</td>
</tr>
<tr>
<td>Palliative RT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obstructive disease (SVC syndrome or obstructive pneumonia)</td>
<td>30-45 Gy</td>
<td>3 Gy</td>
<td>2-3 weeks</td>
</tr>
<tr>
<td>Bone metastases with soft tissue mass</td>
<td>20-30 Gy</td>
<td>4-3 Gy</td>
<td>1-2 weeks</td>
</tr>
<tr>
<td>Bone metastases without soft tissue mass</td>
<td>8-30 Gy</td>
<td>8-3 Gy</td>
<td>1 day-2 weeks</td>
</tr>
<tr>
<td>Brain metastases</td>
<td>CNS GLs</td>
<td>CNS GLs</td>
<td>CNS GLs</td>
</tr>
<tr>
<td>Symptomatic chest disease in patients with poor PS</td>
<td>17 Gy</td>
<td>8.5 Gy</td>
<td>1-2 weeks</td>
</tr>
<tr>
<td>Any metastasis in patients with poor PS</td>
<td>8-20 Gy</td>
<td>8-4 Gy</td>
<td>1 day-1 week</td>
</tr>
</tbody>
</table>

Table 5. Normal Tissue Dose-Volume Constraints for Conventionally Fractionated RT

<table>
<thead>
<tr>
<th>OAR</th>
<th>Constraints in 30-35 Fractions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal cord</td>
<td>Max ≤50 Gy</td>
</tr>
<tr>
<td>Lung</td>
<td>V20 ≤35%; V5 ≤65%; MLD ≤20 Gy</td>
</tr>
<tr>
<td>Heart</td>
<td>V40 ≤80%; V45 ≤60%; V60 ≤30%; Mean ≤35 Gy</td>
</tr>
<tr>
<td>Esophagus</td>
<td>Mean ≤34 Gy; Max ≤105% of prescription dose</td>
</tr>
<tr>
<td>Brachial plexus</td>
<td>Max ≤66 Gy</td>
</tr>
</tbody>
</table>

Vxx = % of the whole OAR receiving ≥xx Gy.

Figure 1. ICRU Report 62 Schema of Target Volume Definitions

The arrow illustrates the influence of the organs at risk on delineation of the PTV (thick, full line).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF RADIATION THERAPY

PRINCIPLES OF RADIATION THERAPY - References (9 of 9)


66Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009; 35:718-723; discussion 723.


CHEMOTHERAPY REGIMENS USED WITH RADIATION THERAPY

Concurrent Chemotherapy/RT Regimens*
- Cisplatin 50 mg/m\(^2\) on days 1, 8, 29, and 36; etoposide 50 mg/m\(^2\) days 1-5, 29-33; concurrent thoracic RT\(^a\) (preferred)**
- Cisplatin 100 mg/m\(^2\) days 1, 29; vinblastine 5 mg/m\(^2\)/weekly x 5; concurrent thoracic RT\(^b\) (preferred)
- Carboplatin AUC 5 on day 1, pemetrexed 500 mg/m\(^2\) on day 1 every 21 days for 4 cycles; concurrent thoracic RT\(^c\) (nonsquamous)
- Cisplatin 75 mg/m\(^2\) on day 1, pemetrexed 500 mg/m\(^3\) on day 1 every 21 days for 3 cycles; concurrent thoracic RT\(^d\) (nonsquamous)

Sequential Chemotherapy/RT Regimens
- Cisplatin 100 mg/m\(^2\) on day 1, 29; vinblastine 5 mg/m\(^2\)/weekly on days 1, 8, 15, 22, 29; followed by RT\(^b\)
- Paclitaxel 200 mg/m\(^2\) every 3 weeks over 3 hours, 2 cycles; carboplatin AUC 6, 2 cycles followed by thoracic RT\(^e\)

Concurrent Chemotherapy/RT Followed by Chemotherapy
- Cisplatin 50 mg/m\(^2\) on days 1, 8, 29, 36; etoposide 50 mg/m\(^2\) days 1-5, 29-33; concurrent thoracic RT followed by cisplatin 50 mg/m\(^2\) and etoposide 50 mg/m\(^2\) x 2 additional cycles (category 2B)\(^a\)
- Paclitaxel 45-50 mg/m\(^2\)/weekly; carboplatin AUC 2, concurrent thoracic RT followed by 2 cycles of paclitaxel 200 mg/m\(^2\) and carboplatin AUC 6\(^e\) (category 2B)

*There are data that support full-dose cisplatin over carboplatin-based regimens. Carboplatin regimens have not been adequately tested.

**This regimen can be used as neoadjuvant chemoradiotherapy. Cisplatin and etoposide is the preferred regimen. If weekly carboplatin and paclitaxel is used because the patient is not able to tolerate concurrent full-dose cisplatin and radiotherapy, the treating physician should consider 3 cycles of full-dose platinum therapy after local treatment is completed.


**Evaluation**
- Determination of resectability, surgical staging, and pulmonary resection should be performed by board-certified thoracic surgeons who perform lung cancer surgery as a prominent part of their practice.
- CT and PET used for staging should be within 60 days before proceeding with surgical evaluation.
- Resection is the preferred local treatment modality (other modalities include radiofrequency ablation, cryotherapy, and SABR). Thoracic surgical oncology consultation should be part of the evaluation of any patient being considered for curative local therapy. In cases where SABR is considered for high-risk patients, a multidisciplinary evaluation (including a radiation oncologist) is recommended.
- The overall plan of treatment as well as needed imaging studies should be determined before any non-emergency treatment is initiated.
- Thoracic surgeons should actively participate in multidisciplinary discussions and meetings regarding lung cancer patients (e.g., multidisciplinary clinic and/or tumor board).
- In current smokers who stop smoking, consider waiting 4 weeks before surgery to maximize outcomes after surgery.

**Resection**
- Anatomic pulmonary resection is preferred for the majority of patients with NSCLC.
- Sublobar resection - Segmentectomy and wedge resection should achieve parenchymal resection margins ≥2 cm or ≥ the size of the nodule.
- Sublobar resection should also sample appropriate N1 and N2 lymph node stations unless not technically feasible without substantially increasing the surgical risk.
- Segmentectomy (preferred) or wedge resection is appropriate in selected patients for the following reasons:
  - Poor pulmonary reserve or other major comorbidity that contraindicates lobectomy
  - Peripheral nodule\(^1\) ≤2 cm with at least one of the following:
    - Pure AIS histology
    - Nodule has ≥50% ground glass appearance on CT
    - Radiologic surveillance confirms a long doubling time (≥400 days)
- VATS is a reasonable and acceptable approach for patients with no anatomic or surgical contraindications, as long as there is no compromise of standard oncologic and dissection principles of thoracic surgery.
- In high-volume centers with significant VATS experience, VATS lobectomy in selected patients results in improved early outcomes (i.e., decreased pain, reduced hospital length of stay, more rapid return to function, fewer complications) without compromise of cancer outcomes.
- Lung-sparing anatomic resection (sleeve lobectomy) is preferred over pneumonectomy, if anatomically appropriate and margin-negative resection is achieved.
- T3 (invasion) and T4 local extension tumors require en-bloc resection of the involved structure with negative margins. If a surgeon or center is uncertain about potential complete resection, consider obtaining an additional surgical opinion from a high-volume specialized center.

**Margins and Nodal Assessment**
- The Role of Surgery in Patients With Stage IIIA (N2) NSCLC

\(^1\) Peripheral is defined as the outer one third of the lung parenchyma.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Margins and Nodal Assessment

- Surgical pathologic correlation is critical to assess apparent close or positive margins, as these may not represent true margins or may not truly represent areas of risk for local recurrence (e.g., medial surface of mainstem or bronchus intermedius when separate subcarinal lymph node dissection has been performed, or pleural margin adjacent to aorta when no attachment to aorta is present).
- N1 and N2 node resection and mapping should be a routine component of lung cancer resections—a minimum of three N2 stations sampled or complete lymph node dissection.
- Formal ipsilateral mediastinal lymph node dissection is indicated for patients undergoing resection for stage IIIA (N2) disease.
- Complete resection requires free resection margins, systematic node dissection or sampling, and the highest mediastinal node negative for tumor. The resection is defined as incomplete whenever there is involvement of resection margins, unremoved positive lymph nodes, or positive pleural or pericardial effusions. A complete resection is referred to as R0, microscopically positive resection as R1, and macroscopic residual tumor as R2.
- Patients with pathologic stage II or greater should be referred to medical oncology for evaluation.
- Consider referral to a radiation oncologist for resected stage IIIA.

The Role of Surgery in Patients With Stage IIIA (N2) NSCLC

The role of surgery in patients with pathologically documented N2 disease remains controversial. Two randomized trials evaluated the role of surgery in this population, but neither showed an overall survival benefit with the use of surgery. However, this population is heterogeneous and the panel believes that these trials did not sufficiently evaluate the nuances present with the heterogeneity of N2 disease and the likely oncologic benefit of surgery in specific clinical situations.

- The presence or absence of N2 disease should be vigorously determined by both radiologic and invasive staging prior to the initiation of therapy since the presence of mediastinal nodal disease has a profound impact on prognosis and treatment decisions. (NSCL-1, NSCL-2, and NSCL-6)
- Patients with occult positive N2 nodes discovered at the time of pulmonary resection should continue with the planned resection along with formal mediastinal lymph node dissection. If N2 disease is noted in patients undergoing VATS, the surgeon may consider stopping the procedure so that induction therapy can be administered before surgery; however, continuing the procedure is also an option.
- The determination of the role of surgery in a patient with N2 positive lymph nodes should be made prior to the initiation of any therapy by a multidisciplinary team, including a board-certified thoracic surgeon who has a major part of his/her practice dedicated to thoracic oncology.
- The presence of N2 positive lymph nodes substantially increases the likelihood of positive N3 lymph nodes. Pathologic evaluation of the mediastinum must include evaluation of the subcarinal station and contralateral lymph nodes. EBUS +/- EUS are additional techniques for minimally invasive pathologic mediastinal staging that are complementary to mediastinoscopy. Even when these modalities are employed it is important to have an adequate evaluation of the number of stations involved and biopsy and documentation of negative contralateral lymph node involvement prior to a final treatment decision.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
The Role of Surgery in Patients With Stage IIIA (N2) NSCLC

- Repeat mediastinoscopy, while possible, is technically difficult and has a lower accuracy compared to primary mediastinoscopy. One possible strategy is to perform EBUS (± EUS) in the initial pretreatment evaluation and reserve mediastinoscopy for nodal restaging after neoadjuvant therapy.\(^5\)
- Patients with a single lymph node smaller than 3 cm can be considered for a multimodality approach that includes surgical resection.\(^1,6,7\)
- Restaging after induction therapy is difficult to interpret, but CT +/- PET should be performed to exclude disease progression or interval development of metastatic disease.
- Patients with negative mediastinum after neoadjuvant therapy have a better prognosis.\(^7,8\)
- Neoadjuvant chemoradiotherapy is used in 50% of the NCCN institutions, while neoadjuvant chemotherapy is used in the other 50%. Overall survival appears similar provided RT is given postoperatively, if not given preoperatively.\(^5,9\) Neoadjuvant chemoradiotherapy is associated with higher rates of pathologic complete response and negative mediastinal lymph nodes.\(^10\) However, that is achieved at the expense of higher rates of acute toxicity and increased cost.
- When neoadjuvant chemoradiotherapy is used with doses lower than those used for standard definitive therapy, all efforts should be made to minimize any possible breaks in radiotherapy for surgical evaluation. Treatment breaks of more than 1 week are considered unacceptable.
- When timely surgical evaluation is not available, the strategy of neoadjuvant chemoradiotherapy should not be used. Another option in individual cases, and with the agreement of the thoracic surgeon, is to complete definitive chemoradiotherapy prior to re-evaluation and consideration for surgery.\(^11,12\) If a surgeon or center is uncertain about the feasibility or safety of resection after definitive doses of radiation, consider obtaining an additional surgical opinion from a high-volume specialized center. These operations may also benefit from additional considerations of soft tissue flap coverage in the radiation field resection.
- Data from a large multi-institutional trial indicate that pneumonectomy after neoadjuvant chemoradiotherapy has unacceptable morbidity and mortality.\(^2\) However, it is not clear if this is also true with neoadjuvant chemotherapy alone. Further, many groups have challenged that cooperative group finding with single institution experiences demonstrating safety of pneumonectomy after induction therapy.\(^13-16\) In addition, there is no evidence that adding RT to induction regimens for patients with operable stage IIIA (N2) disease improves outcomes compared to induction chemotherapy.\(^17\)

A questionnaire was submitted to the NCCN institutions in 2010 regarding their approach to patients with N2 disease. Their responses indicate the patterns of practice when approaching this difficult clinical problem.

a) Would consider surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm: (90.5%)
b) Would consider surgery with more than one N2 lymph node station involved, as long as no lymph node was bigger than 3 cm: (47.6%)
c) Uses EBUS (+/- EUS) in the initial evaluation of the mediastinum: (80%)
d) Uses pathologic evaluation of the mediastinum, after neoadjuvant therapy, to make a final decision before surgery: (40.5%)
e) Would consider neoadjuvant therapy followed by surgery when a patient is likely, based on initial evaluation, to require a pneumonectomy: (54.8%)
The Role of Surgery in Patients With Stage IIIA (N2) NSCLC - References


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin
Paclitaxel 200 mg/m$^2$ on day 1, carboplatin AUC 6 on day 1, every 21 days

**CHEMOTHERAPY REGIMENS FOR NEOADJUVANT AND ADJUVANT THERAPY**

- Cisplatin 50 mg/m$^2$ days 1 and 8; vinorelbine 25 mg/m$^2$ days 1, 8, 15, 22, every 28 days for 4 cycles$^a$
- Cisplatin 100 mg/m$^2$ on day 1; vinorelbine 30 mg/m$^2$ days 1, 8, 15, 22; every 28 days for 4 cycles$^{b,c}$
- Cisplatin 75-80 mg/m$^2$ day 1; vinorelbine 25-30 mg/m$^2$ days 1 + 8, every 21 days for 4 cycles
- Cisplatin 100 mg/m$^2$ on day 1; etoposide 100 mg/m$^2$ days 1-3, every 28 days for 4 cycles$^b$
- Cisplatin 80 mg/m$^2$ on days 1, 22, 43, 64; vinblastine 4 mg/m$^2$ days 1, 8, 15, 22 then every 2 wks after day 43, every 21 days for 4 cycles$^b$
- Cisplatin 75 mg/m$^2$ on day 1; gemcitabine 1250 mg/m$^2$ on days 1, 8, every 21 days for 4 cycles
- Cisplatin 75 mg/m$^2$; docetaxel 75 mg/m$^2$ every 21 days for 4 cycles$^d$
- Pemetrexed 500 mg/m$^2$ on day 1; cisplatin 75 mg/m$^2$ on day 1 for adenocarcinoma and large cell carcinoma and NSCLC NOS (without specific histologic subtype) every 21 days for 4 cycles

Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin
Paclitaxel 200 mg/m$^2$ on day 1, carboplatin AUC 6 on day 1, every 21 days$^e$

---


ADVANCED DISEASE:
• The drug regimen with the highest likelihood of benefit with toxicity deemed acceptable to both the physician and the patient should be given as initial therapy for advanced lung cancer.
• Stage, weight loss, performance status, and gender predict survival.
• Platinum-based chemotherapy prolongs survival, improves symptom control, and yields superior quality of life compared to best supportive care.
• Histology of NSCLC is important in the selection of systemic therapy.
• New agent/platinum combinations have generated a plateau in overall response rate (≈ 25%-35%), time to progression (4-6 mo), median survival (8-10 mo), 1 y survival rate (30%-40%) and 2 y survival rate (10%-15%) in fit patients.
• Unfit of any age (performance status 3-4) do not benefit from cytotoxic treatment, except erlotinib for EGFR mutation-positive patients. 
  First-line therapy
  • Bevacizumab + chemotherapy or chemotherapy alone is indicated in PS 0-1 patients with advanced or recurrent NSCLC. Bevacizumab should be given until disease progression.
  • Cetuximab + vinorelbine/cisplatin is an option for patients with performance status 0-1 (category 2B).
  • Erlotinib is recommended as a first-line therapy in patients with EGFR mutation.
  • Crizotinib is indicated as a first-line therapy in patients who are ALK positive.
  • There is superior efficacy and reduced toxicity for cisplatin/pemetrexed in patients with nonsquamous histology, in comparison to cisplatin/gemcitabine.
  • There is superior efficacy for cisplatin/gemcitabine in patients with squamous histology, in comparison to cisplatin/pemetrexed.
  • Two drug regimens are preferred; a third cytotoxic drug increases response rate but not survival.
  • Single-agent therapy or platinum-based combinations are a reasonable alternative in PS 2 patients or the elderly.
  • Cisplatin or carboplatin have been proven effective in combination with any of the following agents: paclitaxel, docetaxel, gemcitabine, etoposide, vinblastine, vinorelbine, pemetrexed, or albumin-bound paclitaxel.
  • New agent/non-platinum combinations are reasonable alternatives if available data show activity and tolerable toxicity (eg, gemcitabine/docetaxel, gemcitabine/vinorelbine).
SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE (2 OF 3)

Maintenance Therapy
Continuation maintenance refers to the use of at least one of the agents given in first line, beyond 4-6 cycles, in the absence of disease progression. Switch maintenance refers to the initiation of a different agent, not included as part of the first-line regimen, in the absence of disease progression, after 4-6 cycles of initial therapy.

- Continuation Maintenance: Bevacizumab and cetuximab given in combination with chemotherapy should be continued until evidence of disease progression or unacceptable toxicity, as per the design of the clinical trials supporting their use.
  - Continuation of bevacizumab after 4-6 cycles of platinum-doublet chemotherapy and bevacizumab (category 1).
  - Continuation of cetuximab after 4-6 cycles of cisplatin, vinorelbine, and cetuximab (category 1).
  - Continuation of pemetrexed after 4-6 cycles of cisplatin and pemetrexed chemotherapy, for patients with histologies other than squamous cell carcinoma (category 1).
  - Continuation of bevacizumab + pemetrexed after 4-6 cycles of bevacizumab, pemetrexed, cisplatin/carboplatin, for patients with histologies other than squamous cell carcinoma.
  - Continuation of gemcitabine after 4-6 cycles of platinum-doublet chemotherapy.

- Switch Maintenance: Two recent studies have shown a benefit in progression-free and overall survival with the initiation of pemetrexed or erlotinib after first-line chemotherapy, in patients without disease progression after 4-6 cycles of therapy.
  - Initiation of pemetrexed after 4-6 cycles of first-line platinum-doublet chemotherapy, for patients with histologies other than squamous cell carcinoma.
  - Initiation of erlotinib after 4-6 cycles of first-line platinum-doublet chemotherapy.
  - Initiation of docetaxel after 4-6 cycles of first-line platinum-doublet chemotherapy in patients with squamous cell carcinoma (category 2B).

- Close surveillance of patients without therapy is a reasonable alternative to maintenance.

Second-line therapy
- In patients who have experienced disease progression either during or after first-line therapy, single-agent docetaxel, pemetrexed, or erlotinib are established second-line agents.
  - Docetaxel is superior to vinorelbine or ifosfamide.
  - Pemetrexed is considered equivalent to docetaxel with less toxicity in patients with adenocarcinoma and large cell carcinoma.
  - Erlotinib is superior to best supportive care.

Third-line therapy
- Erlotinib is superior to best supportive care.

Continuation After Disease Progression
- With the exception of erlotinib in patients with EGFR sensitizing mutations who have experienced objective regressions with erlotinib, no agent should be continued after disease progression has been documented. (refer to discussion section)
Agents listed below are used in the treatment of patients with NSCLC. Most are used in combination, while others are used as monotherapy (eg, maintenance or second-line therapy).

1. Cisplatin
2. Carboplatin
3. Paclitaxel
4. Docetaxel
5. Vinorelbine
6. Gemcitabine
7. Etoposide
8. Irinotecan
9. Vinblastine
10. Mitomycin
11. Ifosfamide
12. Pemetrexed
13. Erlotinib
14. Bevacizumab
15. Albumin-bound paclitaxel
16. Crizotinib

Albumin-bound paclitaxel may be substituted for either paclitaxel or docetaxel in patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or for patients where the standard premedications (dexamethasone, H2-blockers, H1-blockers) are contraindicated.
CANCER SURVIVORSHIP CARE

NSCLC Long-term Follow-up Care

- Cancer Surveillance
  - H&P and a chest CT scan ± contrast every 6-12 months for 2 years, then H&P and a non-contrast-enhanced chest CT scan annually
  - Smoking status assessment at each visit; counseling and referral for cessation as needed.
- Immunizations
  - Annual influenza vaccination, herpes zoster vaccine
  - Pneumococcal vaccination with revaccination as appropriate
- Counseling Regarding Health Promotion and Wellness
  - Maintain a healthy weight
  - Adopt a physically active lifestyle (Regular physical activity: 30 minutes of moderate-intensity physical activity on most days of the week)
  - Consume a healthy diet with emphasis on plant sources
  - Limit consumption of alcohol if one consumes alcoholic beverages

Additional Health Monitoring

- Routine blood pressure, cholesterol, and glucose monitoring
- Bone health: Bone density testing as appropriate
- Dental health: Routine dental examinations
- Routine sun protection

Resources

- National Cancer Institute Facing Forward: Life After Cancer Treatment
- Cancer Screening Recommendations
  - These recommendations are for average-risk individuals and high-risk patients should be individualized.
  - Colorectal Cancer:
    - See NCCN Guidelines for Colorectal Cancer Screening
  - Prostate Cancer:
    - See NCCN Guidelines for Prostate Cancer Early Detection
  - Breast Cancer:
    - See NCCN Guidelines for Breast Cancer Screening
  - Cervical Cancer:
    - See NCCN Guidelines for Cervical Cancer Screening

1. ACS Guidelines on Nutrition and Physical Activity for Cancer Prevention:
2. Memorial Sloan-Kettering Cancer Center Screening Guidelines:
3. American Cancer Society Guidelines for Early Detection of Cancer:

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Table 1. Definitions for T, N, M*

<table>
<thead>
<tr>
<th>T</th>
<th>Primary Tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumor</td>
</tr>
<tr>
<td>Tis</td>
<td>Carcinoma in situ</td>
</tr>
<tr>
<td>T1</td>
<td>Tumor ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)(^a)</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumor ≤ 2 cm in greatest dimension</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumor &gt; 2 cm but ≤ 3 cm in greatest dimension</td>
</tr>
</tbody>
</table>
| T2 | Tumor > 3 cm but ≤ 7 cm or tumor with any of the following features: b  
Involves main bronchus, ≥ 2 cm distal to the carina  
Invades visceral pleura  
Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung |
| T2a| Tumor > 3 cm but ≤ 5 cm in greatest dimension                                                                                                                                                               |
| T2b| Tumor > 5 cm but ≤ 7 cm in greatest dimension                                                                                                                                                               |
| T3 | Tumor > 7 cm or one that directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium; or tumor in the main bronchus < 2 cm distal to the carina\(^a\) but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung or separate tumor nodule(s) in the same lobe |
| T4 | Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate tumor nodule(s) in a different ipsilateral lobe                                              |

<table>
<thead>
<tr>
<th>N</th>
<th>Regional Lymph Nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodules, including involvement by direct extension</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M</th>
<th>Distant Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX</td>
<td>Distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>M1a</td>
<td>Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural (or pericardial) effusion(^c)</td>
</tr>
<tr>
<td>M1b</td>
<td>Distant metastasis</td>
</tr>
</tbody>
</table>

\(^a\) The uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximally to the main bronchus, is also classified as T1.

\(^b\) T2 tumors with these features are classified T2a if ≤ 5 cm or if size cannot be determined, and T2b if > 5 cm but ≤ 7 cm

\(^c\) Most pleural (and pericardial) effusions with lung cancer are due to tumor. In a few patients, however, multiple cytopathologic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate. Where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be classified as T1, T2, T3, or T4.

---

# Table 2. Anatomic Stage and Prognostic Groups

<table>
<thead>
<tr>
<th>Occult Carcinoma</th>
<th>Stage 0</th>
<th>Stage IA</th>
<th>Stage IIA</th>
<th>Stage IIB</th>
<th>Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Tis</td>
<td>T1a</td>
<td>T2b</td>
<td>T2b</td>
<td>Any T</td>
</tr>
<tr>
<td>N0</td>
<td>N0</td>
<td>N0</td>
<td>N0</td>
<td>N1</td>
<td>Any N</td>
</tr>
<tr>
<td>M0</td>
<td>M0</td>
<td>M0</td>
<td>M0</td>
<td>M0</td>
<td>M1a</td>
</tr>
<tr>
<td>M1a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>M1b</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage IIIA</th>
<th>Stage IIIB</th>
<th>Stage IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1a N2 M0</td>
<td>T1a N3 M0</td>
<td>Any T Any N M1a</td>
</tr>
<tr>
<td>T1b N2 M0</td>
<td>T1b N3 M0</td>
<td>Any T Any N M1b</td>
</tr>
<tr>
<td>T2a N2 M0</td>
<td>T2a N3 M0</td>
<td></td>
</tr>
<tr>
<td>T2b N2 M0</td>
<td>T2b N3 M0</td>
<td></td>
</tr>
<tr>
<td>T3 N1 M0</td>
<td>T3 N3 M0</td>
<td></td>
</tr>
<tr>
<td>T4 N1 M0</td>
<td>T4 N3 M0</td>
<td></td>
</tr>
<tr>
<td>T4 N1 M0</td>
<td>T4 N3 M0</td>
<td></td>
</tr>
</tbody>
</table>

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media, LLC (SBM). (For complete information and data supporting the staging tables, visit [www.springer.com](http://www.springer.com).) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer SBM, on behalf of the AJCC.
### Table 3. Descriptors, T and M Categories, and Stage Grouping*

<table>
<thead>
<tr>
<th>6th Edition T/M Descriptor</th>
<th>7th Edition T/M</th>
<th>N0</th>
<th>N1</th>
<th>N2</th>
<th>N3</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1 (≤2 cm)</td>
<td>T1a</td>
<td>IA</td>
<td>IA</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T1 (&lt;2-3 cm)</td>
<td>T1b</td>
<td>IA</td>
<td>IA</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T2 (≤5 cm)</td>
<td>T2a</td>
<td>IB</td>
<td>IA</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T2 (&lt;5-7 cm)</td>
<td>T2b</td>
<td>IIA</td>
<td>II B</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T2 (&gt;7 cm)</td>
<td>T3</td>
<td>IIB</td>
<td>IIIA</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T3 invasion</td>
<td></td>
<td>IIB</td>
<td>IIIA</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4 (same lobe nodules)</td>
<td></td>
<td>IIB</td>
<td>IIIA</td>
<td>IIIA</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4 extension</td>
<td>T4</td>
<td>IIIA</td>
<td>IIIA</td>
<td>IIIB</td>
<td>IIIB</td>
</tr>
<tr>
<td>M1 (ipsilateral lung)</td>
<td></td>
<td>IIIA</td>
<td>IIIA</td>
<td>IIIB</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4 (pleural effusion)</td>
<td>M1a</td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
</tr>
<tr>
<td>M1 (contralateral lung)</td>
<td></td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
</tr>
<tr>
<td>M1 (distant)</td>
<td>M1b</td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
<td>IV</td>
</tr>
</tbody>
</table>

Cells in bold indicate a change from the sixth edition for a particular TNM category.

Discussion

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ............................................................................................................ MS-2
Risk Factors ................................................................................................. MS-2
Prevention and Screening .......................................................................... MS-2
Classification and Prognostic Factors ......................................................... MS-4
Diagnostic Evaluation of Lung Nodules ...................................................... MS-4
Pathologic Evaluation of Lung Cancer ........................................................ MS-5
Adenocarcinoma ........................................................................................... MS-6
Immunohistochemical Staining .................................................................... MS-6
Staging ........................................................................................................... MS-7
Prognostic and Predictive Biomarkers ......................................................... MS-8
EGFR Mutations ........................................................................................... MS-9
ALK Gene Rearrangements .......................................................................... MS-10
ERCC1 Level of Expression ......................................................................... MS-10
KRAS Mutations ........................................................................................... MS-11
Treatment Approaches ............................................................................... MS-11
Surgery .......................................................................................................... MS-11
Radiation Therapy ......................................................................................... MS-13
Combined Modality Therapy ....................................................................... MS-16
Clinical Evaluation ......................................................................................... MS-24
Additional Pretreatment Evaluation ............................................................. MS-25
Initial Therapy ................................................................................................ MS-27
Stage I, Stage II, and Stage IIIA Disease ..................................................... MS-27
Multiple Lung Cancers ................................................................................ MS-28
Stage IIIB Disease ......................................................................................... MS-29
Stage IV Disease .......................................................................................... MS-29
Adjuvant Treatment ....................................................................................... MS-30
Chemotherapy or Chemoradiation ............................................................... MS-30
Radiation Therapy ........................................................................................ MS-32
Surveillance ................................................................................................... MS-33
Treatment of Recurrences and Distant Metastases ...................................... MS-33
Trial Data ........................................................................................................ MS-35
Number of Cycles of First-Line Systemic Therapy ........................................ MS-36
Maintenance Therapy .................................................................................... MS-36
Continuation of Erlotinib or Gefitinib After Progression ............................. MS-37
Second-Line and Third-Line Systemic Therapy .......................................... MS-37
Table 1: Targeted Agents for Patients With Genetic Alterations ................ MS-39
References .................................................................................................... MS-40
Overview

Lung cancer is the leading cause of cancer death in the United States. In 2012, an estimated 226,000 new cases (116,000 in men and 110,000 in women) of lung and bronchial cancer will be diagnosed, and 160,000 deaths (88,000 in men and 72,000 in women) are estimated to occur because of the disease. Only 15.9% of all lung cancer patients are alive 5 years or more after diagnosis (http://seer.cancer.gov/statfacts/html/lungb.html). However, much progress has been made in the last 10 years for lung cancer (eg, screening, minimally invasive techniques for diagnosis and treatment, targeted therapy). Common symptoms of lung cancer include cough, dyspnea, weight loss, and chest pain; symptomatic patients are more likely to have chronic obstructive pulmonary disease.

Risk Factors

The primary risk factor for lung cancer is smoking tobacco, which accounts for most lung cancer-related deaths (http://www.surgeongeneral.gov/library/smokingconsequences/). Cigarette smoke contains many carcinogenic chemicals (eg, nitrosamines, benzo(a)pyrene diol epoxide). The risk for lung cancer increases with the number of packs of cigarettes smoked per day and with the number of years spent smoking (ie, pack-years of smoking history). Exposed nonsmokers also have an increased relative risk (RR=1.24) of developing lung cancer from "secondhand smoke"; other studies have reported a modest risk (HR=1.05) (http://www.surgeongeneral.gov/library/secondhandsmoke/report/executivesummary.pdf). Radon gas, a radioactive gas that is produced by the decay of radium 226, also seems to cause lung cancer (http://www.surgeongeneral.gov/pressreleases/sg01132005.html). The U.S. Environmental Protection Agency estimates that radon is the main cause of lung cancer in nonsmokers; however, secondhand smoke may also be a factor (http://www.epa.gov/radon/healthrisks.html).

Asbestos, a mineral compound that breaks into small airborne shards, is a known carcinogen that increases the risk for lung cancer in people exposed to airborne fibers, especially in individuals who smoke. It is estimated that about 3% to 4% of lung cancers are caused by asbestos exposure. In addition, other possible risk factors include recurring lung inflammation, lung scarring secondary to tuberculosis, family history, and exposure to other carcinogens (ie, bis(chloromethyl)ether, polycyclic aromatic hydrocarbons, chromium, nickel, organic arsenic compounds). The International Agency for Research on Cancer lists several agents known to cause lung cancer, including arsenic, chromium, asbestos, nickel, cadmium, beryllium, silica, and diesel fumes. Asbestos also causes malignant pleural mesothelioma (see the NCCN Guidelines for Malignant Pleural Mesothelioma).

It is not clear whether hormone replacement therapy (HRT) affects the risk for lung cancer in women. More than 20 studies have been published, but the results have been inconsistent. In a large randomized controlled study, no increase in the incidence of lung cancer was found among postmenopausal women treated with estrogen plus progestin HRT; however, the risk of death from non-small cell lung cancer (NSCLC) was increased.

Prevention and Screening

Approximately 85% to 90% of cases of lung cancer are caused by cigarette smoking. Active smoking and secondhand smoke both cause lung cancer (see Reports of the Surgeon General, which are the next 2 links). There is a causal relationship between active smoking and lung
cancer and also between other cancers (eg, esophageal, oral cavity, laryngeal, pharyngeal, bladder, pancreatic, gastric, kidney, ovarian cancer, colorectal, and cervical cancers) and other diseases and conditions (http://www.cdc.gov/tobacco/data_statistics/sgr/2004/pdfs/executivesummary.pdf). Smoking harms nearly every organ in the body. Those who live with someone who smokes have an increased risk for lung cancer (http://www.surgeongeneral.gov/library/secondhandsmoke/report/executivesummary.pdf). Further complicating this problem, cigarettes also contain nicotine, which is a highly addictive substance.

Oncologists should encourage smoking cessation, especially in patients with cancer (http://www.smokefree.gov/). The 5 A’s framework is a useful tool (that is, Ask, Advise, Assess, Assist, Arrange) (http://www.ahrq.gov/clinic/tobacco/5steps.htm). It is in the best interest of patients to quit smoking. Persistent smoking is associated with second primary cancers, treatment complications, and decreased survival. Some surgeons will not operate on a current smoker. Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useful (see Treating Tobacco Use and Dependence: 2008 Update, which is published by the Agency for Healthcare Research and Quality) (http://www.ahrq.gov/clinic/tobacco/tobaqrg.htm#Findings). The American Cancer Society has a Guide to Quitting Smoking (http://www.cancer.org/healthy/stayawayfromtobacco/guidetoquittingsmoking/index). The E-Quit Study is using email to help smokers quit smoking (http://www.cancer.org/healthy/stayawayfromtobacco/acs-gwu-e-quit-study).

Agents that can be used to promote smoking cessation include nicotine replacement (eg, gum, inhaler, lozenge, nasal spray, patch), bupropion sustained release, and varenicline. Studies have shown that varenicline is better than bupropion or nicotine patch for smoking cessation. However, almost 30% of patients had nausea while using varenicline. The effectiveness of varenicline for preventing relapse has not been clearly established. The FDA has issued an alert for varenicline regarding neuropsychiatric symptoms (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106540.htm). Varenicline has also been associated with other disorders (eg, visual disturbances, movement disorders, unconsciousness, cardiovascular disorders) and, therefore, is banned in truck and bus drivers, pilots, and air traffic controllers. Bupropion is also associated with serious adverse events (http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHealthcareProfessionals/ucm169986.htm). Nicotine replacement has fewer adverse effects than varenicline or bupropion. However, in spite of the potential adverse effects, it is probably more beneficial for motivated patients to use agents to promote smoking cessation.

Lung cancer is still the leading cause of cancer death worldwide, and late diagnosis is a major obstacle to improving lung cancer outcomes. Because localized cancer can be managed curatively and because the mortality rate in other solid tumors (eg, cervix, colon) seems to be decreased by screening and early detection, lung cancer would be an appropriate candidate for a population-based screening approach. Pilot trials of spiral (helical) low-dose CT in lung cancer screening were promising with a frequency of stage I detectable lung cancer in more than 80% of newly diagnosed cases.
The NLST (ACRIN Protocol A6654) was a randomized, controlled study involving more than 53,000 current or former heavy smokers; this trial assessed the risks and benefits of low-dose helical CT scans compared with chest radiographs for detecting lung cancer. Data from the NLST show that screening high-risk patients with low-dose helical CT decreases the mortality rate from lung cancer by 20% when compared with chest radiograph. High-risk patients were either current or former smokers with a 30 or more pack-year smoking history (former smokers had quit 15 years ago), were 55 to 74 years old, and had no evidence of lung cancer.

Additional information on NLST can be found at http://www.cancer.gov/nlst. NCCN recommends lung cancer screening using low-dose helical CT for select high-risk current and former smokers (see the NCCN Guidelines for Lung Cancer Screening).

The I-ELCAP has been assessing whether annual screening by low-dose helical CT scan increases the detection of early-stage lung cancer in patients at risk for cancer. Data from I-ELCAP showed that stage I lung cancer can be detected using annual low-dose CT screening. The 10-year survival rate was 92% for stage I patients whose cancers were promptly removed; however, all stage I patients who chose not to be treated died within 5 years. Additional information on I-ELCAP can be found at http://www.ielcap.org/index.htm. Screening can increase the diagnosis of early-stage lung cancers. Data from the NLST show that screening decreases the mortality rate.

Classification and Prognostic Factors

The WHO divides lung cancer into 2 major classes based on its biology, therapy, and prognosis: NSCLC (discussed in this guideline) and small cell lung cancer (SCLC), see the NCCN Guidelines for SCLC). NSCLC accounts for more than 85% of all lung cancer cases, and it includes 2 major types: 1) non-squamous carcinoma (including adenocarcinoma, large-cell carcinoma, and other cell types); and 2) squamous cell (epidermoid) carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring cell type in nonsmokers. An international panel recently revised the classification of lung adenocarcinoma (see the Pathologic Evaluation of Lung Cancer in this Discussion).

Certain prognostic factors are predictive of survival in patients with NSCLC. Good prognostic factors include early-stage disease at diagnosis, good performance status (PS) (ECOG 0, 1, or 2), no significant weight loss (not more than 5%), and female gender.

Diagnostic Evaluation of Lung Nodules

A new section on evaluating suspicious lung nodules was added for the 2013 update of the NCCN Guidelines for NSCLC (see Principles of Diagnostic Evaluation and corresponding algorithm pages). This new diagnostic section describes the evaluation of suspicious pulmonary nodules that are seen on low-dose helical CT scans. As previously described, low-dose CT has been shown to decrease the mortality rate from lung cancer and is a valuable tool for detecting lung cancer. Data from the NLST show that low-dose CT can be used to detect lung cancer at an early stage when presumably it is still curable. The NCCN Guidelines for Lung Cancer Screening recommend low-dose CT for select high-risk current and former smokers without symptoms of lung cancer (eg, those with a ≥ 30 pack-year smoking history). The new diagnostic algorithm in the NCCN Guidelines for NSCLC incorporates information from the NCCN Guidelines for Lung Cancer Screening. Risk assessment is used to determine which individuals are at high risk for lung cancer and thus are candidates for low-dose CT.
All findings and patient factors need to be carefully evaluated in a multidisciplinary diagnostic team before establishing a diagnosis of lung cancer and before starting treatment. The NCCN Guidelines recommend biopsy or surgical excision for highly suspicious nodules seen on low-dose CT scans or further surveillance for a low suspicion of cancer depending on the type of nodule and a multidisciplinary evaluation of other patient factors (see Risk Assessment in the NCCN Guidelines for NSCLC). However, it is important to note that false-positive results frequently occur with low-dose CT (e.g., benign intrapulmonary lymph nodes, noncalcified granulomas) (see the NCCN Guidelines for Lung Cancer Screening).

The NCCN Guidelines recommend that the diagnostic strategy should be individualized for each patient depending on the size and location of the tumor, the presence of mediastinal or distant disease, patient characteristics (e.g., comorbidities), and local experience. The diagnostic strategy needs to be decided in a multidisciplinary setting. Decisions regarding whether a biopsy (including what type of biopsy) or surgical excision is appropriate depend on several factors as outlined in the NCCN algorithm (see the Principles of Diagnostic Evaluation). For example, a preoperative biopsy may be appropriate if an intraoperative diagnosis seems to be difficult or very risky. The preferred biopsy technique depends on the site of disease and is described in the NCCN algorithm (see the Principles of Diagnostic Evaluation). For example, radial endobronchial ultrasound (EBUS), navigational bronchoscopy, or transthoracic needle aspiration (TTNA) are recommended for patients with suspected peripheral nodules.

If pathology results from biopsy or surgical excision indicate a diagnosis of NSCLC, then further evaluation and staging need to be done so that the patient’s health care team can determine the most appropriate and effective treatment plan (see the next 2 sections on pathology and staging and also see the NCCN NSCLC algorithm). Diagnosis, staging, and planned resection (e.g., lobectomy) are ideally one operative procedure for patients with early-stage disease (see the Principles of Diagnostic Evaluation).

Pathologic Evaluation of Lung Cancer

Pathologic evaluation is performed to classify the histologic type of the lung cancer, determine the extent of invasion, determine whether it is primary lung cancer or metastatic cancer, establish the cancer involvement status of the surgical margins (i.e., positive or negative margins), and do molecular diagnostic studies to determine whether certain gene alterations are present (e.g., epidermal growth factor receptor [EGFR] mutations) (see Principles of Pathologic Review in the NCCN NSCLC algorithm) (http://www.mycancergenome.org/content/disease/lung-cancer). Data show that targeted therapy is potentially very effective in patients with specific gene mutations or rearrangements (see sections on EGFR Mutations and ALK Gene Rearrangements in this Discussion).

Preoperative evaluations include examination of the following: bronchial brushings, bronchial washings, fine-needle aspiration (FNA) biopsy, core needle biopsy, endobronchial biopsy, and transbronchial biopsy. Minimally invasive techniques can be used to obtain specimens in patients with advanced unresectable NSCLC. In addition, the mediastinal lymph nodes are systematically sampled to assess the staging and therapeutic options.

Lobectomy or pneumonectomy specimens are evaluated intraoperatively to determine the surgical resection margin status, diagnose incidental nodules discovered at the time of surgery, or
evaluate the regional lymph nodes. Postoperative evaluation provides the pathology characteristics necessary for the classification of tumor type, staging, and prognostic factors. The surgical pathology report should include the histologic classification published by the WHO for carcinomas of the lung. However, the classification for lung adenocarcinoma was recently revised by an international panel (see the next section on Adenocarcinoma). The new classification requires immunohistochemical, histochemical, and molecular studies (see Principles of Pathologic Review in the NCCN NSCLC algorithm). In addition, the revised classification recommends that use of general categories (eg, NSCLC) should be minimized, because more effective treatment can be selected when the histology is known.

Adenocarcinoma

Recently, the classification for adenocarcinoma was revised; the categories of bronchioloalveolar carcinoma (BAC) or mixed subtype adenocarcinoma are no longer used. If necessary, the term “former BAC” is used. The new categories include: 1) adenocarcinoma in situ (AIS) (formerly BAC), which is a preinvasive lesion; 2) minimally invasive adenocarcinoma (MIA); 3) invasive adenocarcinoma (includes formerly nonmucinous BAC); and 4) variants of invasive adenocarcinoma (includes formerly mucinous BAC). Both AIS and MIA are associated with excellent survival if they are resected. The international panel and NCCN recommend that all patients with adenocarcinoma be tested for the EGFR mutation; the NCCN Panel also recommends that these patients be tested for ALK gene rearrangement. The terms AIS, MIA, and large cell carcinoma should not be used for small samples because of challenges with cytology specimens.

Immunohistochemical Staining

Immunostains are used to differentiate primary pulmonary adenocarcinoma from metastatic adenocarcinoma to the lung (eg, breast, prostate, colorectal), to distinguish adenocarcinoma from malignant mesothelioma, and to determine the neuroendocrine status of tumors. Immunohistochemical staining is described in the NCCN NSCLC algorithm (see Principles of Pathologic Review). However, limited use of immunohistochemistry in small tissue samples is recommended to conserve tumor tissue for molecular studies, especially in patients with advanced disease. Although cytology can be used to distinguish adenocarcinomas from squamous cell carcinomas, immunohistochemistry is also useful for poorly differentiated NSCLC in small biopsy and/or cytology specimens.

Squamous cell carcinomas are often TTF-1 negative and p63 positive, whereas adenocarcinomas are usually TTF-1 positive. These 2 markers may be sufficient to distinguish adenocarcinomas from squamous cell carcinomas. Other markers (eg, p40) may also be useful in distinguishing adenocarcinoma from squamous cell carcinoma.

Immunohistochemistry is most valuable in distinguishing between malignant mesothelioma and lung adenocarcinoma. The stains that are positive for adenocarcinoma include CEA (carcinoembryonic antigen), B72.3, Ber-EP4, MOC-31, and TTF-1; these stains are negative for mesothelioma. Stains that are sensitive and specific for mesothelioma include WT-1, calretinin, D2-40 (podoplanin antibody), and cytokeratin 5/6. A panel of 4 markers can be used to distinguish mesothelioma from adenocarcinoma—2 are positive in mesothelioma and 2 are positive in adenocarcinoma but negative in mesothelioma—
including calretinin, cytokeratin 5/6 (or WT-1), CEA, and MOC-31 (or B72.3, Ber-EP4, or BG-8).\textsuperscript{54,58}

TTF-1 is very important in distinguishing primary lung adenocarcinoma from metastatic adenocarcinoma, because most primary adenocarcinomas are TTF-1 positive. TTF-1 is typically negative for squamous cell carcinoma.\textsuperscript{51} However, TTF-1 is positive in tumors from patients with thyroid cancer.\textsuperscript{59} In addition, thyroglobulin is present in tumors from patients with thyroid cancer, while it is negative in lung cancer tumors. Pulmonary adenocarcinoma of the lung is usually CK7+ and CK20-, whereas metastatic adenocarcinoma of the colorectum is usually CK7- and CK20+. CDX2 is a marker for metastatic gastrointestinal malignancies that can be used to differentiate them from primary lung tumors. All typical and atypical carcinoid tumors are positive for chromogranin and synaptophysin, whereas SCLC is negative in 25\% of the cases.

Although the cytologic diagnosis of NSCLC is generally reliable, it is more difficult to diagnose SCLC.\textsuperscript{60,61} However, many patients with SCLC have characteristic CT and clinical findings (eg, massive lymphadenopathy, mediastinal invasion). Most SCLCs are immunoreactive for TTF-1; they are typically negative for CK34\beta\textsubscript{E12} and p63.\textsuperscript{62,63} Many SCLCs also stain positively for markers of neuroendocrine differentiation, including chromogranin A, neuron-specific enolase, neural cell adhesion molecule, and synaptophysin. However, these markers alone cannot be used to distinguish SCLC from NSCLC, because approximately 10\% of NSCLCs are immunoreactive for at least one of these neuroendocrine markers.\textsuperscript{64} Data suggest that microRNA expression can be used to distinguish SCLC from NSCLC.\textsuperscript{65}

**Staging**

The NCCN Guidelines use the AJCC (7th edition) staging system for lung cancer.\textsuperscript{66} The stage grouping is summarized in Table 2 of the staging tables (see Staging in the NCCN NSCLC algorithm). The descriptors of the TNM classification scheme are summarized in Table 3 of the staging tables (see Staging in the NCCN NSCLC algorithm). The lung cancer staging system was revised by the International Association for the Study of Lung Cancer (IASLC)\textsuperscript{67,68} and was adopted by the AJCC.\textsuperscript{69,70} The recent TNM staging revisions (AJCC 7th edition) became effective for all new cases diagnosed after January 1, 2010.\textsuperscript{66} With the new staging, locally advanced disease is now stage III; advanced disease is now stage IV. Pathologic staging uses both clinical staging information (which is noninvasive and includes medical history, physical examination, and imaging) and other invasive staging procedures (eg, thoracotomy, examination of lymph nodes using mediastinoscopy).\textsuperscript{71}

From 2005 to 2009, the overall 5-year relative survival rate for lung cancer was 15.9\% (from 17 SEER geographic areas in the United States). Of lung and bronchial cancer cases, 15\% were diagnosed while the cancer was still confined to the primary site (localized stage); 22\% were diagnosed after the cancer had spread to regional lymph nodes or directly beyond the primary site; 56\% were diagnosed after the cancer had already metastasized (distant stage); and for the remaining 6\% the staging information was unknown. The corresponding 5-year relative survival rates were 52\% for localized, 25\% for regional, 3.7\% for distant, and 7.9\% for unstaged (http://seer.cancer.gov/statfacts/html/lungb.html). However, these data include SCLC, which has a poorer prognosis.
Five-year survival after lobectomy for pathologic stage I NSCLC ranges from 45% to 65%, depending on whether the patient has stage 1A or 1B disease and on the location of the tumor. Another study in stage I patients (n=19,702) found that 82% had surgical resection and their 5-year overall survival was 54%; however, for untreated stage I NSCLC, 5-year overall survival was only 6%. Of stage I patients who refused surgery (although it was recommended), 78% died of lung cancer within 5 years.

Prognostic and Predictive Biomarkers

Several biomarkers have emerged as prognostic and predictive markers for NSCLC. Among these biomarkers, the evidence is strongest for EGFR, the 5’ endonuclease of the nucleotide excision repair complex (ERCC1), the KRAS oncogene, and the ALK fusion oncogene (fusion between anaplastic lymphoma kinase [ALK] and other genes [eg, echinoderm microtubule-associated protein-like 4]). A prognostic biomarker is a biomolecule that is indicative of patient survival independent of the treatment received; that is, the biomolecule is an indicator of the innate tumor aggressiveness. A predictive biomarker is a biomolecule that is indicative of therapeutic efficacy; that is, there is an interaction between the biomolecule and therapy on patient outcome.

The presence of the EGFR exon 19 deletion (LREA) or exon 21 L858R mutation does not appear to be prognostic of survival for patients with NSCLC, independent of therapy. However, the presence of the EGFR exon 19 deletion or exon 21 L858R mutation is predictive of treatment benefit from EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. High ERCC1 levels are prognostic of better survival for patients with NSCLC when compared to low levels of ERCC1 expression, independent of therapy. High levels of ERCC1 expression are also predictive of poor response to platinum-based chemotherapy. The presence of KRAS mutations is prognostic of poor survival for patients with NSCLC when compared to absence of KRAS mutations, independent of therapy. KRAS mutations are also predictive of lack of benefit from platinum/vinorelbine chemotherapy or EGFR TKI therapy. The ALK fusion oncogene (ie, ALK gene rearrangement) is a new predictive biomarker that has been identified in a small subset of patients with NSCLC (see the section on ALK Gene Rearrangements in this Discussion and Principles of Pathologic Review in the NCCN NSCLC algorithm). Other gene rearrangements (ie, gene fusions) have recently been identified (such as ROS1) that are susceptible to targeted therapy.

Testing for EGFR mutations and ALK gene rearrangements is recommended in the NCCN Guidelines for NSCLC for select patients (eg, those with adenocarcinoma) so that patients with these genetic abnormalities can receive effective treatment (eg, erlotinib, crizotinib). Patients with NSCLC may have other genetic abnormalities (http://www.mycancergenome.org/content/disease/lung-cancer). Mutation screening assays for detecting multiple biomarkers (eg, Sequenom's MassARRAY system, SNaPshot Multiplex System) have been developed that can detect more than 50 point mutations, including EGFR (http://www.mycancergenome.org/content/disease/lung-cancer). However, these systems do not detect gene rearrangements, because they are not point mutations. ALK gene rearrangements are detected using fluorescence in situ hybridization (FISH) (see the section on ALK Gene Rearrangements in this Discussion).
Other driver mutations and gene fusions (ie, driver events) are being identified such as HER2 (also known as ERBB2) and BRAF mutations, ROS1 and RET gene fusions, and MET amplification. Targeted agents are available for patients with these genetic alterations, although they are FDA approved for other indications (see Table 1 in this Discussion). However, note that the NCCN Guidelines for NSCLC only recommend crizotinib and erlotinib for patients with ALK or ROS1 gene fusions or EGFR mutations, respectively. Several online resources are available that describe NSCLC driver events such as DIRECT (DNA-mutation Inventory to Refine and Enhance Cancer Treatment) and My Cancer Genome.

**EGFR Mutations**

EGFR is a transmembrane receptor that is detectable in approximately 80% to 85% of patients with NSCLC, and the levels of expression vary widely on a continual scale. The most commonly found EGFR mutations in patients with NSCLC are deletions in exon 19 (Exon19del with conserved deletion of the LREA sequence in 45% of patients) and a mutation in exon 21 (L858R in 40%). Both mutations result in activation of the tyrosine kinase domain, and both are associated with sensitivity to the small molecule TKIs, erlotinib and gefitinib. These drug-sensitive mutations are found in approximately 10% of Caucasian patients with NSCLC and up to 50% of Asian patients. Other drug-sensitive mutations include point mutations at exon 21 (L861Q) and exon 18 (G719X). Primary resistance to TKI therapy is associated with KRAS mutations and ALK gene rearrangements. The EGFR T790M mutation is associated with acquired resistance to TKI therapy and has been reported in about 50% of patients with disease progression after initial response to erlotinib. Acquired resistance is also associated with histologic transformation from NSCLC to SCLC and with epithelial to mesenchymal transition (see Principles of Pathologic Review in the NCCN NSCLC algorithm).

DNA mutational analysis is the preferred method to assess for EGFR status. Various DNA mutation detection assays can be used to determine the EGFR mutation status in tumor cells. Direct sequencing of DNA corresponding to exons 18 to 21 (or just testing for exons 19 and 21) is a reasonable approach; however, more sensitive methods are available. Multiplex mutation screening assays (eg, Sequenom's MassARRAY system, SNaPshot Multiplex System) can detect more than 100 point mutations, including EGFR.

The predictive effects of the drug-sensitive EGFR mutations—Exon19del (LREA deletion) and L858R—are well defined. Patients with these mutations have a significantly better response to erlotinib or gefitinib. Retrospective studies have shown an objective response rate of approximately 80% with a median progression-free survival (PFS) of 13 months to single-agent therapy in patients with a bronchioloalveolar variant of adenocarcinoma and an EGFR mutation. A prospective study has shown that the objective response rate in North American patients with non-squamous NSCLC and EGFR mutations (53% Exon19del [LREA deletion], 26% L858R, 21% other mutations) is 55% with a median PFS of 9.2 months. EGFR mutation testing is not usually recommended in patients with pure squamous cell carcinoma, unless they are never smokers or only a small biopsy specimen (ie, not a surgical resection) was used to assess histology. Data suggest that EGFR mutations can occur in patients with adenosquamous carcinoma, which is harder to discriminate from squamous cell carcinoma in small specimens.
Recent data suggest that erlotinib (instead of standard first-line chemotherapy) should be used as first-line systemic therapy in patients with EGFR mutations documented before first-line therapy. Data show that PFS is improved with use of EGFR TKI in patients with EGFR mutations when compared with standard chemotherapy, although overall survival is not statistically different. Patients receiving erlotinib have fewer treatment-related severe side effects when compared with those receiving chemotherapy.

**ALK Gene Rearrangements**

Estimates are that 2% to 7% of patients have ALK gene rearrangements, about 10,000 patients in the United States. These patients are resistant to EGFR TKIs but have similar clinical characteristics to those with EGFR mutations (ie, adenocarcinoma histology, never smokers or light smokers) except they are more likely to be men and may be younger. In these selected populations, estimates are that about 30% of patients will have ALK rearrangements. EGFR mutations and ALK rearrangements are generally mutually exclusive. Thus, erlotinib (or gefitinib) is not recommended as second-line therapy in patients with ALK rearrangements who relapse on crizotinib (see Second-Line Therapy in the NCCN Guidelines for NSCLC). A molecular diagnostic test (using FISH) has been approved by the FDA for detecting ALK and is a prerequisite before treatment with crizotinib. Studies suggest that immunohistochemistry can be used to screen for ALK rearrangements; if positive, FISH analysis can be done to confirm ALK positivity.

Crizotinib is an inhibitor of ALK and MET tyrosine kinases that is approved by the FDA for patients with locally advanced or metastatic NSCLC who have the ALK gene rearrangement. Recently, crizotinib has been shown to yield very high response rates (>60%) and improve survival when used in patients with advanced NSCLC who have ALK rearrangements and have progressed on previous therapy. Crizotinib has relatively few side effects (eg, eye disorders, edema). However, a few patients have had life-threatening pneumonitis; crizotinib should be discontinued in these patients. Patients have responded rapidly to crizotinib with improvement in symptoms (eg, cough, dyspnea, pain), although median time to progression on crizotinib is less than 1 year. Newer ALK inhibitors are in development. Randomized phase III trials are comparing crizotinib with standard second-line chemotherapy (PROFILE-1007) and with standard first-line therapy (PROFILE 1014). Preliminary data presented at the European Society for Medical Oncology (ESMO) suggest that second-line therapy with crizotinib improves PFS and response rate when compared with single-agent therapy (either docetaxel or pemetrexed).

**ERCC1 Level of Expression**

ERCC1 is the 5' endonuclease of the nucleotide excision repair complex. It is found in all tumor cells, and its level of expression varies widely. In patients with completely resected NSCLC who did not receive perioperative chemotherapy or radiation, ERCC1 mRNA levels were prognostic of survival. Multiple translational investigations have provided evidence for the predictive use of ERCC1 levels to assess the efficacy of platinum-based chemotherapies in NSCLC; high levels are...
associated with resistance, while low levels are associated with sensitivity.\textsuperscript{78,134-136}

**KRAS Mutations**

Data suggest that approximately 25\% of adenocarcinomas in a North American population have KRAS mutations; KRAS is the most common mutation.\textsuperscript{44,75,81,94,95} KRAS mutation prevalence is associated with cigarette smoking.\textsuperscript{137} In its mutated form, KRAS is constitutively active, able to transform immortalized cells, and able to promote cell proliferation and survival.

KRAS mutational status is prognostic of survival. Patients with KRAS mutations appear to have a shorter survival than patients with wild-type KRAS.\textsuperscript{80,81,138} KRAS mutational status is also predictive of lack of therapeutic efficacy with EGFR-TKIs; however, it does not appear to affect chemotherapeutic efficacy.\textsuperscript{44,75} EGFR and KRAS mutations appear to be mutually exclusive.\textsuperscript{134} Targeted therapy is not currently available for patients with KRAS mutations, although MEK inhibitors are in clinical trials.\textsuperscript{95,139}

**Treatment Approaches**

Surgery, radiation therapy (RT), and chemotherapy are the 3 modalities commonly used to treat patients with NSCLC. They can be used either alone or in combination depending on the disease status. In the following sections, the clinical trials are described that have led to the standard treatments.

**Surgery**

In general, for patients with stage I or II disease, surgery provides the best chance for cure. However, thoracic surgical oncology consultation should be part of the evaluation of any patient being considered for curative local therapy. The overall plan of treatment and the necessary imaging studies should be determined before any nonemergency treatment is initiated.

The *Principles of Surgical Therapy* are described in the NCCN NSCLC algorithm and are summarized here. Determination of resectability, surgical staging, and pulmonary resection should be performed by board-certified thoracic surgeons who should participate in multidisciplinary clinics and/or tumor boards for lung cancer patients. Patients with pathologic stage II or greater disease can be referred to medical oncology for evaluation. Before surgery, patients with clinical stage II or greater disease can be referred to medical oncology for consideration of induction therapy.\textsuperscript{140-148} For patients with clinical stage IB disease, consider referral to a medical oncologist for possible induction therapy. For resected stage IIIA, consider referral to a radiation oncologist. If stereotactic ablative radiotherapy (SABR), also known as stereotactic body RT (SBRT), is considered for high-risk patients, a multidisciplinary evaluation is recommended (including a radiation oncologist). Treatment delays, because of poor coordination among specialists, should be avoided.

The surgical procedure used depends on the extent of disease and on the cardiopulmonary reserve of the patient. Lung-sparing anatomic resection (sleeve lobectomy) is preferred over pneumonectomy, if anatomically appropriate and if margin-negative resection can be achieved; lobectomy or pneumonectomy should be done if physiologically feasible.\textsuperscript{149,150} Sublobular resection, either segmentectomy (preferred) or wedge resection, is appropriate in select patients; the parenchymal resection margins are defined in the NCCN NSCLC algorithm (see *Principles of Surgical Therapy*).\textsuperscript{151,152} Resection
Sublobular resection, either segmentectomy (preferred) or wedge resection, is appropriate in select patients (see Principles of Surgical Therapy in the NCCN NSCLC algorithm): 1) those who are not eligible for lobectomy; and 2) those with a peripheral nodule 2 cm or less with very low-risk features. Segmentectomy (preferred) or wedge resection should achieve parenchymal resection margins that are: 1) 2 cm or more; or 2) the size of the nodule or more.

**Lymph Node Dissection**

A randomized trial (ACOSOG Z0030) compared systematic mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in patients with N0 (no demonstrable metastasis to regional lymph nodes) or N1 (metastasis to lymph nodes in the ipsilateral peribronchial and/or hilar region, including direct extension) NSCLC disease. In patients with early-stage disease who had negative nodes by systematic lymph node dissection, complete mediastinal lymph node dissection did not improve survival.\(^{157-159}\) Thus, systematic lymph node sampling is appropriate during pulmonary resection; one or more nodes should be sampled from all mediastinal stations. For right-sided cancers, an adequate mediastinal lymphadenectomy should include stations 2R, 4R, 7, 8, and 9. For left-sided cancers, stations 4L, 5, 6, 7, 8, and 9 should be sampled.\(^{160,161}\) Patients should have N1 and N2 node resection and mapping (American Thoracic Society map) with a minimum of 3 N2 stations sampled or a complete lymph node dissection. The lymph node map from the IASLC may be useful.\(^{162}\) Formal ipsilateral mediastinal lymph node dissection is indicated for patients undergoing resection for stage IIIA (N2) disease. For patients undergoing sublobular resection, the appropriate N1 and N2 lymph node stations should be sampled unless not technically feasible because it would substantially increase the surgical risk.

**Stage IIIA N2 Disease**

The role of surgery in patients with pathologically documented stage IIIA (N2) disease is discussed in the NCCN NSCLC algorithm (see Principles of Surgical Therapy) and is summarized here. Before treatment, it is essential to carefully evaluate for N2 disease using radiologic and invasive staging (ie, EBUS-guided procedures, mediastinoscopy, thorascopic procedures) and to discuss whether surgery is appropriate in a multidisciplinary team (which should include a board-certified thoracic surgeon).\(^{142,163}\) Randomized controlled trials suggest that surgery does not increase survival in these patients.\(^{164,165}\) However, one of these trials (EORTC) only enrolled unresectable patients. Most clinicians agree that resection is appropriate for patients with a negative preoperative mediastinum and with a single positive node (<3 cm) found at thoracotomy.\(^{166}\) Neoadjuvant therapy is recommended for select patients. In N2 patients, 50% of the NCCN Member Institutions use neoadjuvant chemoradiotherapy whereas 50% use neoadjuvant chemotherapy.\(^{167}\) However, there is no evidence that adding RT to induction regimens improves outcomes for patients with stage IIIA (N2) disease when compared with using chemotherapy alone.\(^{168}\) Clinicians also agree that resection is not appropriate for patients with multiple pathologically proven malignant lymph nodes
greater than 3 cm; definitive chemoradiotherapy is recommended for these patients.

The NCCN Panel believes that surgery may be appropriate for select patients with N2 disease, especially those who respond to induction chemotherapy (see Principles of Surgical Therapy in the NCCN NSCLC algorithm). However, it is controversial whether pneumonectomy after neoadjuvant chemoradiotherapy is appropriate. Patients with resectable N2 disease should not be excluded from surgery, because some of them may have long-term survival or may be cured.

Thorascopic Lobectomy

Video-assisted thoracic surgery (VATS), which is also known as thorascopic lobectomy, is a minimally invasive surgical treatment that is currently being investigated in all aspects of lung cancer (see Principles of Surgical Therapy in the NCCN NSCLC algorithm). Published studies suggest that thorascopic lobectomy has several advantages over the standard thoracotomy (or pleurotomy). Acute and chronic pain associated with thorascopic lobectomy is minimal; thus, this procedure requires a shorter length of hospitalization. Thorascopic lobectomy is also associated with low postoperative morbidity and mortality, minimal risk of intraoperative bleeding, or minimal locoregional recurrence. Thorascopic lobectomy is associated with less morbidity, fewer complications, and more rapid return to function than lobectomy by thoracotomy.

In stage I NSCLC patients who had thorascopic lobectomy with lymph node dissection, the 5-year survival rate, long-term survival, and local recurrence were comparable to those achieved by routine open lung resection. Thorascopic lobectomy has also been shown to improve discharge independence in older populations and in high-risk patients. Data show that thorascopic lobectomy improves the ability of patients to complete postoperative chemotherapy regimens. Based on its favorable effects on postoperative recovery and morbidity, thorascopic lobectomy is recommended in the NCCN NSCLC algorithm as an acceptable approach for patients who are surgically resectable (and have no anatomic or surgical contraindications) as long as standard principles of thoracic surgery are not compromised (see Principles of Surgical Therapy).

Radiation Therapy

General Principles

RT can be used as 1) adjuvant therapy for patients with resectable NSCLC who have no contraindications for surgery; 2) the primary local treatment (ie, definitive RT or SABR for patients with medically inoperable or unresectable NSCLC); and/or 3) palliative therapy for patients with incurable NSCLC. Treatment recommendations should be made by a multidisciplinary team. The goals of RT are to maximize tumor control and to minimize treatment toxicity. Advanced technologies such as 4D-conformal RT simulation, intensity-modulated radiotherapy/volumetric modulated arc therapy (IMRT/VMAT), image-guided RT, motion management strategies, and proton therapy have been shown to reduce toxicity and increase survival in nonrandomized trials. CT-planned 3D-conformal RT is now considered to be the minimum standard.

The NCCN NSCLC algorithm contains a Principles of RT section, which includes the following: 1) general principles for early-stage, locally advanced, and advanced NSCLC; 2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally advanced, and advanced NSCLC; and 3) radiation simulation, planning,
Whole brain RT and stereotactic radiosurgery (SRS) for brain metastases are also discussed in this section. The abbreviations for RT are defined in the NCCN NSCLC algorithm (see Table 1 in Principles of RT).

SABR is recommended for early-stage NSCLC patients (ie, stage I) who are medically inoperable and those who refuse surgery (see SABR in this Discussion). SABR is also an option for high surgical risk patients who cannot tolerate a lobectomy (eg, age 75 years or older, poor lung function). However, resection is recommended for medically fit patients with early-stage NSCLC (see Principles of Surgical Therapy in the NCCN NSCLC algorithm). Definitive chemoradiation is recommended for patients with locally advanced (ie, stage II–III) disease who are medically inoperable. For patients with advanced lung cancer (ie, stage IV) with extensive metastases, palliative RT can be used for primary or distant sites. The RT recommendations for stages I to IV are described in the Principles of RT section in the NCCN NSCLC algorithm.

The indications for using preoperative or postoperative chemoradiation or RT alone are described in the NCCN NSCLC algorithm (see Principles of Radiation Therapy). For example, in patients with clinical stage I or II NSCLC who are upstaged to N2+ after surgery, postoperative chemotherapy can be administered followed by postoperative RT depending on the margin status (see Adjuvant Treatment in the NCCN NSCLC algorithm). However, some suggest that preoperative chemoradiation alone is sufficient in patients with stage IIIA NSCLC; this is also an option in the NCCN NSCLC algorithm, although definitive concurrent chemoradiation is category 1. NCCN Member Institutions are evenly split in their use of neoadjuvant chemotherapy versus neoadjuvant chemoradiation in patients with stage IIIA N2 NSCLC.

To avoid postoperative pulmonary toxicity, some clinicians feel that preoperative chemoradiotherapy should be avoided if pneumonectomy would be required; however, this is a controversial issue (see Principles of Surgical Therapy in the NCCN NSCLC algorithm). Surgery is difficult in a field that has had 60 Gy, because the landmarks disappear with high doses of radiation. Thus, surgeons are often wary of resection in areas that have previously received RT doses of more than 45 Gy, especially in patients who have received RT doses of more than 60 Gy (ie, patients who have received definitive concurrent chemoradiation). Therefore, the radiation dose should be carefully considered if patients might be eligible for surgery. Soft tissue flap coverage can be considered in these patients. RT should continue to definitive dose without interruption if the patient is not a surgical candidate.

**Target Volumes, Prescription Doses, and Normal Tissue Dose Constraints**

The dose recommendations for preoperative, postoperative, definitive, and palliative RT are described in the Principles of RT section in the NCCN NSCLC algorithm (see Table 4). After surgery, lung tolerance to RT is much less than for patients with intact lungs. Thus, every effort should be made to minimize the [postoperative] dose of RT. Although the dose volume constraints for normal lungs are a useful guide (see Table 5 in Principles of Radiation Therapy in the NCCN NSCLC algorithm), more conservative constraints should be used for postoperative RT. For definitive RT, the commonly prescribed dose is 60 to 70 Gy in 2 Gy fractions. The use of higher RT doses is discussed in the Principles of RT section in the NCCN NSCLC algorithm.
Preliminary results from a phase III randomized trial (RTOG 0617) suggest that high-dose radiation (74 Gy) with concurrent chemotherapy does not improve survival when compared with standard-dose RT (60 Gy). For treatment volume consideration for 3D-conformal RT, planning target volume should be defined using the ICRU-50 and ICRU-62 (International Commission on Radiation Units and Measurements Reports 50 and 62) reports, based on gross tumor volume (GTV), plus clinical target volume margins for microscopic diseases, internal target volume margins for target motion, and margins for daily set-up errors (see Figure 1). ICRU Report 83 is used for IMRT. Additional volume considerations are described in the NCCN NSCLC algorithm (see the Principles of Radiation Therapy). It is essential to evaluate the dose volume histogram (DVH) of critical structures and to limit the doses to the spinal cord, lungs, heart, esophagus, and brachial plexus to minimize normal tissue toxicity (see Table 5 in Principles of Radiation Therapy in the NCCN NSCLC algorithm). These limits are mainly empirical. For patients receiving postoperative RT, more strict DVH parameters should be considered for the lungs.

**Radiation Simulation, Planning, and Delivery**

Treatment planning should be based on CT scans obtained in the treatment position. Intravenous contrast CT scans are recommended for better target delineation whenever possible, especially in patients with central tumors or with nodal diseases. PET/CT is recommended for select patients (ie, those with significant atelectasis, when IV contrast is contraindicated). PET/CT can significantly improve the target accuracy. In the Principles of RT section of the NCCN NSCLC algorithm, recommendations are provided for patients receiving chemoradiation (including those with compromised lung or cardiac function), photon beams, or IMRT (see Simulation, Planning, and Delivery). Whenever feasible, respiratory motion should be managed. Acceptable methods of accounting for tumor motion, per the AAPM Task Group 76 guideline, are described in the Principles of RT section of the NCCN NSCLC algorithm (see Simulation, Planning, and Delivery).

**Stereotactic Ablative Radiotherapy**

SABR (also known as SBRT) uses short courses of very high-dose RT that are precisely delivered to the target. Studies have shown that SABR is very useful for patients with inoperable stage I NSCLC or for those who refuse surgery. With conventional treatment, 3-year survival is only about 20% to 35% in these patients. There is a high rate of local failure in patients receiving conventional RT. However, local control is increased after SABR. In patients with stage I NSCLC, SABR provides a significantly longer survival than 3-D conformal RT. SABR yields a median survival of 32 months and a 3-year overall survival of about 43% in patients with stage I disease; patients with T1 tumors survive longer than those with T2 tumors (39 vs. 25 months). Randomized clinical trials are currently comparing SABR to surgery (ACOSOG Z4099/RTOG 1021). SABR can also be used for patients with limited lung metastases and for palliative therapy. Studies also suggest that SABR can be used for bone, liver, and brain metastases. A recent study reported that SABR increased survival in elderly patients (75 years or older) with stage I NSCLC who otherwise would not have received treatment. SABR is discussed in the Principles of RT section of the NCCN NSCLC algorithm; fractionation regimens and normal tissue constraints are also provided (see Tables 2 and 3). Decisions about whether to recommend SABR should be based on multidisciplinary discussion.
Hypofractionated or dose-intensified conventional 3D-conformal RT is an option if an established SABR program is not available.\textsuperscript{275}

**Radiofrequency Ablation**
Studies suggest that radiofrequency ablation (RFA) may be an option for node-negative patients who either refuse surgery or cannot tolerate surgery because of poor PS, significant cardiovascular risk, poor pulmonary function, and/or comorbidities. Optimal candidates for RFA include patients with an isolated peripheral lesion less than 3 cm; RFA can be used for previously irradiated tissue and for palliation.\textsuperscript{276} A study with RFA in 33 patients with NSCLC yielded overall survival of 70\% (95\% CI, 51\%–83\%) at 1 year and 48\% (95\% CI, 30\%–65\%) at 2 years. A 2-year overall survival of 75\% (95\% CI, 45\%–92\%) was reported in patients with stage I NSCLC (\textit{n}=13) who received RFA.\textsuperscript{277} The procedure-specific 30-day mortality rate is reported to be 2.6\%.\textsuperscript{278}

**Whole Brain RT and Stereotactic Radiosurgery**
Many patients with NSCLC have brain metastases (30\%–50\%), which substantially affect their quality of life.\textsuperscript{279} Surgery followed by whole brain RT is recommended (category 1) for select patients (those with good PS) with a single brain metastasis (see the NCCN Guidelines for NSCLC and Central Nervous System Cancers).\textsuperscript{280–283} SRS is another option after surgical resection, although there are only a few retrospective case series supporting this option.\textsuperscript{280} Patients with a single brain metastasis who cannot tolerate or refuse surgery may be treated with SRS with or without whole brain RT.\textsuperscript{279,284,285} Data suggest that erlotinib may be useful to manage brain metastases.\textsuperscript{286,287} Decisions about whether to recommend surgery, whole brain RT, SRS, or combined modality therapy for brain metastases should be based on multidisciplinary discussion, weighing the potential benefit over the risk for each individual patient.\textsuperscript{280,288} Treatment should be individualized for patients with recurrent or progressive brain lesions.\textsuperscript{289}

Some oncologists have been concerned that whole brain RT adversely affects neurocognition. However, a study of 208 patients with brain metastases found that patients who responded (with tumor shrinkage) after whole brain radiation had improved neurocognitive function and that tumor progression affects neurocognition more than whole brain RT.\textsuperscript{290} In 132 patients with 1 to 4 brain metastases who received SRS with or without whole brain RT, survival was similar in both groups.\textsuperscript{285} In a subset of 92 of these patients who received SRS with or without whole brain RT, controlling the brain tumor with combined therapy was more important for stabilizing neurocognitive function.\textsuperscript{291} However, a study in 58 patients found that patients who received SRS plus whole brain RT had fewer CNS recurrences but had worse neurocognition when compared with patients receiving SRS alone.\textsuperscript{292} Some have suggested that using resection with SRS (instead of resection with whole brain RT) will decrease neurocognitive problems.\textsuperscript{293}

**Combined Modality Therapy**
As previously mentioned, surgery provides the best chance for cure for patients with stage I or II disease who are medically fit and can tolerate surgery. However, SABR can be considered for patients with stage I disease who are unresectable or refuse surgery (see section on Stereotactic Ablative Radiotherapy in this Discussion). In patients with completely resected NSCLC, adjuvant chemotherapy has been shown to improve survival in patients with early-stage disease.\textsuperscript{294–296} Studies suggest that neoadjuvant chemotherapy (which is the administration of chemotherapy before surgery) is as effective as and better tolerated than adjuvant chemotherapy (see Neoadjuvant Chemotherapy).
Followed by Surgery: Trial Data in this Discussion. Neoadjuvant chemotherapy is also referred to as induction chemotherapy or preoperative chemotherapy. Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease.

For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial. Of interest, data show that early palliative care combined with standard care improves quality of life, mood, and survival in patients with metastatic NSCLC, even though these patients had less aggressive therapy when compared with those receiving standard care alone. Surgery is rarely done for patients with stage IV disease. However, surgical resection of a solitary brain metastasis may improve survival in selected patients with stage IV disease and is recommended in the NCCN NSCLC algorithm (see also the NCCN Guidelines for Central Nervous System Cancers).

Local therapy of a solitary metastasis located in sites other than the brain remains controversial and thus is a category 2B recommendation; however, SRS or SABR may be useful in these settings (see Stage IV, M1b: Solitary Site/Initial Treatment in the NCCN NSCLC algorithm). The trials supporting the recommendations for combined modality therapy are discussed in this section.

Surgery Followed by Chemotherapy: Trial Data
In the NCCN algorithm for stage IA disease, adjuvant chemotherapy is not recommended based on the trials described in the following paragraphs. Adjuvant chemotherapy is only recommended for high-risk, margin-negative, stage IB disease (see the NCCN NSCLC algorithm). Recommended chemotherapy regimens for neoadjuvant and adjuvant therapy are provided in the NCCN NSCLC algorithm.

The International Adjuvant Lung Cancer Trial (IALT) reported a statistically significant survival benefit with cisplatin-based adjuvant therapy in patients with completely resected stage I, II, or III NSCLC. The study included 1867 patients with surgically resected lung cancer who were randomly assigned either to cisplatin-based adjuvant chemotherapy or to observation, with a median follow-up duration of 56 months. A significantly higher survival rate (45% vs. 40% at 5 years; hazard ratio for death, 0.86; 95% CI, 0.76–0.98; P < .03) and disease-free survival rate (39% vs. 34% at 5 years; hazard ratio, 0.83; 95% CI, 0.74–0.94; P < .003) were observed for patients assigned to chemotherapy when compared with observation. IALT data suggest that cisplatin-based adjuvant chemotherapy improves survival 5 years after treatment in patients with completely resected NSCLC. However, after 7.5 years of follow-up, there were more deaths in the chemotherapy group and the benefit of chemotherapy decreased over time. However, data show that adjuvant chemotherapy prevents recurrences.

The NCIC CTG JBR.10 trial and the ANITA trial compared the effectiveness of adjuvant vinorelbine plus cisplatin versus observation in early-stage NSCLC. In the JBR.10 trial, 482 patients (ECOG PS of 0–1) with completely resected stage IB (T2, N0) or stage II (T1, N1, or T2, N1) NSCLC were randomly assigned either to vinorelbine plus cisplatin or to observation. Adjuvant chemotherapy significantly prolonged overall survival (94 vs. 73 months, hazard ratio for death, 0.69, P = .04) and relapse-free survival (not reached vs. 47 months, hazard ratio for recurrence, 0.60; P < .001) when compared with observation alone. The 5-year survival rates were 69% and 54%, respectively (P = .03). However, updated data from JBR.10 after 9 years of follow-up show that when compared with observation alone,
adjuvant chemotherapy is beneficial for stage II but not for stage IB patients. In stage II patients receiving adjuvant chemotherapy, median survival is 6.8 versus 3.6 years in those who were only observed. Of note, patients receiving chemotherapy did not have an increased death rate.

In the ANITA trial, 840 patients with stage IB (T2, N0), II, or IIIA NSCLC were randomly assigned either to adjuvant vinorelbine plus cisplatin or to observation. Grade 3/4 toxicities were manageable in the chemotherapy group; however, 7 toxic deaths were reported. After a median follow-up of 76 months, median survival was 66 months in the chemotherapy group and 44 months in the observation group. Adjuvant chemotherapy significantly improved (8.6%) the 5-year overall survival in patients with completely resected stage II and IIIA disease, although no benefit was observed in stage I. Some clinicians consider vinorelbine/cisplatin to be the preferred regimen for completely resected early-stage NSCLC based on the number of trials and the amount of use.

A meta-analysis of 4,584 patients (LACE) found that postoperative cisplatin-based chemotherapy increased survival over 5 years (absolute benefit of 5.4%); there was no difference among the chemotherapy regimens (vinorelbine, etoposide, and others). A subgroup analysis found that cisplatin/vinorelbine also increased survival. The benefit was greater in patients with stage II and III disease and with good PS. Postoperative adjuvant chemotherapy benefited elderly patients up to 80 years old.

The CALGB 9633 trial assessed paclitaxel and carboplatin in patients with T2, N0, M0, stage IB lung cancer; updated results have been reported. In this trial, 344 patients were randomly assigned either to paclitaxel and carboplatin or to observation (within 4–8 weeks of resection) with a median follow-up duration of 74 months. Adjuvant chemotherapy was well tolerated with no chemotherapy-related toxic deaths. Overall survival at 6 years was not significantly different, although 3-year survival was significant (80% vs. 73%, \( P = .02 \)). The original results from CALGB suggested that the paclitaxel and carboplatin regimen improved survival in patients with stage I disease; however, the updated results did not show improved survival (although a subset analysis showed a benefit for tumors 4 cm or more). Thus, the carboplatin/paclitaxel regimen is only recommended if patients cannot tolerate cisplatin (see Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy in the NCCN NSCLC algorithm). However, it is important to note that the CALGB trial was underpowered for stage 1B patients.

Neoadjuvant Chemotherapy Followed by Surgery: Trial Data
Data from adjuvant clinical trials in patients with resected NSCLCs indicate that delivery of chemotherapy is an important problem. In the postoperative setting, significant comorbidities and incomplete recovery after surgery often make it difficult for patients to tolerate therapy. This problem was recently demonstrated in the NATCH phase III trial (which compared surgery alone to preoperative or postoperative chemotherapy with paclitaxel/carboplatin), because 90% of the preoperative cohort completed 3 cycles of chemotherapy but only 61% of the postoperative cohort completed chemotherapy; however, survival was equivalent among all 3 arms.

Several trials suggest that neoadjuvant therapy is beneficial in patients with N2 disease. Other trials suggest that neoadjuvant therapy is beneficial in patients with earlier stage disease. A randomized trial by Depierre et al. enrolled 355 patients with stage IB to IIIA NSCLC.
and assessed preoperative chemotherapy followed by surgery compared with surgery alone. The objective response rate was 64% to preoperative therapy and the pathologic complete response rate was 11%. Patients receiving neoadjuvant therapy had a median survival of 37 months compared with 26 months for surgery alone. Median disease-free survival was significantly better for the neoadjuvant chemotherapy arm (27 vs. 13 months).

The BLOT trial evaluated neoadjuvant and adjuvant paclitaxel/carboplatin in 94 patients with stage IB to IIIA NSCLC. Most patients (96%) received the planned preoperative chemotherapy, and 56% attained a major objective response. The pathologic complete response rate was 6%. After 5 years, the improvement in overall survival was 9%; postoperative mortality was 3% for those who had lobectomy. In this study, 96% of patients completed preoperative chemotherapy, whereas only 45% completed postoperative chemotherapy. A follow-up, randomized intergroup trial (SWOG 9900) evaluated neoadjuvant paclitaxel/carboplatin in 354 patients with stage IB to IIIA (but not N2) disease versus surgery alone. The trial closed prematurely because of practice changes and was therefore not appropriately powered. However, this SWOG trial did show a trend toward improved PFS (33 vs. 20 months) and overall survival (62 vs. 41 months) with neoadjuvant chemotherapy, and no difference in resection rates between the 2 arms.

Scagliotti et al. published a phase III trial of preoperative cisplatin and gemcitabine versus surgery alone in 270 patients with stage IB to IIIA disease. Although the trial closed early, a significant survival benefit was seen in patients with stages IIB and IIIA disease who received chemotherapy (HR, 0.63). Song et al. published a meta-analysis of all available randomized clinical trials evaluating preoperative chemotherapy in resectable NSCLCs. This meta-analysis evaluated 13 randomized trials and found improvement in overall survival in the neoadjuvant chemotherapy arm when compared with the surgery alone arm (HR, 0.84; 95% CI, 0.77–0.92; \( P = .0001 \)). These results are similar to those recently reported in another meta-analysis (HR, 0.89; 95% CI, 0.81–0.98; \( P = .02 \)). The benefit from neoadjuvant chemotherapy is similar to that attained with postoperative chemotherapy.

**Chemoradiation: Trial Data**

The major controversies in NSCLC relate to the management of patients with stage IIIA disease (see the Role of Surgery in Patients with Stage IIIA (N2) NSCLC in Principles of Surgical Therapy in the NCCN NSCLC algorithm). All 3 treatment modalities—surgical resection, chemotherapy, and radiation—may be used in treating stage III disease. The ongoing debate centers on which modalities to use and in what sequence. For patients with unresectable stage IIIA or stage IIIB disease, combined modality therapy (chemoradiation) is superior to radiation alone. However, concurrent chemoradiation is superior to sequential therapy. Concurrent chemoradiation has a higher rate of grade 3 or 4 esophagitis than sequential therapy. Patient selection affects not only the response to therapy but also how well the patient tolerates therapy.

Concurrent chemoradiation regimens that may be used for all histologies for initial treatment include cisplatin/etoposide (preferred) or cisplatin/vinblastine (preferred) (see Chemotherapy Regimens Used With RT in the NCCN NSCLC algorithm). For non-squamous NSCLC, other concurrent chemoradiation regimens include carboplatin/pemetrexed and cisplatin/pemetrexed. A randomized controlled trial in 203 unresectable patients with either stage IIIA or IIIB
NSCLC assessed induction chemotherapy followed by either radiotherapy alone or chemoradiation using paclitaxel; median survival was 14.1 versus 18.7 months ($P = .091$), respectively.\textsuperscript{328}

**Chemotherapy: Trial Data**

Patients with stage IV disease who have a good PS benefit from chemotherapy, usually with a platinum-based regimen.\textsuperscript{303,304,329} Many drugs are useful for stage IV NSCLC. These drugs include platinum agents (eg, cisplatin, carboplatin), taxanes (eg, paclitaxel, albumin-bound paclitaxel, docetaxel), vinorelbine, vinblastine, etoposide, pemetrexed, and gemcitabine (see *Systemic Therapy for Advanced or Metastatic Disease* in the NCCN NSCLC algorithm). Combinations using many of these drugs produce 1-year survival rates of 30\% to 40\% and are superior to single agents. Regimens include carboplatin/paclitaxel, cisplatin/paclitaxel, cisplatin/vinorelbine, gemcitabine/cisplatin, cisplatin/pemetrexed, and docetaxel/cisplatin.\textsuperscript{316,330-333} In the United States, frequently used first-line regimens for non-squamous NSCLC include: 1) cisplatin (or carboplatin)/pemetrexed; or 2) carboplatin/paclitaxel (with or without bevacizumab).\textsuperscript{334,335} Gemcitabine/cisplatin is used for patients with squamous cell carcinoma.\textsuperscript{333-336} These regimens are commonly used based on phase III randomized trials (ie, cisplatin/pemetrexed, carboplatin/paclitaxel [with or without bevacizumab], gemcitabine/cisplatin).\textsuperscript{333,337}

Recently, many oncologists have been using pemetrexed-based regimens for adenocarcinomas, because taxane-based regimens are associated with more toxicity (eg, neurotoxicity).\textsuperscript{333,338,339} The POINTBREAK trial showed that carboplatin/pemetrexed/bevacizumab is a reasonable option and confirmed that taxane-based regimens are more toxic than pemetrexed-based regimens.\textsuperscript{339} However, the POINTBREAK trial showed that both regimens are similar in regard to overall survival rates; therefore, oncologists may return to using taxane-based regimens, which are well established.\textsuperscript{339} A retrospective cohort study suggests that the addition of bevacizumab (to carboplatin/paclitaxel) does not increase survival in older patients (65 years or older) with advanced non-squamous NSCLC.\textsuperscript{340}

For patients with advanced NSCLC who have a PS of 2 (ie, poor PS), single-agent chemotherapy or platinum-based combinations are recommended in the NCCN Guidelines.\textsuperscript{341} Single-agent chemotherapy includes vinorelbine, gemcitabine, pemetrexed, or taxanes; combination chemotherapy regimens include carboplatin/paclitaxel or carboplatin/pemetrexed.\textsuperscript{342,344} However, patients with a PS of 2 are often just treated with one chemotherapy agent because of concerns about toxicity.\textsuperscript{345} Preliminary results from a recent trial reported that treatment with carboplatin/pemetrexed increased median overall survival when compared with pemetrexed alone (9.1 vs. 5.6 months) in patients with a PS of 2; however, 4 treatment-related deaths occurred in the carboplatin/pemetrexed arm.\textsuperscript{342}

Phase III randomized trials have shown that many of the platinum-doublet combinations yield similar objective response rates and survival.\textsuperscript{346,347} The platinum-doublet regimens differ slightly for toxicity, convenience, and cost; thus, clinicians can individualize therapy for their patients.\textsuperscript{336,348,349} Other carboplatin-based regimens include gemcitabine/carboplatin, docetaxel/carboplatin, and pemetrexed/carboplatin,\textsuperscript{330,350-352} non–platinum-based regimens such as gemcitabine/vinorelbine and gemcitabine/docetaxel are also options.\textsuperscript{353-356} In spite of the development of new chemotherapy regimens, the prognosis for advanced inoperable lung cancer remains poor.
Note that albumin-bound paclitaxel can be substituted for paclitaxel or docetaxel for patients 1) who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication; or 2) in whom the standard premedications (ie, dexamethasone, H2 blockers, H1 blockers) to prevent hypersensitivity are contraindicated. A recent phase III randomized trial reported that an albumin-bound paclitaxel/carboplatin regimen is associated with less neurotoxicity and improved response rate, when compared with standard paclitaxel/carboplatin, in patients with advanced NSCLC. The FDA has approved albumin-bound paclitaxel/carboplatin for patients with locally advanced or metastatic NSCLC who are not candidates for curative surgery or RT. Based on the recent trial and the FDA approval, the NCCN Panel recommends an albumin-bound paclitaxel/carboplatin regimen as first-line therapy for patients with advanced NSCLC and good PS (0–1).

**Targeted Therapies**

Specific targeted therapies have been developed for the treatment of advanced lung cancer. Bevacizumab is a recombinant monoclonal antibody that blocks the vascular endothelial growth factor. Erlotinib is a small molecule inhibitor of EGFR; crizotinib is a small molecule inhibitor that targets ALK and MET. Both erlotinib and crizotinib are oral TKIs. Cetuximab is a monoclonal antibody that targets EGFR.

In 2006, the FDA approved bevacizumab for patients with unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. ECOG recommends bevacizumab in combination with paclitaxel and carboplatin for select patients with advanced non-squamous NSCLC based on the results of phase II to III clinical trials (ECOG 4599). To receive treatment with bevacizumab and chemotherapy, patients must meet the following criteria: non-squamous NSCLC and no recent history of hemoptysis. Any regimen with a high risk for thrombocytopenia—and, therefore, possible bleeding—should be used with caution when combined with bevacizumab. For patients with non-squamous NSCLC and PS 0 to 1 who are negative for either EGFR mutations or ALK gene fusions, bevacizumab in combination with chemotherapy is one of the recommended options (see Adenocarcinoma, Large Cell, NSCLC NOS: EGFR Mutation or ALK Negative/First-Line Therapy in the NCCN NSCLC algorithm).

Erlotinib was approved by the FDA in 2004 for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. However, erlotinib is also recommended as first-line therapy in patients with advanced, recurrent, or metastatic non-squamous NSCLC who have known active EGFR mutation or gene amplification regardless of their PS (see Adenocarcinoma, Large Cell, NSCLC NOS: EGFR Mutation or ALK Positive in the NCCN NSCLC algorithm). This recommendation is based on the results of a phase III randomized trial (IPASS) in which patients with EGFR mutations who received gefitinib had increased PFS (24.9% vs. 6.7%), response rate (71.2% vs. 47.3%), and quality of life with fewer side effects (eg, neutropenia) when compared with those receiving chemotherapy (carboplatin/paclitaxel). Updated results from the IPASS study show that overall survival was similar in patients receiving gefitinib or chemotherapy regardless of EGFR mutation status. However, these results probably occurred because patients who had been assigned to first-line chemotherapy were able to receive TKIs as subsequent therapy if they were found to have EGFR mutations. TKIs are recommended in patients with EGFR mutations, because quality of life is improved when compared with chemotherapy. Gefitinib is not
Erlotinib is an orally active TKI that is very well tolerated by most patients. An analysis of 5 clinical trials in mainly Western patients (n = 223) with advanced NSCLC (stage IIIB or IV) found that patients with EGFR mutations who received TKIs had a 67% response rate and an overall survival of about 24 months. The recent TORCH trial suggests that EGFR mutation testing should be done in patients with advanced non-squamous NSCLC. Survival was increased in patients with wild-type EGFR who received first-line chemotherapy compared with those who received erlotinib first followed by second-line chemotherapy (11.6 vs. 8.7 months). The OPTIMAL trial found that PFS was increased in patients with EGFR mutations who received erlotinib. ASCO recommends that patients be tested for EGFR mutations. However, the NCCN and ESMO Guidelines specify that only patients with non-squamous NSCLC (eg, adenocarcinoma) be assessed for EGFR mutations. Patients with pure squamous cell carcinoma are unlikely to have EGFR mutations; however, those with adenosquamous carcinoma may have mutations. Crizotinib is approved by the FDA for patients with locally advanced or metastatic NSCLC who are positive for the ALK gene rearrangement. The approval is based on an ongoing phase II trial that showed dramatic response rates (>80%) in patients who had previously progressed. Patients receiving crizotinib reported clinically significant improvements in pain, dyspnea, and cough.

A large phase III randomized trial (FLEX) assessed cisplatin/vinorelbine with or without cetuximab for patients with advanced NSCLC (most patients had stage IV disease). Adding cetuximab slightly increased overall survival (11.3 vs. 10.1 months, \(P = .04\)). Cetuximab/cisplatin/vinorelbine is an option for patients with advanced NSCLC without EGFR mutations or ALK rearrangements, regardless of histology (see First-Line Therapy for Adenocarcinoma or Squamous Cell Carcinoma in the NCCN NSCLC algorithm). However, the cetuximab/cisplatin/vinorelbine regimen has a category 2B recommendation in the NCCN guidelines because the benefits are very slight, it is a difficult regimen to administer, and patients have poorer tolerance for this regimen when compared with other regimens (eg, almost 40% of patients have grade 4 neutropenia). Patients may also have comorbid conditions that prevent them from receiving cisplatin (eg, poor kidney function). Some clinicians feel that although the FLEX trial results were statistically significant they were not clinically significant.

**Maintenance Therapy**

Maintenance therapy refers to systemic therapy that may be given for patients with advanced NSCLC after 4 to 6 cycles of first-line chemotherapy. However, patients are only candidates for maintenance therapy if they have responded to their previous treatment (ie, tumor response) or have stable disease and their tumors have not progressed. **Continuation maintenance** therapy refers to the use of at least one of the agents that was given in the first-line regimen. **Switch maintenance** therapy refers to the initiation of a different agent that was not included as part of the first-line regimen. Selection of appropriate maintenance therapy depends on several factors (eg, histologic type, PS). Maintenance therapy is an option in the NCCN Guidelines for select patients with tumor response or stable disease and is not considered standard of care for all patients (eg, not recommended for PS 3–4, those with progression); close observation or continuation of the current regimen until disease progression are also valid treatment options (see the NCCN NSCLC algorithm).
For continuation maintenance therapy, select agents (which were initially given in combination with conventional chemotherapy) may be continued until evidence of disease progression or unacceptable toxicity, as per the design of the clinical trials that led to their approval. Single-agent bevacizumab (category 1) may be continued beyond 4 to 6 cycles of initial therapy (ie, platinum-doublet chemotherapy given with bevacizumab) in patients with non-squamous NSCLC who are negative for EGFR mutations or ALK fusions. Single-agent pemetrexed (category 1) may also be given as continuation maintenance therapy in patients with non-squamous NSCLC (who are negative for EGFR mutations or ALK fusions). A recent phase III randomized trial (PARAMOUNT) found that continuation maintenance therapy with pemetrexed slightly increased PFS when compared with placebo (4.1 vs. 2.8 months). Preliminary results suggest that continuation maintenance therapy with pemetrexed also improves overall survival (13.9 vs. 11.0 months). Based on the recent trial and the FDA approval, the NCCN Panel recommends single-agent pemetrexed as continuation maintenance therapy (category 1) in patients with non-squamous NSCLC who are EGFR mutation negative or ALK fusion negative. Single-agent cetuximab (category 1) may be continued beyond 4 to 6 cycles of initial therapy (ie, cisplatin, vinorelbine, and cetuximab therapy) in patients with non-squamous NSCLC (who are negative for EGFR mutations or ALK fusions) or those with squamous histology.

Continuation maintenance therapy using bevacizumab/pemetrexed is also an option in patients with non-squamous NSCLC (who are negative for EGFR mutations or ALK fusions); this is a category 2A recommendation. Preliminary data from the recent POINTBREAK study showed a very slight improvement in PFS (6 vs. 5.6 months) when comparing bevacizumab/pemetrexed versus bevacizumab alone as maintenance therapy; the initial regimens were either bevacizumab/carboplatin/pemetrexed or bevacizumab/carboplatin/paclitaxel. It is important to note that the pemetrexed-based arm was associated with less toxicity (eg, less neurotoxicity, less neutropenia, less hair loss) than the paclitaxel-based arm. When using bevacizumab/pemetrexed versus bevacizumab alone as maintenance therapy, preliminary data from the recent AVAPERL study showed a 3.6-month increase in PFS (10.2 vs. 6.6 months); the initial regimen was bevacizumab/cisplatin/pemetrexed. A recent phase III randomized trial compared using maintenance therapy with either gemcitabine or erlotinib after first-line therapy with cisplatin-gemcitabine. Data show that continuation maintenance therapy with single-agent gemcitabine increased PFS to a greater extent (3.8 months) than switch maintenance therapy with erlotinib (2.9 months) when compared with observation (1.9 months). Another phase III randomized trial assessed continuation maintenance therapy with gemcitabine versus best supportive care after an initial regimen of cisplatin/gemcitabine. The data showed a slight difference in PFS but no difference in overall survival. The NCCN guidelines recommend using gemcitabine as continuation maintenance therapy regardless of histology in patients negative for EGFR mutations or ALK fusions.

Use of continuation maintenance therapy depends on several factors such as whether the patient had minimal toxicity during treatment. A drug “vacation” may be more appropriate for some patients.
clinchars feel that continuation maintenance therapy is only appropriate for select patients, because it has not been shown to improve overall survival or quality of life, although it has been shown to improve PFS. In addition, maintenance therapy has not been shown to be superior to second-line therapy, which is initiated at disease progression.

Data from a phase III randomized trial suggest that conventional cytotoxic agents should not be continued beyond 4 to 6 cycles of therapy; however, many patients assigned to a longer duration of therapy did not receive the planned number of cycles (see Maintenance Therapy in this Discussion). Clinicians feel that if the patient is responding to the cytotoxic chemotherapy then it should be continued, because increasing evidence indicates that outcomes are improved (see Maintenance Therapy in this Discussion).

For switch maintenance therapy, 2 phase III randomized trials have shown a benefit in PFS and overall survival with the initiation of pemetrexed or erlotinib after first-line chemotherapy (4–6 cycles) in patients with no apparent disease progression. Switch maintenance therapy with pemetrexed may be initiated in patients with histologies other than squamous cell carcinoma who are negative for EGFR mutations or ALK fusions. The FDA has approved maintenance therapy with pemetrexed (http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021462s043lbl.pdf). Likewise, switch maintenance therapy with erlotinib may be initiated in patients with or without EGFR mutations or with squamous cell carcinoma. Both erlotinib and pemetrexed have a category 2A recommendation for switch maintenance therapy in the NCCN NSCLC algorithm, although pemetrexed is not recommended for squamous cell carcinoma. A phase III trial assessed switch maintenance therapy with docetaxel given either immediately after chemotherapy or delayed until progression. However, switch maintenance therapy with docetaxel is a category 2B recommendation in the NCCN Guidelines for patients with squamous cell carcinoma only because many patients in the delayed chemotherapy arm did not receive docetaxel. Switch maintenance therapy is actually the early administration of a therapy known to improve outcome. However, issues have been raised about the design of the trials for switch maintenance therapy.

Recently, an updated study (CALGB 30406) compared erlotinib alone versus erlotinib/carboplatin/paclitaxel in patients (mainly Caucasian) with advanced NSCLC. The data showed that erlotinib alone was associated with fewer side effects in patients with EGFR mutations when compared with erlotinib/chemotherapy. Thus, it is appropriate to switch to maintenance therapy with erlotinib in patients found to have EGFR mutations during chemotherapy (see EGFR Mutation Positive/First-Line Therapy in the NCCN NSCLC algorithm). The FDA has approved maintenance therapy with erlotinib (http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021743s017lbl.pdf).

Clinical Evaluation

As previously described, low-dose CT screening is now recommended for asymptomatic select patients who are at high risk for lung cancer (see the NCCN Guidelines for NSCLC and Lung Cancer Screening). Low-dose CT screening may find lung nodules that are suspicious for cancer; the workup and evaluation of these lung nodules is described in the NCCN algorithm (see Diagnostic Evaluation of Lung Nodules in this Discussion and see Principles of Diagnostic Evaluation in the NCCN NSCLC algorithm). This new section on workup and evaluation of...
suspicious lung nodules was added for the 2013 update along with a new section on multiple lung cancers (see Multiple Lung Cancers in this Discussion and the NCCN NSCLC algorithm).

After patients are confirmed to have NSCLC based on a pathologic diagnosis, a clinical evaluation needs to be done (see the NCCN NSCLC algorithm). In symptomatic patients, the clinical stage is initially determined from disease history (ie, cough, dyspnea, chest pain, weight loss) and physical examination together with a limited battery of tests (see Evaluation and Clinical Stage in the NCCN NSCLC algorithm). Note that for some patients, the diagnosis, staging, and surgical resection are done during the same operative procedure. A multidisciplinary evaluation should be done before treatment. The NCCN Panel also recommends that smoking cessation counseling be provided to patients (http://www.smokefree.gov/expert.aspx). Based on the initial evaluation, the clinical stage is determined and the patient is assigned to one of the pathways that are defined by the stage, specific subdivision of the particular stage, and location of the tumor.

Additional Pretreatment Evaluation

Mediastinoscopy

As previously noted, evaluation of the mediastinal nodes is a key step in the further staging of the patient. Although PET/CT scans can be used as an initial assessment of the hilar and mediastinal nodes (ie, the presence of N1, N2, or N3, which are key determinants of stage II and stage III disease), CT scans have known limitations for evaluating the extent of lymph node involvement in lung cancer.\textsuperscript{393-395} Mediastinoscopy is the gold standard for evaluating mediastinal nodes. Thus, mediastinoscopy is encouraged as part of the initial evaluation, particularly if the results of imaging are not conclusive and the probability of mediastinal involvement is high (based on tumor size and location). Therefore, mediastinoscopy is appropriate for patients with T2 to T3 lesions even if the PET/CT scan does not suggest mediastinal node involvement. Mediastinoscopy may also be appropriate to confirm mediastinal node involvement in patients with a positive PET/CT scan. In contrast, because of the low prior probability of lymph node involvement in patients with peripheral T1ab, N0 lesions, some NCCN Member Institutions do not use routine mediastinoscopy in these patients (category 2B). However, in patients with peripheral T2a, central T1ab, or T2 lesions with negative PET/CT scans, the risk for mediastinal lymph node involvement is higher and mediastinoscopy and/or endoscopic ultrasound–guided FNA (EUS-FNA) and EBUS–guided transbronchial needle aspiration (EBUS-TBNA) are recommended (see next section and the NCCN NSCLC algorithm).

Dillems et al. have reported a selective mediastinoscopy strategy, proceeding straight to thoracotomy without mediastinoscopy for T1 peripheral tumors without enlarged mediastinal lymph nodes on preoperative CT.\textsuperscript{397} This strategy resulted in a 16% incidence of positive N2 nodes discovered only at the time of thoracotomy. For identifying N2 disease, chest CT scans had sensitivity and specificity rates of 69% and 71%, respectively. However, using both the chest CT scan plus mediastinoscopy was significantly more accurate (89% vs. 71%) than using the chest CT scan alone for identifying N2 disease. When using CT scans, node positivity is based on the size of the lymph nodes. Therefore, the CT scan will miss small metastases that do not result in node enlargement. To address this issue, Arita et al. specifically examined lung cancer metastases to normal size mediastinal lymph nodes in 90 patients and found an incidence of 16% (14/90).
false-negative chest CT scans with histologic identification of occult N2 or N3 disease.  

Bronchoscopy is used in diagnosis and local staging of both central and peripheral lung lesions and is recommended for pretreatment evaluation of stage I to IIA tumors. However, in patients who present with a solitary pulmonary nodule where the suspicion of malignancy is high, surgical resection without prior invasive testing may be reasonable.

**Other Imaging Studies**

As previously mentioned, CT scans have known limitations for evaluating the extent of lymph node involvement in lung cancer. PET scans have been used to help evaluate the extent of disease and to provide more accurate staging. The NCCN Panel reviewed the diagnostic performance of CT and PET scans. The NCCN Panel believes that PET scans can play a role in the evaluation and more accurate staging of NSCLC, for example, in identifying stage I (peripheral and central T1–2, N0), stage II, stage III, and stage IV diseases. However, PET/CT is even more sensitive and is recommended by NCCN.

The NCCN Panel assessed studies that examined the sensitivity and specificity of chest CT scans for mediastinal lymph node staging. Depending on the clinical scenario, a sensitivity of 40% to 65% and a specificity of 45% to 90% were reported. Because they detect tumor physiology, as opposed to anatomy, PET scans may be more sensitive than CT scans. Moreover, if postobstructive pneumonitis is present, there is little correlation between the size of the mediastinal lymph nodes and tumor involvement. Chin et al. found that PET, when used to stage the mediastinal nodes, was 78% sensitive and 81% specific with a negative predictive value of 89%. Kernstine et al. compared PET scan to CT scan for identifying N2 and N3 disease in NSCLC. The PET scan was found to be more sensitive than the CT scan in identifying mediastinal node disease (70% vs. 65%). PET/CT has been shown to be useful in restaging patients after adjuvant therapy.

When patients with early-stage disease are accurately staged using PET/CT, inappropriate surgery is avoided. However, positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation (eg, MRI of bone). If the PET/CT scan is positive in the mediastinum, the lymph node status needs pathologic confirmation. Transesophageal EUS-FNA and EBUS-TBNA have proven useful to stage patients or to diagnose mediastinal lesions; these techniques can be used instead of invasive staging procedures in select patients. When compared with CT and PET, EBUS-TBNA has a high sensitivity and specificity for staging mediastinal and hilar lymph nodes in patients with lung cancer. In patients with positive nodes on CT or PET, EBUS-TNBA can be used to clarify the results. However, in patients with negative findings on EBUS-TNBA, conventional mediastinoscopy can be done to confirm the results. Note that EBUS is also known as endosonography.

The routine use of bone scans (to exclude bone metastases) is not recommended. Brain MRI (to rule out asymptomatic brain metastases) is recommended for patients with stage II, III, and IV disease to rule out metastatic disease if aggressive combined-modality therapy is being considered. For patients with stage IB NSCLC, brain MRI only has a category 2B recommendation because they are less likely to have brain metastases. Note that PET scans are not recommended for assessing the presence of brain metastases (see the NCCN Guidelines for Central Nervous System Cancers).
Initial Therapy

Before treatment, it is strongly recommended that determination of tumor resectability be made by board-certified thoracic surgeons who perform lung cancer surgery as a prominent part of their practice (see Principles of Surgical Therapy in the NCCN NSCLC algorithm). Principles of RT recommends doses for RT (see the NCCN NSCLC algorithm). In addition, the NCCN NSCLC algorithm also recommends regimens for chemotherapy and chemoradiation (see Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy, Chemotherapy Regimens Used With Radiation Therapy, and Systemic Therapy for Advanced or Metastatic Disease).

Stage I, Stage II, and Stage IIIA Disease

Depending on the extent and type of comorbidity present, patients with stage I or a subset of stage II (T1–2, N1) tumors are generally candidates for surgical resection and mediastinal lymph node dissection. In some instances, positive mediastinal nodes (N2) are discovered at surgery; in this setting, an additional assessment of staging and tumor resectability must be made, and the treatment (ie, inclusion of systematic mediastinal lymph node dissection) must be modified accordingly. Therefore, the NCCN NSCLC algorithm includes 2 different tracks for T1–3, N2 disease (ie, stage IIIA disease): 1) T1–3, N2 disease discovered unexpectedly at surgical exploration; and 2) T1–3, N2 disease confirmed before thoracotomy. In the second case, an initial brain MRI and PET/CT scan (if not previously done) are recommended to rule out metastatic disease.

For patients with clinical stage IIB (T3, N0) and stage IIIA (T4, N0–1) tumors, treatment options are organized according to the location of the tumor (ie, the superior sulcus, chest wall, proximal airway, or mediastinum). For each location, a thoracic surgeon needs to determine whether the tumor is resectable (see Principles of Surgical Therapy in the NCCN NSCLC algorithm).

For patients with resectable tumors (T3 invasion, N0–1) in the superior sulcus, the NCCN Panel recommends preoperative concurrent chemoradiation therapy followed by surgical resection and chemotherapy (see the NCCN NSCLC algorithm). Neoadjuvant concurrent chemoradiation followed by surgical resection of a superior sulcus tumor has shown 2-year survival in the 50% to 70% range. The overall 5-year survival rate is approximately 40%. Patients with marginally resectable superior sulcus tumors should undergo concurrent chemoradiation before surgical re-evaluation. For patients with unresectable tumors (T4 extension, N0–1) in the superior sulcus, definitive concurrent chemoradiation is recommended followed by 4 cycles of full-dose chemotherapy if full-dose chemotherapy was not initially given.

Surgical resection is the preferred treatment option for patients with tumors of the chest wall, proximal airway, or mediastinum (T3–4, N0–1). Other treatment options include chemotherapy or concurrent chemoradiation before surgical resection. For unresectable T4, N0–1 tumors without pleural effusion, definitive concurrent chemoradiation (category 1) is recommended. If full-dose chemotherapy was not given initially as concurrent treatment, then an additional 4 cycles of full-dose chemotherapy can be administered (see Adjuvant Treatment in the NCCN NSCLC algorithm).
For patients with stage IIIA disease and positive mediastinal nodes (T1–3, N2), treatment is based on the findings of pathologic mediastinal lymph node evaluation (see the NCCN NSCLC algorithm). Patients with negative mediastinal biopsy findings are candidates for surgery, with additional assessment of resectability at the time of thoracotomy. For those patients with resectable lesions, mediastinal lymph node dissection or lymph node sampling should be performed during the surgery. Those individuals found to have unresectable lesions should be treated according to pathologic stage (see the NCCN NSCLC algorithm). For patients with (T1–2 or T3) node-positive disease, a brain MRI and PET/CT scan (if not done previously) are recommended to search for distant metastases. When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy (see the NCCN NSCLC algorithm). Induction chemotherapy with (or without) RT is another option for patients with T1–3, N2 disease. Recommended therapy for metastatic disease is described in the NCCN NSCLC algorithm.

When a lung metastasis is present, it usually occurs in patients with other systemic metastases; the prognosis is poor. Therefore, many of these patients are not candidates for surgery; however, systemic therapy is recommended. Although uncommon, patients with lung metastases but without systemic metastases have a better prognosis and are candidates for surgery (see next section on Multiple Lung Cancers in this Discussion). Patients with separate pulmonary nodule(s) in the same lobe or ipsilateral non-primary lobe without other systemic metastases are potentially curable by surgery; 5-year survival rates are about 30%. Intrapulmonary metastases have been downstaged in the TNM staging (ie, AJCC 7th edition).

After surgery, chemoradiation plus chemotherapy is recommended for those with positive margins and chemotherapy alone is recommended for those with negative margins (see Adjuvant Treatment in the NCCN NSCLC algorithm). In patients with synchronous solitary nodules (contralateral lung), the guidelines recommend treating them as 2 primary lung tumors if both are curable, even if the histology of the 2 tumors is similar (see the NCCN NSCLC algorithm).431

Multiple Lung Cancers
In 2013, a new algorithm was added for patients with multiple lung cancers (see the NCCN NSCLC algorithm). Multiple lung cancers may be suspected or detected in various ways. Patients with a history of lung cancer or those with biopsy-proven synchronous lesions may be suspected of having multiple lung cancers (see “Clinical Presentation” in the NCCN Guidelines for NSCLC).432,433 It is important to determine whether the multiple lung cancers are metastases or separate lung primaries (synchronous or metachronous), because most multiple lung tumors are metastases.40,434,435 Therefore, it is essential to determine the histology of the lung tumor (see Principles of Pathologic Review in the NCCN NSCLC algorithm). Infection and other benign diseases also need to be ruled out (eg, inflammatory granulomas).436,437 Although criteria have been established for diagnosing multiple lung cancers, no definitive method has been established before treatment.437-440 The Martini and Melamed criteria are often used to diagnose multiple lung cancers as follows: 1) the histologies are different; 2) the histologies are the same but there is no lymph node involvement and no extrathoracic metastases.440

Treatment of multiple lung cancers depends on status of the lymph nodes (eg, N0–1) and on whether the lung cancers are asymptomatic,
Multiple lung nodules (e.g., solid, subsolid nodules) may also be detected on low-dose CT scans; some of these nodules can be followed with imaging, whereas others need to be biopsied or excised (see the NCCN Guidelines for Lung Cancer Screening). The Fleischner Society has recommendations for patients with solid nodules and has recently developed recommendations for those with subsolid nodules. Subsolid nodules include pure ground glass nodules and part-solid ground glass nodules. Ground glass nodules are also known as non-solid nodules or ground glass opacities. Solid nodules are more likely to be malignant than part-solid nodules, but ground glass nodules are the least malignant, which is reflected in the NCCN Guidelines for Lung Cancer Screening.

Stage IIIIB Disease

Stage IIIIB tumors comprise 2 groups, including: 1) T1–3, N3 tumors; and 2) T4 extension and N2–3 tumors, which are unresectable and include contralateral mediastinal nodes (T4, N3). Surgical resection is not recommended in patients with T1–3, N3 disease. However, in patients with suspected N3 disease, the guidelines recommend pathologic confirmation of nodal status (see Pretreatment Evaluation in the NCCN NSCLC algorithm). In addition, PET/CT scans (if not previously done) and brain MRI should also be included in the pretreatment evaluation. If these tests are negative, then treatment options for the appropriate nodal status should be followed (see the NCCN NSCLC algorithm). If N3 disease is confirmed, definitive concurrent chemoradiation (category 1) is recommended followed by 4 cycles of full-dose chemotherapy if full-dose chemoradiation was not initially given. For metastatic disease that is confirmed by PET/CT scan and brain MRI, treatment is described in the NCCN NSCLC algorithm.

For patients with T4 extension, N2–3 disease (stage IIIIB), surgical resection is not generally recommended. The initial workup includes biopsies of the N3 and N2 nodes. If these biopsies are negative, the same treatment options may be used as for stage IIIA (T4, N0–1) disease (see the NCCN NSCLC algorithm). If either the contralateral or ipsilateral mediastinal node is positive, definitive concurrent chemoradiation therapy is recommended (category 1) followed by 4 cycles of full-dose chemotherapy if full-dose chemoradiation was not given initially (see the NCCN NSCLC algorithm).

Stage IV Disease

Pleural or pericardial effusion is a criterion for stage IV, M1a disease. T4 with pleural effusion is classified as stage IV, M1a (see Table 3 in the Staging section of the NCCN NSCLC algorithm). Although pleural effusions are malignant in 90% to 95% of patients, they may be related to obstructive pneumonitis, atelectasis, lymphatic or venous obstruction, or a pulmonary embolus. Therefore, pathologic confirmation of a malignant effusion by using thoracentesis or pericardiocentesis is recommended. In certain cases where thoracentesis is inconclusive, thorascopy may be performed. In the absence of nonmalignant causes (e.g., obstructive pneumonia), an exudate or sanguinous effusion is considered malignant no matter what
the results of cytologic examination. If the pleural effusion is considered negative, recommended treatment is based on the confirmed T and N stage (see the NCCN NSCLC algorithm). However, all pleural effusions, whether malignant or not, are associated with unresectable disease in 95% of cases. In patients with effusions that are positive for malignancy, the tumor is treated as M1a with local therapy (ie, ambulatory small catheter drainage, pleurodesis, and pericardial window) in addition to treatment as for stage IV disease (see the NCCN NSCLC algorithm).

The NCCN NSCLC algorithm for patients with distant metastases (ie, stage IV, M1b) depends on the location of the metastases—a solitary nodule in the brain or adrenal gland—the diagnosis of which is aided by mediastinoscopy, bronchoscopy, PET/CT scan, and brain MRI. The increased sensitivity of PET/CT scans, compared with other imaging methods, may identify additional metastases and, thus, spare some patients from unnecessary surgery. However, positive PET/CT scan findings for distant disease need pathologic or other radiologic confirmation. If the PET/CT scan is positive in the mediastinum, the lymph node status needs pathologic confirmation.

Patients with solitary brain metastases may benefit from surgical resection (see the section on Whole Brain RT and Stereotactic Radiosurgery in this Discussion, and the NCCN Guidelines for Central Nervous System Cancers and NSCLC). The 5-year survival rates with such an approach range from 10% to 20%; median survival is about 40 weeks. Follow-up whole brain RT (category 1) or SRS may be used. SRS alone or followed by whole brain radiation are additional treatment options. Such therapy can be effective in patients who have surgically inaccessible brain metastases and in individuals with multiple lesions. After their brain lesions are treated, further treatment options for these patients with T1–2, N0–1 NSCLC or for those with T3, N0 then include: 1) surgical resection of the lung lesion followed by chemotherapy; 2) SABR of the lung lesion; or 3) additional chemotherapy followed by surgical resection of the lung lesion. Systemic therapy is an option after surgery for patients with higher stage NSCLC.

Metastases to the adrenal gland from lung cancer are a common occurrence, with approximately 33% of patients having such disease at autopsy. In patients with otherwise resectable primary tumors, however, many solitary adrenal masses are not malignant. Any adrenal mass found on a preoperative CT scan in a patient with lung cancer should be biopsied to rule out benign adenoma. Local therapy (category 2B) of the adrenal lesion has produced some long-term survivors when an adrenal metastasis has been found and the lung lesion has been curable (see the NCCN NSCLC algorithm). Some NCCN Panel members feel that local therapy for adrenal metastases is only advisable if the synchronous lung disease is stage I or possibly stage II (ie, resectable). Systemic therapy is another treatment option for adrenal metastasis.

Adjuvant Treatment
Chemotherapy or Chemoradiation
Treatment options for patients with stage IA tumors (T1ab, N0) and with positive surgical margins (R1, R2) include re-resection (preferred) or RT (category 2B). Observation is recommended for patients with T1ab, N0 tumors and with negative surgical margins (R0). Patients with T2ab, N0 tumors with negative surgical margins are usually observed; chemotherapy (category 2B) is recommended as adjuvant treatment for patients with high-risk features (including poorly differentiated tumors,
vascular invasion, wedge resection, tumors greater than 4 cm, visceral pleural involvement, and incomplete lymph node sample [Nx]) (see the NCCN NSCLC algorithm). \(^{315}\) If the surgical margins are positive in patients with T2ab, N0 tumors, these patients should have either 1) re-resection (preferred) with or without chemotherapy; or 2) RT with or without chemotherapy (chemotherapy is used for stage IIA). \(^{209,315}\)

The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab–2a, N1; 2) T2b, N1; or 3) T3, N0 disease. \(^{311,463}\) If surgical margins are positive in these patients, options include: 1) re-resection and chemotherapy; or 2) chemoradiation and chemotherapy. Patients with T1–3, N2 disease (discovered only at surgical exploration and mediastinal lymph node dissection) and positive margins may be treated with chemoradiation and chemotherapy (see the NCCN NSCLC algorithm). Patients with negative margins may be treated with chemotherapy (category 1) and RT. \(^{311}\)

NCCN Panel members disagreed about the use of chemoradiation for stage II disease with negative margins based on the results of the Intergroup E3590 trial. \(^{208}\) In this trial, no difference in survival rates was observed between stage II and stage IIIA patients who had a surgical resection and received either adjuvant radiotherapy alone (median survival = 39 months) or radiotherapy given with concurrent chemotherapy (median survival = 38 months).

As with stage IB and stage II surgically resected disease, cisplatin-based doublet adjuvant chemotherapy can be used in stage III NSCLC patients who have had surgery (see the NCCN NSCLC algorithm). In the case of marginally resectable superior sulcus tumors (T4 extension, N0–1), if the lesion converts to a resectable status following concurrent chemoradiation, resection followed by chemotherapy is recommended (see the NCCN NSCLC algorithm). If the lesion does not convert (ie, it remains unresectable), the full course of definitive RT followed by chemotherapy is administered as an adjuvant treatment. Among patients with chest wall lesions with T3 invasion–T4 extension, N0–1 disease, those who are initially treated with surgery (preferred) may receive chemotherapy alone if the surgical margins are negative; when surgical margins are positive, they may receive either chemoradiation and chemotherapy or re-resection with chemotherapy. A similar treatment plan is recommended for resectable tumors of the proximal airway or mediastinum (T3–4, N0–1).

For patients with stage IIIA disease and positive mediastinal nodes (T1–3, N2) with no apparent disease progression after initial treatment, recommended treatment includes surgery with (or without) chemotherapy (category 2B) (see the NCCN NSCLC algorithm). In addition, postoperative RT is recommended if not used preoperatively. Alternatively, if the disease progresses, patients may be treated with either 1) local therapy using RT (if not given previously) with (or without) chemotherapy; or 2) systemic treatment (see the NCCN NSCLC algorithm). In patients with separate pulmonary nodules in the same lobe or ipsilateral lung, surgery is recommended (see the NCCN NSCLC algorithm). If the margins are negative, adjuvant chemotherapy is recommended. If the resection margins are positive, concurrent chemoradiation with chemotherapy is recommended.

Because patients with stage III disease have both local and distant failures, theoretically, the use of chemotherapy may eradicate micrometastatic disease obviously present but undetectable at diagnosis. The timing of this chemotherapy varies, with no one clear preference. Such chemotherapy may be given alone, sequentially, or
concurrently with RT. In addition, chemotherapy could be given preoperatively or postoperatively in appropriate patients.

On the basis of clinical studies on neoadjuvant and adjuvant chemotherapy for NSCLC, the NCCN Panel has included cisplatin combined with vinorelbine, vinblastine, or etoposide for adjuvant chemotherapy in the guidelines; other options include cisplatin combined with gemcitabine, pemetrexed, or docetaxel (see the NCCN NSCLC algorithm). For patients with comorbidities or those who cannot tolerate cisplatin, carboplatin combined with paclitaxel is an option. A recent phase III randomized trial in elderly (70–89 years) patients with advanced NSCLC reported that combined therapy with weekly paclitaxel and monthly carboplatin improved survival when compared with single-agent therapy using either gemcitabine or vinorelbine (10.3 vs. 6.2 months). A number of phase II studies have evaluated neoadjuvant chemotherapy for stage III NSCLC, with or without RT, followed by surgery.

Three phase III trials have assessed neoadjuvant chemotherapy followed by surgery compared with surgery alone in the treatment of stage III NSCLC. The S9900 trial (a SWOG study)—one of the largest randomized trials examining preoperative chemotherapy in early-stage NSCLC—assessed surgery alone compared with surgery plus preoperative paclitaxel and carboplatin in patients with stage IB/IIIA and stage IIB/IIIA NSCLC (excluding superior sulcus tumors). PFS and overall survival were improved with preoperative chemotherapy. All 3 studies showed a survival advantage for patients who received neoadjuvant chemotherapy. The 2 earlier phase III studies had a small number of patients, while the SWOG study was stopped early because of the positive results of the IALT study. However, the induction chemotherapy-surgery approach needs to be compared with induction chemotherapy-RT in large, randomized clinical trials.

Radiation Therapy

NCCN Panel Members disagreed (category 2B) about using postoperative RT alone as adjuvant treatment for T1ab, N0 tumors based on a 1998 published report (PORT Meta-analysis Trialists Group, 1998). This study showed that postoperative radiotherapy is detrimental to patients with early-stage, completely resected NSCLC and should not be given routinely to such patients. However, the NCCN Panel found several flaws in the meta-analysis, including:

- Many patients were treated with cobalt-60 equipment, which delivers an inhomogeneous dose distribution;
- Studies from the 1960s, when there was no adequate staging, were included in the meta-analysis;
- The data analysis lacked detailed timing for postoperative RT;
- Node-negative NSCLC patients were included (these patients routinely do not receive postoperative RT); and
- The meta-analysis included unpublished data.

An assessment of postoperative radiation in 7,465 patients with resected stage II or III NSCLC found that postoperative radiation increased survival in patients with N2 disease but not in those with N1 or N0 disease. Therefore, guidelines from some cancer organizations recommend that postoperative RT should only be given to those with N2 disease. The ANITA trial also found that postoperative RT increased survival in patients with N2 disease who received adjuvant chemotherapy. Postoperative adjuvant chemotherapy (category 1) with RT is recommended for T1–3, N2 patients with negative margins (see Adjuvant Treatment in the NCCN NSCLC algorithm).
A meta-analysis assessed postoperative chemotherapy with or without postoperative RT in patients mainly with stage III disease.\textsuperscript{463} In this meta-analysis, 70% of the eligible trials used adjuvant chemotherapy before RT; 30% used concurrent chemo/RT. Regimens included cisplatin/vinorelbine followed by RT or concurrent cisplatin/etoposide. The American College of Radiology appropriateness criteria provide specific recommendations for postoperative adjuvant therapy.\textsuperscript{475,476}

Either concurrent or sequential chemoradiation may be used for postoperative adjuvant therapy, depending on the type of resection and the setting (eg, N2 disease) (see the NCCN NSCLC algorithm). Concurrent chemo/RT is recommended for R2 resections, whereas sequential chemo/RT is recommended for R1 resections. Cisplatin/etoposide is the preferred concurrent neoadjuvant chemoradiation regimen recommended by the NCCN Panel.\textsuperscript{324} Chemoradiation regimens cited in the NCCN Guidelines may also be used for stage II to III disease.\textsuperscript{210,211,297,298,325-327}

**Surveillance**

The surveillance guidelines are described in the NCCN NSCLC algorithm. A helical chest CT scan with or without contrast is recommended every 6 to 12 months postoperatively for 2 years (category 2B); a non–contrast-enhanced chest CT is recommended annually thereafter (category 2B), although there was less consensus among the NCCN Panel about these recommendations for helical chest CT scans.\textsuperscript{32} Information about smoking cessation (eg, advice, counseling, therapy) should be provided to aid the treatment of lung cancer and to improve the quality of life of the patients (http://www.smokefree.gov/). Recent data show that low-dose CT screening of select current and former smokers at high risk for lung cancer (ie, $\geq 30$ pack-years of smoking) decreased the mortality from lung cancer.\textsuperscript{36} However, use of low-dose CT for surveillance is not currently recommended by the NCCN Panel for patients who have been previously treated for lung cancer.

The NCCN Guidelines for NSCLC include a section on long-term follow-up care of NSCLC survivors (see Cancer Survivorship Care in the NCCN NSCLC algorithm). These recommendations include guidelines for routine cancer surveillance, immunizations, health monitoring, counseling for wellness and health promotion, and cancer screening. A recent analysis suggests that patients who survive lung cancer have a high symptom burden 1 year after diagnosis and therefore need management after treatment.\textsuperscript{477}

**Treatment of Recurrences and Distant Metastases**

Recurrences are subdivided into locoregional recurrences and distant metastases. Management of locoregional recurrences (eg, endobronchial obstruction, mediastinal lymph node recurrence, superior vena cava obstructions, severe hemoptysis) is described in the NCCN NSCLC algorithm (see Therapy for Recurrence and Metastasis). For patients with endobronchial obstruction, relieving airway obstruction may increase survival, especially in severely compromised patients, and may improve the quality of life.\textsuperscript{478} After the treatment for the locoregional recurrence, observation or systemic chemotherapy (category 2B for chemotherapy) is recommended if disseminated disease is not evident. However, for observed disseminated disease, systemic chemotherapy is recommended. The type of systemic therapy depends on the histologic type, EGFR mutation or ALK rearrangement status, and PS (see the NCCN NSCLC algorithm).
Management of distant metastases (eg, localized symptoms; bone, solitary, diffuse brain, or disseminated metastases) is described in the NCCN NSCLC algorithm (see Therapy for Recurrence and Metastasis). Palliation of symptoms can be achieved with external-beam RT for distant metastases with localized symptoms, diffuse brain metastases, or bony metastasis. Bisphosphonate therapy or denosumab can be considered in patients with bone metastasis. In patients with NSCLC who have bone metastases, data suggest that denosumab increases median overall survival when compared with zoledronic acid (9.5 vs. 8 months). Denosumab can be associated with severe hypocalcemia; patients with hypoparathyroidism and vitamin D deficiency are at increased risk for hypocalcemia. The FDA has approved the use of zoledronic acid in patients with bone metastases from solid tumors.

For patients with recurrent and metastatic disease, the NCCN NSCLC guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected (see Histologic Subtype in the NCCN NSCLC algorithm). EGFR mutation testing is recommended in patients with non-squamous NSCLC (ie, adenocarcinoma, large cell carcinoma) or in NSCLC not otherwise specified (NOS), because erlotinib is recommended for patients who are positive for EGFR mutations (see section on EGFR Mutation Positive/First-Line Therapy in the NCCN NSCLC algorithm). Testing for ALK rearrangements is also recommended in patients with non-squamous histology, because crizotinib is recommended for patients who are positive for ALK rearrangements. Crizotinib is also recommended for patients who are positive for ROS1 rearrangements. As previously mentioned, recent recommendations from an international panel suggest that general categories be avoided (eg, NSCLC), because more effective treatment can be selected when the histology is known. However, very few patients with pure squamous cell carcinoma have EGFR mutations (<4%); therefore, routine testing is not recommended in these patients.

Treatment recommendations and eligibility criteria for patients with non-squamous NSCLC (or NSCLC NOS) who are negative for EGFR mutations or ALK rearrangements are described in the NCCN NSCLC algorithm. Treatment recommendations and eligibility criteria for patients with squamous cell carcinoma are also described in the NCCN NSCLC algorithm. These recommendations are briefly summarized in the following paragraph. Data supporting these recommendations are described in the following section (see next section on Trial Data).

In general, 2-drug regimens (ie, doublet chemotherapy) are recommended over single agents (see Systemic Therapy for Advanced or Metastatic Disease in the NCCN NSCLC algorithm); however, targeted therapy can also be added to the 2-drug regimen (eg, the addition of bevacizumab to carboplatin/paclitaxel). Single-agent targeted therapy may also be recommended for select patients with EGFR mutations or ALK rearrangements.

Cisplatin/pemetrexed is recommended (category 1) for patients with non-squamous NSCLC who are negative for EGFR mutations or ALK rearrangements if eligibility criteria are met (ie, they do not have squamous cell carcinoma). Bevacizumab/chemotherapy is another option for patients with non-squamous NSCLC who are negative for EGFR mutations or ALK rearrangements if eligibility criteria are met. Previously, patients with brain metastases were excluded from receiving bevacizumab because of concerns about CNS hemorrhage; however, data suggest that bevacizumab can be used in patients with...
treated CNS metastases.\textsuperscript{390} Other chemotherapy options are also recommended, although some regimens may be more appropriate for certain patients, depending on PS and other factors (see next section on \textit{Trial Data}). NCCN Panel Members disagree (category 2B) about using cetuximab with cisplatin and vinorelbine, because data only show a slight improvement in survival with the addition of cetuximab (11.3 vs. 10.1 months, \(P = .04\)) and because this regimen is generally not used in the United States because of concerns about toxicity with cisplatin.\textsuperscript{369} Cisplatin/gemcitabine is an option for patients with squamous cell carcinoma.\textsuperscript{333} Another option is cetuximab with cisplatin and vinorelbine, although this is a category 2B recommendation.\textsuperscript{369}

\textbf{Trial Data}

In a phase II/III trial (ECOG 4599), 878 patients were randomly assigned to either 1) bevacizumab in combination with paclitaxel and carboplatin; or 2) paclitaxel and carboplatin alone.\textsuperscript{337,491} Both regimens were well tolerated with selected toxicities. Patients receiving bevacizumab/paclitaxel/carboplatin showed an improved median survival (12.3 vs. 10.3 months, \(P = .003\)) when compared to patients receiving paclitaxel and carboplatin alone.\textsuperscript{337} The overall 1-year and 2-year survival was 51\% vs. 44\% and 23\% vs. 15\%, respectively, in favor of the bevacizumab/paclitaxel/carboplatin arm.\textsuperscript{337} However, more significant toxicities were observed with bevacizumab/paclitaxel/carboplatin compared to paclitaxel and carboplatin (grade 4 neutropenia: 25.5\% vs. 16.8\%, grade 5 hemoptysis: 1.2\% vs. 0\% and grade 3 hypertension: 6.8\% vs. 0.5\%). Treatment-related deaths were more common with bevacizumab/paclitaxel/carboplatin (15 patients) than with paclitaxel and carboplatin (2 patients) \((P = .001)\).

A recent analysis of ECOG 4599 found that adenocarcinoma histology was associated with improved survival in patients receiving bevacizumab/paclitaxel/carboplatin compared with chemotherapy alone (14.2 vs. 10.3 months).\textsuperscript{489} However, a trial (AVAiL) comparing cisplatin/gemcitabine with or without bevacizumab did not show an increase in survival with the addition of bevacizumab.\textsuperscript{492,493} A noninferiority trial in 1725 patients with advanced NSCLC (either stage IIIb or IV; most were stage IV) assessed cisplatin plus gemcitabine compared with cisplatin plus pemetrexed.\textsuperscript{333} Patients with either adenocarcinoma or large cell carcinoma (ie, non-squamous NSCLC) had improved survival with cisplatin/pemetrexed (adenocarcinoma: 12.6 vs. 10.9 months). Patients with squamous cell carcinoma had improved survival with the cisplatin/gemcitabine regimen (10.8 vs. 9.4 months). When compared with the cisplatin/gemcitabine regimen, the cisplatin/pemetrexed regimen had significantly lower rates of grade 3 or 4 neutropenia, anemia, and thrombocytopenia \((P \leq .001)\); febrile neutropenia \((P = .002)\); and alopecia \((P < .001)\). Treatment-related deaths were similar for both regimens (cisplatin plus pemetrexed, 9 patients [1.0\%]; cisplatin plus gemcitabine, 6 patients [0.7\%]). A recent analysis of three phase 3 trials confirmed that pemetrexed improves survival for patients with non-squamous NSCLC in first-line, second-line, and maintenance therapy.\textsuperscript{494} In the FLEX trial, 1125 patients with advanced NSCLC (either stage IIIB or IV; most were stage IV) were randomly assigned to either 1) cetuximab in combination with vinorelbine and cisplatin; or 2) vinorelbine and cisplatin alone.\textsuperscript{369} The response rate was increased with cetuximab (36\% vs. 29\%, \(P = .01)\); there was no difference in PFS. Overall survival was slightly better in patients receiving cetuximab (11.3
vs. 10.1 months, \( P = .04 \)). However, patients receiving cetuximab had increased grade 4 events versus control (62% vs. 52%, \( P < .01 \)); cetuximab was also associated with grade 2 acne-like rash. Treatment-related deaths were similar in both groups (3% vs. 2%).

Data show that platinum-based combination therapy is superior to best supportive care for patients with advanced, incurable disease. Cisplatin or carboplatin have been proven effective in combination with any of the following agents: docetaxel, etoposide, gemcitabine, paclitaxel (and albumin-bound paclitaxel), pemetrexed, vinblastine, and vinorelbine. Non-platinum regimens (e.g., gemcitabine/docetaxel, gemcitabine/vinorelbine) are reasonable alternatives because data show they are active and less toxic than platinum-based regimens.

Number of Cycles of First-Line Systemic Therapy

Patients receiving first-line systemic therapy for advanced disease should be evaluated for tumor response with a CT scan. Approximately 25% of patients show disease progression after the initial cycle of chemotherapy; second-line therapy is recommended for these patients (see the NCCN NSCLC algorithm). Patients with responsive or stable disease can continue to receive a total of 4 to 6 cycles of systemic therapy or until the disease progresses. Recent data from the PARAMOUNT trial suggest that 4 cycles of platinum-based therapy is not optimal; tumors can shrink between 4 to 6 cycles of chemotherapy. However, patients may not be able to tolerate more than 4 cycles of chemotherapy, and most of the maintenance trials used only 4 cycles of chemotherapy. A meta-analysis suggests that continuing the initial regimen beyond 4 to 6 cycles is associated with increased PFS; however, patients have more adverse events. A phase III randomized trial suggested that continuing chemotherapy beyond 4 to 6 cycles is not beneficial; however, many patients assigned to longer duration of therapy did not receive the planned number of cycles. In this phase III trial, taxane-based regimens were used and patients had increasing neurotoxicity as more cycles were used.

Many patients with adenocarcinoma now receive pemetrexed-based regimens and not taxane-based regimens. Pemetrexed-based regimens are less toxic than taxane-based regimens. Thus, data suggesting that more than 6 cycles of first-line chemotherapy are not appropriate may only apply to taxane-based regimens. Studies report that 60% of patients were able to receive 6 cycles of pemetrexed-based chemotherapy (and had a low incidence of toxicity), whereas only 42% were able to receive more than 5 cycles of taxane-based chemotherapy and often dropped out because of neurotoxicity. Evidence suggests that continuing first-line therapy (i.e., the current regimen) beyond 4 to 6 cycles and until disease progression benefits select patients who are responding to the therapy and do not have toxicity issues.

Maintenance Therapy

In patients with advanced NSCLC, maintenance therapy is another option for those with responsive or stable disease after first-line systemic therapy (see the NCCN NSCLC algorithm). For patients with non-squamous NSCLC who are negative for EGFR mutations or ALK fusions, continuation maintenance therapy regimens include bevacizumab (category 1), cetuximab (category 1), pemetrexed (category 1), bevacizumab/pemetrexed, or gemcitabine (see the NCCN NSCLC algorithm). Switch maintenance therapy regimens for these patients include pemetrexed or erlotinib.
Close observation is another option. Maintenance therapy is discussed in greater detail earlier in this Discussion.

For patients with squamous cell carcinoma, cetuximab (category 1) or gemcitabine can be used as continuation maintenance therapy (see the NCCN NSCLC algorithm). Switch maintenance therapy for these patients includes erlotinib or docetaxel (category 2B for docetaxel). Close observation is another option. A phase III trial assessed switch maintenance therapy with docetaxel given either immediately after chemotherapy or delayed until progression. However, switch maintenance therapy with docetaxel is a category 2B recommendation in the NCCN Guidelines, because many patients in the delayed chemotherapy arm did not receive docetaxel. A phase III randomized trial (n = 663) assessed the effect of best supportive care with or without maintenance pemetrexed in patients with advanced NSCLC who had received platinum-based chemotherapy but had not progressed. In patients with non-squamous NSCLC, overall survival was increased with pemetrexed when compared with placebo (13.4 vs. 10.6 months, P = .012).

Continuation of Erlotinib or Gefitinib After Progression

Erlotinib is commonly used in the United States in select patients with EGFR mutations because of restrictions on the use of gefitinib. However, gefitinib may be used if available. Patients may continue to derive benefit from erlotinib or gefitinib after disease progression; discontinuation of erlotinib or gefitinib leads to more rapid progression of disease (symptoms, tumor size, and FDG-avidity on PET scan). This strategy mirrors the experience in other oncogene-addicted cancers, particularly HER2-amplified breast cancer. In women with HER2-amplified breast cancer who have had progression of disease on trastuzumab, improved radiographic response rate, time to progression, and overall survival are observed when conventional chemotherapy is added to trastuzumab. Data support the continued use of erlotinib in patients with lung adenocarcinoma with EGFR mutations after development of acquired resistance to erlotinib when conventional chemotherapy is initiated. In 2013, the NCCN Panel added a new algorithm for treatment of patients who progress on erlotinib. In most cases, erlotinib is continued for these patients; however, additional therapy may be added (eg, whole brain RT, local therapy, systemic therapy).

Accumulating data suggest how cancers become resistant to EGFR inhibitors. The most common known mechanism is the acquisition of a secondary mutation in EGFR—T790M—that renders the kinase resistant to erlotinib and gefitinib. Amplification of the MET oncogene is another validated resistance mechanism. To overcome resistance, EGFR must still be inhibited. In the case of MET amplification, new inhibitors must be added to the EGFR inhibitor; however, EGFR inhibition is still required to induce remission. Furthermore, data by Riely et al. show that when cancers start to progress, which were once sensitive to EGFR inhibitors, discontinuation of the EGFR TKI can lead to a much more accelerated progression of the cancer. Thus, continuing EGFR TKIs is beneficial in many patients even after they develop resistance to EGFR TKIs.

Second-Line and Third-Line Systemic Therapy

Although many new active drugs are available for lung cancer, the reported response rates to second-line systemic therapy have generally been less than 10%. Docetaxel, pemetrexed (only for patients with non-squamous NSCLC), erlotinib, or platinum doublet with (or without)
bevacizumab (non-squamous only) are recommended as second-line systemic therapy regimens for patients with PS of 0 to 2 and who have experienced disease progression during or after first-line therapy (see the NCCN NSCLC algorithm). Docetaxel has been proven superior to best supportive care, vinorelbine, or ifosfamide with improved survival and quality of life. When compared with docetaxel, pemetrexed has similar median survival but less toxicity. Pemetrexed is recommended in patients with adenocarcinoma or large cell carcinoma (ie, non-squamous NSCLC). Erlotinib has been proven superior to best supportive care with significantly improved survival and delayed time to symptom deterioration. In patients with PS of 3 to 4 who have the EGFR mutation, erlotinib is recommended for second- or third-line therapy for progressive disease (see the NCCN NSCLC algorithm). A platinum doublet with (or without) bevacizumab is an option for patients with non-squamous NSCLC who have progressed after first-line therapy with erlotinib or crizotinib.

In a randomized, placebo-controlled, double-blind trial (NCIC CTG trial), 731 patients (stage IIIB or IV, PS 0–3) were randomly assigned (2:1) to receive either erlotinib or placebo, following failure of first- or second-line chemotherapy. Patients treated with erlotinib showed an overall survival of 6.7 versus 4.7 months for placebo (hazard ratio, 0.70; \( P < .001 \)). PFS was 2.2 months for the erlotinib group versus 1.8 months for placebo (hazard ratio, 0.61, adjusted for stratification categories; \( P < .001 \)). However, 5% of patients discontinued erlotinib because of toxic side effects. This trial confirms that erlotinib can prolong survival in patients after failure of first- or second-line systemic therapy. A randomized phase III trial in 829 patients found that oral topotecan was not inferior to docetaxel. Pemetrexed (non-squamous only), docetaxel, or erlotinib are recommended for second-line or third-line therapy in patients with advanced NSCLC if these agents have not already been given. If disease progression occurs after third-line chemotherapy, patients with PS of 0 to 2 may be treated with best supportive care or be enrolled in a clinical trial (see the NCCN Guidelines for Palliative Care).
<table>
<thead>
<tr>
<th>Genetic Alteration (ie, Driver Event)</th>
<th>Available Targeted Agents (FDA-Approved for Other Indications) With Activity Against Driver Event</th>
<th>NCCN Recommendation*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK gene rearrangements (ie, gene fusions)</td>
<td>Crizotinib</td>
<td>Category 2A</td>
</tr>
<tr>
<td>EGFR mutations</td>
<td>Erlotinib†</td>
<td>Category 1 or 2A (see algorithm)</td>
</tr>
<tr>
<td>HER2 mutations</td>
<td>Trastuzumab, lapatinib, pertuzumab</td>
<td></td>
</tr>
<tr>
<td>BRAF mutations</td>
<td>Vemurafenib</td>
<td></td>
</tr>
<tr>
<td>MET amplification</td>
<td>Crizotinib</td>
<td></td>
</tr>
<tr>
<td>ROS1 gene fusions</td>
<td>Crizotinib</td>
<td>Category 2A</td>
</tr>
<tr>
<td>RET gene fusions</td>
<td>Vandetanib, sunitinib, sorafenib</td>
<td></td>
</tr>
</tbody>
</table>

*The NCCN Guidelines for NSCLC only recommend crizotinib and erlotinib, although several targeted agents have been approved for other indications.

†Most EGFR mutations are sensitive to erlotinib (eg, deletions in exon 19 [Exon19del (LREA deletion)] and a mutation in exon 21 [L858R]). However, some EGFR mutations are resistant to erlotinib (eg, T790M). In areas of the world where gefitinib is available, it may be used instead of erlotinib.
References


47. Cameron SE, Andrade RS, Pambuccian SE. Endobronchial ultrasound-guided transbronchial needle aspiration cytology: a state of


108. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial...


NSCLC Table of Contents

Discussion


284. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice


408. Kernstine KH, Trapp JF, Croft DR, et al. Comparison of positron emission tomography (PET) and computed tomography (CT) to identify N2 and N3 disease in non small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 1998;17:458. Available at:


523. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted
